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Abstract
The main function of pancreatic beta cells is to maintain correct glu-
cose homeostasis within the body by secretion of insulin in response
to increased blood glucose concentration. Beta cell dysfunction con-
tributes to the pathogenesis of diabetes. Using transgenic mouse
models, the work described in this thesis has investigated the role
of AMP-activated protein kinase (AMPK) and phosphatidylinositol
3-kinase (PI3K) in beta cell function and their role in the regulation
of glucose-stimulated insulin secretion (GSIS). AMPK is activated by
low cellular energy levels. Once activated it acts as a cellular fuel
gauge to restore energy levels back to normal. An anti-diabetic drug
metformin is thought to achieve its blood glucose lowering eﬀect by
activation of AMPK in liver and skeletal muscle. However, the role
of AMPK in pancreatic beta cells has remained uncertain and contro-
versial. This thesis shows that transgenic mice, which lack functional
AMPK in beta cells are glucose intolerant caused by impaired GSIS.
Investigation of islet function in vitro revealed that lack of AMPK in
beta cells alters glucose sensing and insulin secretory behaviour, which
is associated with down-regulation of mitochondrial uncoupling pro-
tein 2.
PI3K functions as a lipid kinase downstream of receptor tyrosine ki-
nases such as insulin receptor. Previous studies have shown that it
has an important role in the regulation of energy metabolism, but
no studies to date have investigated the specific role of PI3K in beta
cells using mouse knockout models. The study in this thesis demon-
strates that transgenic mice that lack functional PI3K catalytic sub-
units p110α and p110β in beta cells develop marked glucose intoler-
ance and impaired GSIS. Together these two studies demonstrate that
AMPK and PI3K signalling in beta cells is essential for the regulation
of whole-body glucose homeostasis and insulin secretion.
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Chapter 1
Introduction
1.1 Diabetes – a global problem
Diabetes has become a major burden for health care systems throughout the
world. For example in United Kingdom approximately 10 % of NHS resources are
used in the management of diabetes (Gloyn, 2003). Currently, diabetes aﬀects over
180 million people worldwide. Of all the individuals with diabetes, 90% have type
2 diabetes mellitus (T2DM), the non-insulin dependent form of diabetes (WHO,
2006). It has been predicted that by 2030 over 377 million people will suﬀer from
T2DM worldwide (Albright, 2008). Alarmingly, a significant number of new cases
of T2DM will be diagnosed among children and adolescent (Gloyn, 2003). T2DM
is defined as a systemic disorder of glucose homeostasis. It is characterised in terms
of hyperglycaemia, peripheral tissue insulin resistance, abnormal splanchic (liver
and gut) glucose uptake, impaired insulin secretion, and is also associated with
hyperlipidaemia (DeFronzo, 2004). A fasting blood glucose level of > 7 mmol/L,
and/or > 11 mmol/L glucose two hours after an oral glucose load are the bench
marks of T2DM (Kuzuya et al., 2002). T2DM is associated with a variety of other
diseases including microvascular diseases (such as neuropathy, nephropathy and
retinopathy) and macrovascular diseases (such as atherosclerosis and coronary
artery disease) (Milicevic et al., 2008; Reasner, 2008; Soldatos and Cooper, 2008).
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1.1.1 Genome-wide association studies
Type 2 diabetes is a polygenic, multifactorial disease that can arise due to poly-
morphisms in multiple genes. However, environmental factors such as diet and
physical activity can also have a major influence on disease prevalence and sever-
ity (Ridderstr˚ale and Groop, 2009). At least eighteen genes associated with
TD2M have recently been identified by the whole genome-wide association stud-
ies (GWAS) (McCarthy and Zeggini, 2009; Ridderstr˚ale and Groop, 2009). Most
of the recognised genes are involved in beta cell function, suggesting that beta
cell dysfunction plays a key role in the pathogenesis of the disease. A study
using a cohort of non-diabetic Finnish men found that 8 of the previously identi-
fied loci are significantly (TCF7L2, SLC30A8, HHEX, CDKN2B, CDKAL1 and
MTNR1B), or nominally (KCNJ11 and IGF2BP2 ) associated with a decreased
early-phase insulin secretion. TCF7L2, SLC30A8, HHEX, and CDKAL1 could
also be associated with impaired conversion of proinsulin to insulin (Sladek et al.,
2007; Stanca´kova´ et al., 2009). However, each loci only a have modest risk eﬀect
on the development of T2DM (Rung et al., 2009). Candidate gene studies have
identified a Pro12Ala variant in a transcription factor peroxisome proliferator-
activator receptor γ (PPARG) gene that is associated with T2DM (Gloyn, 2003).
Another new risk locus near IRS-1 has been identified, which is associated with
insulin resistance and hyperinsulinaemia (Rung et al., 2009). Defect in glucose-
and tolbutamide stimulated insulin secretion was observed in beta cells that con-
tained a similar polymorphisms in IRS-1 (Aspinwall et al., 2000). In order to
understand the cellular and molecular mechanisms responsible for T2DM, it is
necessary to conceptualise the framework within which glycaemia is controlled,
and this is discussed further below.
1.2 Glycaemic control
Glucose is an important source of energy for all tissue types of the body, espe-
cially to the brain that is acutely dependent on energy provided by glucose (Marty
et al., 2007). It is essential to maintain the blood glucose concentration within
the healthy limits of 4-7 mmol/L. This involves a balance between hepatic glu-
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coneogenesis and uptake of glucose by tissues including the gut, skeletal muscle
and adipose tissue, although most (80-85 %) of peripheral glucose uptake occurs
in muscle (DeFronzo, 2004) (Figure 1.1). Two primary hormones involved in reg-
ulating these processes are insulin and glucagon, both secreted by the endocrine
pancreas.
1.3 Endocrine pancreas
Beta cells are a central part of the pancreatic endocrine system. They are clustered
together with other endocrine cells such as alpha cells (glucagon secretion), delta
cells (somatostatin secretion) and PP cells (pancreatic polypeptide secretion) to
form the islets of Langerhans. Beta cells constitute more than 70 % of the islet
cells mass followed by alpha cells which make up 10 % of total islet cell mass
(Cabrera et al., 2006). Regulation of pancreatic beta cell mass is achieved by
balanced action between beta cell proliferation, regulation of cell size and cell
death, as well as beta cell neogenesis (Leibiger and Berggren, 2008). However,
maintenance of beta cell mass is largely achieved by proliferation of existing beta
cells, a process which is controlled by the interplay of various proteins of the cell
cycle machinery (Chang-Chen et al., 2008).
1.4 Insulin secretion by pancreatic beta cells –
a two phase process
The main function of pancreatic beta cells is to maintain correct glucose home-
ostasis within the body by secretion of insulin in response to increased blood
glucose concentration. Other nutrients such as some amino acids (leucine, glu-
tamine and arginine), fatty acids, neurotransmitters (e.g. acetylcholine) and in-
cretins (gut-derived hormones) such as gastric inhibitory polypeptide (GIP) and
glucagon-like peptide-1 (GLP-1) also exhibit an insulinotropic eﬀect on the pan-
creatic beta cells (DeFronzo, 2004; Leclerc and Rutter, 2004; Maechler and Woll-
heim, 2001; Tarasov et al., 2004; Thorens, 2008; Wollheim and Maechler, 2002).
Classically, insulin secretion can be divided into two phases, which are described
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Figure 1.1: Insulin action and control of glucose homeostasis. Raised blood glu-
cose stimulates insulin release from pancreatic beta cells. Insulin stimulates glu-
cose uptake and glycogen and lipid synthesis in skeletal muscle and adipose tis-
sue. In liver, insulin stimulates glycogen synthesis and inhibits gluconeogenesis
and glycogenolysis. Thus, insulin action on peripheral tissues leads to reduction
in blood glucose levels. Opposing the insulin action, glucagon, secreted from pan-
creatic alpha cells in response to hypoglycaemia, stimulates liver gluconeogenesis
and raises blood glucose levels.
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further below.
1.4.1 The first phase of insulin release – the KATP -channel
dependent insulin secretion
Glucose is taken up into beta cells via a glucose transporter GLUT2 (in mice) and
GLUT1 (in humans) (Hiriart and Aguilar-Bryan, 2008; Vos et al., 1995). Glucose
is then metabolised by glycolysis and the tricarboxylic acid (TCA) cycle (Herman
and Kahn, 2006). Both pathways provide substrates (NADH and FADH2) for the
respiratory chain within mitochondria to produce ATP (Duchen, 2004). ATP is
transported into the cytoplasm, where it binds to the Kir6.2 subunit of the KATP -
channel (Ashcroft, 2005; Klingenberg, 2008). The binding of ATP causes channel
closure, resulting in the depolarisation of the plasma membrane. The depolari-
sation triggers the opening of the L-type voltage-gated calcium channels, which
leads to the influx of Ca2+-ions. Calcium triggers the exocytosis of insulin secre-
tory vesicles and results in the release of insulin from beta cells (Straub and Sharp,
2002). As calcium uptake and insulin release are dependent on potassium chan-
nel closure by ATP, this pathway is called the KATP -channel dependent insulin
secretion pathway. See Figure 1.2 for a graphical representation of the first-phase
insulin release in beta cells.
1.4.2 The second phase of insulin release – the KATP -
channel independent insulin secretion
The sustained second phase of insulin secretion is called KATP -channel indepen-
dent insulin secretion, as insulin secretion occurs despite the potassium channel
being open or otherwise dysfunctional (Tengholm and Gylfe, 2009). The sec-
ond phase involves augmented insulin release in response to elevated intracellular
calcium levels. The mechanisms for this are still unknown but are thought to
involve changes in concentrations and actions of cAMP, phospholipase C and
plasma membrane phosphoinositides (Straub and Sharp, 2002; Tengholm and
Gylfe, 2009). Poorly defined metabolic coupling pathways such as generation of
mitochondrial NADH, malonyl-CoA and cytosolic long chain-CoA esters are also
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required (Prentki, 1996; Prentki et al., 1997). I will now discuss in further details
about diﬀerent steps involved in the glucose-stimulated insulin secretory path-
way including glucose sensing and glucose metabolism coupled beta cell electrical
activity.
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plasma membrane
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Figure 1.2: A simplified model of beta cell function. Glucose is taken up into the
cells via GLUT2 (mouse)/GLUT1(human) glucose transporters. Glucose is then
metabolised in the cytosol and mitochondria to yield ATP. ATP closes the KATP
-channels on the plasma membrane, which leads to membrane depolarisation.
This triggers the opening of L-type voltage-gated calcium channels and calcium
influx into the cytosol stimulates insulin granule exocytosis. G6P = glucose-6-
phosphate, TCA = tricarboxylic acid, ETC = electron transport chain
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1.5 Glucose sensing by beta cells
Two high Km enzymes, glucose transporter GLUT2 and glucokinase (GK) are
responsible for glucose sensing and initiation of glucose-stimulated insulin secre-
tion pathway in pancreatic beta cells. GLUT2 is an integral membrane protein
that facilitates glucose transport across the plasma membrane, thus regulating
beta cell glucose uptake (Herman and Kahn, 2006; Hiriart and Aguilar-Bryan,
2008). GLUT2 has a low aﬃnity for glucose and has a Km of ≈ 20-66 mM,
meaning that increases in blood glucose concentration over a range of physio-
logical glucose concentrations are met by increased capacity to transport glucose
across the membrane (Kahn, 1992; Shepherd and Kahn, 2000). It has been shown
repeatedly that GLUT2 is important for beta cell glucose-stimulated insulin se-
cretion. Glucose stimulated, but not arginine stimulated insulin secretion is re-
duced in islets obtained from type 2 diabetic patients. In these islets, GLUT2
mRNA expression is decreased over 40 % (Guerra et al., 2005). Similar results
have been obtained from mouse islets that are deficient in GLUT2. The GLUT2
deficient mice are hyperglycaemic and hypoinsulinaemic, and investigation of in
vitro glucose-stimulated insulin secretion in GLUT2 deficient islet showed a loss
of first-phase insulin secretion, and reduced second-phase insulin secretion indi-
cating the importance of GLUT2 in the regulation of GSIS (Thorens, 2001).
The rate of glucose uptake by GLUT2 usually exceeds the rate of glucose phospho-
rylation by glucokinase (GK) i.e. hexokinase IV, which is a rate-limiting enzyme
of glucose metabolism, and is the primary glucose sensor in beta cells (Herman
and Kahn, 2006; Thorens, 2001). Expression of high-aﬃnity hexokinases (hex-
okinase I, II and III) in beta cells is very low. This means that when glucose
concentration is low (<2.5 mmol/L), phosphorylation of glucose to glucose-6-
phosphate is kept at minimum, resulting in low glycolytic flux and low ATP levels,
consequently keeping insulin release at basal level (Schuit et al., 2001). When glu-
cose concentration increases (>2.5 mmol/L), the low-aﬃnity GK phosphorylates
glucose and increases glycolytic flux, which eventually leads to increased cellu-
lar ATP/ADP levels and stimulation of insulin secretion from beta cells (Schuit
et al., 2001). GK has a Km of 10 mM for glucose and enzyme kinetics have shown
that there is a sigmoidal relationship between glucokinase activity and glucose
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concentration (Matschinsky et al., 1993; Thorens, 2008). Because GK is not neg-
atively inhibited by glucose-6-phosphate, unlike the high aﬃnity hexokinases I, II
and III, glycolytic flux remains high as long as the glucose concentration remains
elevated.
Mice lacking GK in pancreatic beta cells develop perinatal diabetes and die a
few days after birth (Remedi and Nichols, 2009). Over 200 mutations (overacti-
vating and inactivating) have been identified along the GK gene (Gloyn et al.,
2008). Inactivating mutations generally result in decreased insulin secretion and
T2DM (Beall et al., 2010). GK was also the first gene to be found to cause
maturity onset diabetes of young (MODY), and over 140 mutations have been
identified along the GK gene that cause MODY2, characterised by mild hyper-
glycaemia and progressive beta cell failure over time (Gloyn, 2003; Gloyn et al.,
2008). Overactivating mutations in GK result in increased insulin secretion and
hypoglycaemia, as seen in persistent hyperinsulinaemic hypoglycaemia of infancy
(PHHI) (Gloyn et al., 2008). Hence it is easy to understand why GK has a key
role as a primary cellular glucose sensor.
1.6 Glucose metabolism
Once glucose has been transported into the beta cells it enters glycolysis in the cy-
toplasm where it is metabolised to pyruvate (Herman and Kahn, 2006). Pyruvate
enters mitochondrial matrix where it acts as a substrate for pyruvate carboxy-
lase, which converts pyruvate to oxaloacetate, and for pyruvate dehydrogenase,
which converts it to acetyl-CoA (Herman and Kahn, 2006). Both oxaloacetate and
acetyl-CoA are substrates for the TCA cycle that provides NADH and FADH2
for the mitochondrial respiratory chain (Wollheim and Maechler, 2002).
1.7 Mitochondrial function in beta cells
The mitochondrial respiratory chain is located on the inner mitochondrial mem-
brane. Briefly, its function is to transfer electrons from NADH (complex I) and
FADH2 (complex II) along the complexes on the inner membrane to complex IV
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where electrons are used to reduce molecular oxygen to H2O. Transfer of elec-
trons is coupled to pumping of protons through complex I, III and IV into the
inner membrane space, creating a membrane potential (proton gradient) across
the inner mitochondrial membrane. When protons move down the proton gradi-
ent back to the matrix through ATP synthase (complex V), it is able to use the
proton motive force, created by the proton gradient, to phosphorylate ADP to
produce ATP (Duchen, 2004). ATP is then transported back to the cytoplasm by
adenine nucleotide transferase (ANT) where it is used as an energy source, and
more importantly in beta cells, used as a signalling molecule to stimulate insulin
secretion (Maechler and Wollheim, 2001).
1.7.1 Mitochondrial ROS production and beta cell insulin
secretion
Mitochondrial dysfunction has been shown to contribute to the development of
type 2 diabetes (Molina et al., 2009). As described above, mitochondria function
as cellular energy factors that couple metabolism of glucose and other nutrients to
the production of ATP. Most of the cellular production of reactive oxygen species
(ROS) occurs in mitochondria when reduction of molecular oxygen is incomplete
(Maechler and Wollheim, 2001). ROS are chemically unstable and highly reactive
species that contain oxygen (D’Autre´aux and Toledano, 2007). Superoxide anion
is the most reactive form of ROS and is quickly converted to H2O2 by superoxide
dismutase (SOD). Increased glycolytic flux, decreased ADP levels and increased
intracellular Ca2+ can lead to considerable increase in the production of super-
oxide anion, mainly at complex I and between ubiquinone and complex III (Pi
et al., 2010). By its chemical virtues (small, uncharged) and cellular functions,
H2O2 can be considered as an intracellular messenger. Its cellular downstream
targets include protein tyrosine phosphatases, tumour suppressor phosphatase
PTEN, c-Jun N-terminal kinase, NF-κB, SIRT1 deacetylase and voltage-gated
K+ channels (Pi et al., 2010). It has been brought into focus that production of
ROS from glucose metabolism, such as H2O2 and superoxide anion, might serve
as a signal for glucose-stimulated insulin secretion in beta cells (Pi et al., 2007b,
2010). In general, it has been shown that, stimulation of cellular H2O2 levels
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enhance insulin secretion, and antioxidants and other agents that act to reverse
oxidative stress, inhibit insulin secretion (Pi et al., 2010). Acute treatment of
rat islets with ROS generators alloxan and xanthine oxidase leads to short-term
increased insulin release (Ebelt et al., 2000). Increasing H2O2 levels in INS-1 cells
and mouse islets also increased insulin secretion, whereas exogenous antioxidants
inhibited insulin secretion (Pi et al., 2010). However, stimulation of insulin se-
cretion is still dependent on ATP generation, as inhibitors of ATP production
(e.g. oligomycin) that also increase ROS production, cannot stimulate insulin
secretion (Pi et al., 2010).
1.7.2 UCP2 in beta cells
Uncoupling protein 2 (UCP2) is located on the inner mitochondrial membrane
where it acts to dissipate the proton gradient created by the respiratory chain
across the mitochondrial inner membrane. Uncoupling of the respiratory chain
causes a mild depolarisation of the mitochondrial membrane potential and di-
minished ATP production (Duchen, 2004). It has also been suggested that mild
uncoupling can protect against ROS generation is some cases as there is less
electron leakage and increased rate of respiration that leads to the reduction of
oxygen to water (Duchen, 2004).
Polymorphism in the UCP2 promoter (-866G/A), which leads to increased UCP2
expression, has been associated with beta cell dysfunction, decreased insulin se-
cretion and T2DM (Chan and Kashemsant, 2006; Sesti et al., 2003). The polymor-
phism has also been shown to be a predictor of development of T2DM (Chan and
Kashemsant, 2006). UCP2 protein and mRNA levels are increased in the islets
of obese ob/ob mice, and mice fed with high fat diet, and this has been shown
to cause beta cell dysfunction (Zhang et al., 2001). In ob/ob islets, UCP2 levels
were increased before progression of hyperglycaemia and diabetes in these ani-
mals, suggesting that upregulation of UCP2 protein expression may have a causal
eﬀect on the obesity associated development of T2DM (Chan and Kashemsant,
2006; Zhang et al., 2001). In general, overexpression of UCP2 in beta cells leads
to decreased insulin secretion as production of ATP is attenuated (Maechler and
Wollheim, 2001). However, another study failed to reproduce these results, leav-
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ing some discrepancies between the eﬀects of UCP2 overexpression on beta cell
insulin secretion (Produit-Zengaﬃnen et al., 2007). On the other hand, UCP2
deficient mice have higher islet ATP content and increased GSIS in vitro (Zhang
et al., 2001). They also have increased fasted and fed plasma insulin levels and
improved glucose tolerance (Aﬀourtit and Brand, 2008). Similarly, treating islets
with genipin, an active compound of Gardenia fruit extract, is thought to in-
hibit UCP2 mediated proton leak, increase ATP levels and enhance GSIS in vitro
(Zhang et al., 2006). UCP2 deficient ob/ob mice also showed improved glucose
tolerance and GSIS, and treatment of ob/ob islets with genipin caused an acute
improvement in GSIS (Zhang et al., 2006). Overall, it has been shown that
UCP2 is involved in the regulation of GSIS in beta cells, possibly by regulation
of mitochondrial ROS production (Aﬀourtit and Brand, 2008).
1.7.3 KATP -channels
ATP-sensitive K+-channels (i.e. KATP -channels) in beta cells consist of four in-
wardly rectifying pore-forming K+ channel subunits (Kir6.2) that are surrounded
by four sulphonylurea receptor subunits (SUR1) (Henquin et al., 2003; McTag-
gart et al., 2010). KATP -channels have an important role in beta cells in coupling
glucose metabolism to cell excitability, which eventually leads to stimulation of in-
sulin secretion. At basal glucose concentration (<5 mmol/L), glucose metabolism
and cellular ATP/ADP ratio are low, plasma membrane KATP -channels remain
open and active and beta cells are electrically silent (Rorsman, 1997). Active
KATP -channels mediate K+-ion outflux that keeps the resting membrane potential
near -70 mV (near the K+ equilibrium potential) (Macdonald et al., 2005). When
glucose concentration rises above 5 mmol/L, glucose metabolism increases, which
leads to a rise in cellular ATP/ADP ratio (Rorsman, 1997). ATP binds to the
Kir6.2 subunits of the KATP -channel, which leads to channel closure. This causes
plasma membrane depolarisation, as the inside of the beta cell becomes more
positive due to accumulation of potassium ions inside the cell.
Loss of functional KATP -channels or mutations in Kir6.2 or SUR1 subunits, lead
to increased electrical activity and insulin secretion at low glucose (Ashcroft, 2005;
Miki et al., 1998; Seghers et al., 2000). Over 150 mutations have been found in
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SUR1 encoding gene (ABCC8 ) and 24 in Kir6.2 gene (KCNJ11 ). These muta-
tions cause congenital hyperinsulinism (HI), which is characterised by very high
levels of insulin secretion, even at low glucose levels (McTaggart et al., 2010). It
appears that the beta cells in HI individuals are permanently depolarised, which
leads to a constant calcium influx and stimulation of insulin secretion.
Gain-of-function mutations in Kir6.2 and SUR1 subunits cause neonatal diabetes
(ND). In general, these mutations prevent ATP from channel closure, which leads
to a constant hyperpolarisation of the plasma membrane, even at high glucose
concentrations, and suppression of insulin secretion, causing diabetes (McTaggart
et al., 2010). A common polymorphism in Kir6.2 (E23K) has been associated with
T2DM, but the mechanisms underlying this association are as yet unknown (Mc-
Taggart et al., 2010).
1.7.4 L-type Ca2+-channels
As mentioned above, beta cells become electrically active when KATP -channel clo-
sure causes depolarisation of the plasma membrane. This opens L-type voltage-
gated calcium channels, which leads to calcium influx in to the cell, an increase
in intracellular free calcium concentration and triggering of insulin granule ex-
ocytosis (Henquin, 2009, 2000). The opening of calcium channels occurs in a
pulsatile manner. Initial membrane depolarisation results in the opening of
few calcium channels, which upon opening, trigger further depolarisation of the
plasma membrane and opening of the remaining, closed L-type channels (Rors-
man, 1997). Hence, firing of calcium potentials are observed as membrane de-
polarisation, which are separated by brief electrically silent periods when the
membrane repolarises (Rorsman and Renstro¨m, 2003).
1.7.5 Insulin granule exocytosis
A single beta cell contains over 10,000 insulin secretory granules, in which insulin
is associated with zinc (Rorsman and Renstro¨m, 2003). Insulin secretory granules
are divided into diﬀerent cellular pools of granules that diﬀer in terms of their
cellular location and in their releasability status (Macdonald et al., 2005). At
least three diﬀerent type of pools exist: an intracellular reserve pool (accounts
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for 90 % of all the granules), a morphologically docked pool (≈ 10 %) and a readily
releasable pool, primed for release (≈ 0.3-2.2 %). Insulin granules are likely to
move along microtubules, powered by the ATP-dependent motor activity of the
conventional kinesin KIF5B in the cytoplasm and along cortical actin network
near the plasma membrane by the ATP-dependent myosin (Macdonald et al.,
2005). Insulin granule fusion to the plasma membrane is mediated by SNARE
proteins that include the vesicular protein VAMP and Syntaxin and SNAP-25 on
the plasma membrane (Macdonald et al., 2005).
1.7.6 cAMP
Cyclic AMP (cAMP) is an important cellular second messenger that can stimu-
late beta cell insulin secretion, independently from glucose and KATP -channels.
It is formed from ATP by adenylyl cyclase, which is activated by G-protein cou-
pled receptors (GPCR) such as GLP-1 (glucagon-like peptide 1) receptor at the
plasma membrane (Maechler and Wollheim, 2001). Thus incretins such as GLP-
1 and GIP (gastric inhibitory polypeptide) and other agonists of the GPCRs
are thought to stimulate insulin secretion by generation of cAMP. Cyclic AMP
can stimulate and amplify insulin secretion via activation of several, distinct cel-
lular processes, for example inhibition of KATP -channel activity, stimulation of
L-type Ca2+-channels and stimulation of calcium release from intracellular cal-
cium stores, either by activation of protein kinase A (PKA) or independently of
PKA (Eliasson, 2003; Maechler and Wollheim, 2001).
1.8 The pathophysiology of T2DM
Insulin resistance is in general the earliest pathophysiological sign in the develop-
ment of T2DM. However, while pancreatic beta cells are able to compensate for
the increased insulin demand via insulin hypersecretion, thus maintaining blood
glucose within reasonable limits, once relative beta cell failure occurs, T2DM be-
comes manifest (Figure 1.3). It is therefore key to understand the mechanisms of
beta cell failure in T2DM.
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Figure 1.3: The pathogenesis of T2DM. Genetics and environmental factors af-
fect the insulin sensitivity of peripheral tissues that can lead to insulin resistance
and hyperglycaemia. Increased insulin demand is compensated by insulin hyper-
secretion from the pancreatic beta cells, thus maintaining blood glucose within
reasonable limits. However, once relative beta cell failure occurs, T2DM becomes
manifest.
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1.8.1 Insulin resistance
Insulin resistance in liver and skeletal muscle is often present in individuals with
T2DM. Overall about 25 % of the adult population are insulin resistant, but in
most individuals, pancreatic beta cells are able to compensate for the increased
insulin demand by increasing their insulin secretion (DeFronzo, 2004). The char-
acteristics of insulin resistance are increased hepatic glucose output and decreased
muscle glucose uptake that often leads to fasting hyperglycaemia and glucose in-
tolerance (DeFronzo, 2004). Decreased insulin receptor tyrosine kinase activity,
reduced IRS-1 phosphorylation, and reduced PI3K activity in muscle are often
found in insulin resistant subjects and in individuals with T2DM (DeFronzo,
2004). Gly-972-Arg mutation in the IRS-1 gene has been associated with T2DM
and insulin resistance, although the physiological consequences of this mutation
is still unknown (DeFronzo, 2004). Prkaa2 gene (encoding AMPKα2) has been
found to be located at the Japanese T2DM loci. Hence, AMPKα2 is another
candidate gene for insulin resistance and T2DM diabetes, at least in Japanese
population (Horikoshi et al., 2006). I will discuss AMPK in more detail further
in this chapter.
1.8.2 Beta cell dysfunction
Insulin resistance is usually compensated by insulin hypersecretion from beta
cells and enhanced insulin secretion in response to acute glucose challenge. This
is usually seen as an increase in beta cell mass or insulin production from individ-
ual beta cells (Chang-Chen et al., 2008). Expansion of beta cell mass is achieved
mainly by increased beta cell proliferation but also by beta cell hypertrophy, often
found in humans and rodent models of insulin resistance (Weir and Bonner-Weir,
2004). However, if T2D ensues despite the beta cell compensatory eﬀect, a sig-
nificant reduction in beta cell mass can be detected, and this is thought to be
due to increased beta cell apoptosis (Butler et al., 2003; de Koning et al., 2008).
Apoptosis is only one disorder that contributes to beta cell dysfunction. Loss of
first phase insulin secretion and reduced and delayed second phase, decreased
insulin gene expression and beta cell insulin content are also associated with beta
cell dysfunction in T2DM (de Koning et al., 2008; DeFronzo, 2004; Robertson
15
and Harmon, 2006; Zhang et al., 2001). The cause for the loss of the first phase
insulin secretion is not well understood, but it is thought to involve dysregula-
tion of gene expression needed in the first phase, and can possibly be caused by
glucotoxicity (Weir and Bonner-Weir, 2004).
Beta cell dysfunction is also accompanied by general changes in gene expres-
sion profile in the beta cells, involving both upregulation and downregulation of
genes. For example, glucose-6-phosphatase, lactate dehydrogenase, antioxidants
and apoptotic and proapoptotic genes are found to be upregulated (Weir and
Bonner-Weir, 2004). Even though an acute increase in plasma glucose levels
stimulates insulin gene expression and insulin release from beta cells, chronic
exposure to elevated glucose concentration and fatty acids has the opposite ef-
fect on beta cell function. Increased levels of oxidative stress are associated with
chronic hyperglycaemia and are often recorded in diabetic patients (Robertson
and Harmon, 2006). These can be termed as gluco- and lipotoxicity of the beta
cells (Robertson et al., 2004). Chronic elevation of glucose concentration results
in increased glucose oxidation that in turn causes mitochondrial dysfunction and
increased production of reactive oxygen species (ROS) (Chang-Chen et al., 2008;
Robertson et al., 2004). It also increases cytosolic calcium levels that can have a
pro-apoptotic eﬀect in beta cells and induces endoplasmic reticulum (ER) stress
(Chang-Chen et al., 2008; Eizirik et al., 2008).
In conclusion, insulin resistance is the first step in the development of T2DM,
compensated by increased beta cell mass and insulin secretion. However, chronic
hyperglycaemia can cause mitochondrial dysfunction, increased oxidative stress
and activation of apoptotic pathways that leads to beta cell dysfunction. Beta
cell dysfunction progressively leads to beta cell failure, which means that beta
cells are unable to meet the increased insulin demand and T2DM manifests (See
Figure 1.4).
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Figure 1.4: Beta cell dysfunction and development of T2DM. Insulin resistance
and hyperglycaemia lead to increase in insulin demand from pancreatic beta
cells. Beta cells compensate by increased proliferation, increased mass and in-
sulin hypersecretion. However, if normoglycaemia cannot be achieved, chronic
hyperglycaemia and constant insulin hypersecretion eventually lead to beta cell
dysfunction, characterised by increased apoptosis and oxidative stress, mitochon-
drial dysfunction, altered gene expression and reduced beta cell mass and in-
sulin secretion. Ultimately beta cell failure occurs, which leads to development of
T2DM.
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1.9 Regulation of energy homeostasis by the cen-
tral nervous system (CNS)
Yet, the beta cells are not the only important regulators of glucose homeosta-
sis. The central nervous system (CNS) also participates in the regulation of
energy- and glucose homeostasis. It is also thought that altered neuronal path-
ways can possibly contribute to the development of metabolic diseases such as
obesity and T2DM. Therefore, understanding how the CNS participates in the
regulation of whole-body glucose and energy homeostasis is important.
Glucose is the primary fuel source for the brain. Hence it is essential that
the brain glucose levels are kept within a narrow range, regulated by the central
nervous system (CNS) (Marty et al., 2007). The CNS receives hormonal and nu-
tritional status of the body that translates to changes in neuronal activity in the
brain stem and hypothalamus (Seeley and Tschop, 2006). Autonomic nervous
system also signals additional information in response to nutrients such as amino
acids, glucose and lipids (Marty et al., 2007). For example, the CNS controls pe-
ripheral glucose homeostasis, including hepatic glucose production by the hepatic
portal vein that acts as a glucose sensor, which then projects to the diﬀerent parts
of the hypothalamus such as the paraventricular hypothalamus and the arcuate
nucleus (ARC) (Marty et al., 2007). A subset of neurons located in the arcuate nu-
cleus of the hypothalamus have a central role in the regulation of energy homeosta-
sis (Elmquist et al., 2005). Neuronal populations that co-express the orexigenic
neuropeptide Y (NPY) and agouti-related peptide (AgRP), inhibited by insulin
and leptin, regulate energy homeostasis by stimulating feeding and decreasing
energy expenditure (Seo et al., 2008; Woods et al., 2006). Another neuronal pop-
ulation that acts in the opposite direction by stimulating food intake and energy
expenditure, activated by insulin and leptin, co-express the pro-opiomelanocortin
(POMC) and cocaine-amphetamine-regulated-transcript (CART) neuropeptides
(Seo et al., 2008; Woods et al., 2006).
One of the most essential roles for the CNS in regulation of glucose homeostasis
is hypoglycaemic sensing. Failure to respond to hypoglycaemia can lead to re-
duced neuronal activity and in severe cases to complete neuronal damage (Mobbs
et al., 2001). Several brain regions including the ventromedial and paraventricu-
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lar hypothalamus and arcuate nucleus participate in the hypoglycaemic sensing
(Donovan and Bohland, 2009). Specialised glucose sensing neurons respond to
changes in extracellular glucose levels in the brain and change their electrical
activity accordingly. These neurons are divided into two types according to their
activity in response to extracellular glucose levels. Glucose excited neurons be-
come activated by increase in extracellular glucose (Marty et al., 2007). Most of
the glucose excited neurons are thought to work similarly to the pancreatic beta
cells. This means that they are dependent on GLUT2 and glucokinase as glucose
sensors, and production of ATP from glucose metabolism to inhibit KATP -channel
activity, which leads to depolarisation of the plasma membrane (Burdakov et al.,
2005). For example POMC neurons are glucose excited neurons that are lo-
cated in the hypothalamic arcuate nucleus. Transgenic mice with a disruption
of KATP -channel activity in POMC neurons developed impaired whole-body glu-
cose homeostasis, and glucose sensing in the mutated POMC neurons was blunted
(Parton et al., 2007). Less is known about the mechanisms of glucose inhibited
neurons that become electrically silent in response to increase in glucose levels. It
is thought that inhibition of these neurons involves activation of Cl− currents
and reduced Na+/K+ pump activity (Burdakov et al., 2005). One key enzyme
regulating brain hypoglycaemic sensing and whole-body energy homeostasis is
AMP-activated protein kinase (AMPK). AMPK is regarded as a cellular energy
gauge that is activated by decreased energy levels in order to restore energy levels
back to normal. In the hypothalamus, AMPK activity is increased upon fasting,
which leads to increased food intake and body weight. Vice versa, feeding inhibits
hypothalamic AMPK activity, which leads to a reduction in food intake and loss
in body weight (Xue and Kahn, 2006). Both insulin and leptin, the key signalling
molecules involved in the hypothalamus in the regulation of energy homeostasis,
suppress hypothalamic AMPK activity (Kim and Lee, 2005). For example inhi-
bition of AMPK activity by leptin, secreted from adipocytes in proportion to fat
mass, leads to reduction in food intake (Bjørbaek and Kahn, 2004; Obici, 2009;
Okamoto et al., 2008).
In conclusion, the CNS regulation of hypoglycaemia and whole-body energy
homeostasis is essential. Food intake, body weight and energy storage and expen-
diture are regulated by a complex signalling network within the CNS. In addition,
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peripheral glucose homeostasis such as production of hepatic glucose as well as
insulin secretion from the pancreatic beta cells can also be controlled by the CNS.
Therefore, in order to understand diseases such as obesity and T2DM, it is im-
portant to understand the complexity involved in the regulation of whole-body
glucose- and energy homeostasis.
1.10 AMP-activated protein kinase
Beta cell energetics, mitochondrial function and generation of ATP are essential
for proper beta cell function and insulin secretion. Dysfunction in these mech-
anisms can lead to impaired beta cell function and development of diabetes.
Therefore, understanding the pathways that regulate beta cell energy homeosta-
sis is important. One key enzyme whose main function is to regulate cellular
energy levels is AMP-activated protein kinase (AMPK).
AMP-activated protein kinase (AMPK) is a serine/threonine protein kinase
that phosphorylates proteins with a specific sequence motif Φ(X,β)XX(S/T)XXXΦ,
where Φ is a bulky hydrophobic residue, and β is a basic residue (Corton et al.,
1995). AMPK functions as a regulator of cellular and whole-body energy home-
ostasis, and as the name suggests, it is activated by low energy levels associated
with a rise in the cellular AMP/ATP ratio (Corton et al., 1994). In general any
environmental stress that causes depletion of cellular ATP, such as hypoxia, heat
shock, starvation or prolonged exercise leads to the activation of AMPK (Cor-
ton et al., 1995; Viollet et al., 2009). Human tumour suppressor liver kinase B1
(LKB1) is a direct upstream kinase of AMPK that activates AMPK by phos-
phorylating threonine 172, located in the activation loop of the catalytic subunit
(Shackelford and Shaw, 2009). Another AMPK upstream kinase that phosphory-
lates and activates AMPK is a Ca2+/calmodulin-dependent protein kinase kinase
(CaMKK)α/β, which is activated by increased intracellular Ca2+. However, the
activity of CaMKKs is mainly restricted to the brain, whereas LKB1 is ubiqui-
tously expressed (Carling et al., 2008; Kola, 2008; Xue and Kahn, 2006). Active
AMPK switches on ATP-producing, catabolic processes that aid in restoring the
depleted energy levels. These include glucose transport, glycolysis, mitochon-
drial biogenesis and fatty acid oxidation (Kurth-Kraczek et al., 1999; Merrill
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et al., 1997; Reznick et al., 2007). AMPK also switches oﬀ ATP-consuming, an-
abolic processes such as protein translation, fatty acid and cholesterol synthesis
(Hardie and Carling, 1997), as well as gluconeogenesis in the liver (Lochhead
et al., 2000). AMPK therefore acts as a fuel gauge, restoring cellular energy bal-
ance short-term directly by phosphorylation of key enzymes, and long-term via
regulation of gene expression (Holmes et al., 1999; Kurth-Kraczek et al., 1999;
Zheng et al., 2001) (See Figure 1.5).
1.10.1 Heterotrimeric AMPK
AMPK is an evolutionary conserved protein kinase and its gene homologues are
expressed in almost all eukaryotes from fruit fly (Drosophila melanogaster) (Cor-
ton et al., 1995; Pan and Hardie, 2002) and yeast (Saccharomyces cerevisae) to
rodents and humans (Richter and Ruderman, 2009). In mammals, AMPK con-
sists of a complex of three subunits, each encoded by a diﬀerent gene, and each
subunit is expressed as at least two diﬀerent isoforms.
AMPK catalytic subunits, AMPKα1 (Prkaa1 ) and AMPKα2 (Prkaa2 ) contain
a serine/threonine kinase domain in the N-terminus, a phosphorylation site at
Thr172 (Hawley et al., 1996), immediately followed by an inhibitory domain be-
tween residues 312-392. In addition, ≈150 amino acid residues at the C-terminus
are needed for association with the two regulatory subunits β and γ (Crute et al.,
1998).
The regulatory subunit β (1 and 2) act as a scaﬀolding subunit for the other two
subunits and also contains a glycogen binding domain (Woods et al., 1996). The
γ subunit (1, 2 and 3) contains a regulatory subunit that consists of four cys-
tathione -synthase (CBS) domains that function in pairs to bind adenosine nu-
cleotides (AMP, ATP and ADP) (Cheung et al., 2000). AMPK activity is thought
to be regulated allosterically by the binding of AMP to the CBS domains in the γ
subunit, and by reversible phosphorylation of the Thr172, essential for activation,
by the upstream kinases (Xavier et al., 2003). The allosteric activation promotes
Thr172 phosphorylation and prevents dephosphorylation by protein phosphatases
(Carling, 2004; Xiao et al., 2007).
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Figure 1.5: Evolutionary conserved AMPK acts as a cellular fuel gauge. AMPK is
a heterotrimeric serine/threonine protein kinase that consists of catalytic subunit
α and two regulatory subunits β and γ. AMPK is activated by a change in cellular
AMP/ATP ratio and cellular stress, but the main activator is phosphorylation of
the catalytic subunit alpha by upstream kinases such as LKB1. Active AMPK
switches on catabolic ATP-producing processes and switches oﬀ ATP-consuming
processes through acute phosphorylation of metabolic enzymes and long term by
alteration in gene expression, thus restoring energy levels back to normal. AMPK
was initially recognised as a regulator of cellular energy status but now it is well
known that it has a key role in the regulation whole-body energy homeostasis.
Adapted from Carling (2004).
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1.10.2 The role of AMPK in the beta cells
Islet beta cells use ATP as an energy source, but ATP is also a key signalling
molecule for insulin secretion. Glucose metabolism is tightly coupled to produc-
tion of ATP, and small changes in glucose concentrations are met with adjust-
ments in cellular ATP/ADP and ATP/AMP ratios that are kept within narrow
limits. As AMPK functions as a cellular energy regulator and its activity is
linked to changes in cellular ATP/AMP ratio, it seems obvious that it could have
a key role in the regulation of beta cell function and insulin secretion (See Figure
1.6). The role of AMPK in pancreatic beta cells has been of great interest for
several years. However, despite the numerous studies conducted over the years,
no clear conclusion has been made yet, and discrepancies between studies exists,
especially about the role of AMPK in the regulation of insulin secretion.
Most of the studies that have investigated the role of AMPK in beta cells have
been carried out on imperfect beta cell models (such as INS-1 and MIN6), which
are immortalised insulinoma cell lines (Hohmeier and Newgard, 2004). Secondly,
manipulation of AMPK has involved the overexpression of constitutively active
(AMPK CA) or dominant negative (AMPK DN) constructs of AMPK, or use
of pharmacological agents to activate (AICAR, metformin) or inhibit AMPK
(Compound C). The problem in using pharmacological agents in the activation
and inhibition of AMPK is that the drugs are not very specific. For example
AICAR (5-aminoimidazole-4-carboxamide ribonucleoside) has been long used as
an activator of AMPK and many AMPK studies have been based on AICAR
activated AMPK (Corton et al., 1995).
AICAR is metabolised in the cell, which leads to accumulation of 5-aminoimidazole-
4-carboxamide ribonucleoside (ZMP), a mimic of AMP, without changing the
cellular ATP/ADP or ATP/AMP ratio. ZMP is then thought to act similarly
to AMP in activating AMPK (Corton et al., 1995). However, ZMP can also
activate other enzymes within the cell such as a glycolytic enzyme fructose-1,6-
bisphosphatase, which is also regulated by AMP (Iancu et al., 2005). Hence
the current approaches to determine the function of AMPK in beta cells have
their drawbacks and it is unclear whether the observed results are attributable
to AMPK activation or inhibition.
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Figure 1. Role of AMP-activated protein kinase (AMPK) in the control of whole-body energy homeostasis
Activation of AMPK in many tissues switches off ATP-consuming processes while switching on catabolic processes that generate ATP. Some key metabolic effects are
shown. The adipocyte-derived hormones leptin and adiponectin, as well as exercise, activate AMPK in skeletal muscle, stimulating fatty acid oxidation. Leptin’s
activation of AMPK in skeletal muscle involves the hypothalamic-sympathetic nervous system (SNS) axis. Adiponectin also activates AMPK in liver, increasing fatty
acid oxidation and reducing gluconeogenesis, and in adipocytes, where the downstream biologic pathway has not been studied. Resistin inhibits AMPK in liver. AMPK
inhibits insulin secretion from pancreatic β cells.
*Insulin inhibits AMPK activation in ischemic heart and hypothalamus, whereas it has no effect on AMPK in skeletal muscle or adipocytes. In hypothalamus, AMPK
activity plays a role in regulation of food intake and body weight (see Figure 3).
ing processes, especially anabolic (biosynthetic) pathways. It food intake and substrate flux and metabolism (Figure 1). It
regulates many molecules and pathways in skeletal muscle,achieves these effects both by rapid, direct phosphorylation of
metabolic enzymes and via more long-term effects on gene heart, adipose tissue, liver, pancreatic β cells, and the brain
that control glucose and lipid uptake, storage, and utilizationand protein expression. Some of its overall effects on metabo-
lism are summarized in Figure 1 and target proteins and path- (see Table 1, Supplemental Table 1, and Figure 1) (Hardie et al.,
2003). A major recent advance has been the discovery thatways downstream of AMPK are listed in Table 1 and Supple-
mental Table 1 (which is more extensive with references) and AMPK elicits this regulation in part by responding to hormonal
and nutrient signals.reviewed in Carling (2004), Hardie (2004) and Hardie et al.
(2003). In this article we will focus on recent findings regarding One pathway that is central to the integrated effects of
AMPK in peripheral tissues to reduce the risk for obesity andthe role of AMPK in whole body energy balance.
Obesity results from an imbalance between energy intake insulin resistance is the stimulation of fatty acid oxidation (Fig-
ure 2). AMPK phosphorylates acetyl CoA carboxylase (ACC), aand expenditure. It has long been known that increased adi-
posity is associated with insulin resistance and a markedly rate-controlling step in the conversion of acetyl-CoA to malonyl
CoA. This phosphorylation inhibits the activity of ACC, whichincreased risk of developing type 2 diabetes, but only recently
have data suggested that AMPK may play a role. AMPK affects results in decreased malonyl CoA levels. Malonyl CoA inhibits
carnitine:palmitoyl-CoA transferase-1 (CPT1), a rate-limitingenergy intake, utilization, and storage through regulation of
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F gure 1.6: AMPK is involved in the regulation of whole-body energy home-
ostasis. Changes in AMPK activity lead to changes in energy expenditure and
feeding. AMPK regulates lipid metabolism in skeletal muscle, liver, adipose tissue
and hypothalamus by in ibition of fatty acid synth sis and sti ulatio of fatty
acid oxidati n. AMPK is also thought to timulate lipolysis by phosphorylation
of hormo e sensiti e lipase. In sk letal muscle, AMPK also sti ul tes glucose
uptake and glycolysis. In liver, one of the main functions for AMPK is i hibition
of gluc neogenesis. In hypothalamus, AMPK activation, in addition to activation
of fatty acid oxid ion, stimulates food i take a d increases body weigh gain. It
has also been shown that AMPK activation i sev ral hypothalamic nucl i s ems
to have a rol in hypoglycaemic sen ing. Adapted fro Kahn et al. (2005).
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1.10.3 AMPK regulated expression of key beta cell genes
AMPK is reported to play an important role in beta cell gene regulation. For ex-
ample, one such gene, which is regulated by AMPK, is the hepatic nuclear factor-4
(HNF4), a transcription factor that regulates gene expression in liver, intestine
and pancreas. Mutations in HNF4 cause maturity-onset diabetes of the young 1
(MODY1), an autosomal-dominant form of T2DM (Yamagata et al., 1996). Genes
regulated by HNF4 in beta cells include GLUT2, L-PK (liver type pyruvate ki-
nase) and aldolase B (Leclerc et al., 2001). HNF4 is thought to be a direct target
for AMPK phosphorylation. This results in the reduction of HNF4 protein levels,
which then leads to a significant reduction in mRNA levels of HNF4 regulated
genes (Leclerc et al., 2001). Other genes reported to have an altered expres-
sion in islets overexpressing AMPK are peroxisome proliferator activated receptor
(PPAR) (Ravnskjaer et al., 2006) and pre-proinsulin (PPI ) (da Silva Xavier
et al., 2000), both of whose gene expression were downregulated by AMPK. Acti-
vation of AMPK by AICAR has also been reported to suppress expression of the
preproinsulin gene by decreasing the expression of transcription factor BETA2,
which regulatesinsulin gene transcription (Kim et al., 2008). AMPK phospho-
rylates transcriptional coactivator p300 at serine-89 in vivo and in vitro, which
inhibits the interaction between p300 and transcription factors PPARγ, thyroid-,
retinoic acid- and retinoid X receptors (Yang et al., 2001b). However, the physi-
ological role of the p300 phosphorylation by AMPK is yet unknown.
1.10.4 Role of AMPK in beta cell apoptosis
Chronic exposure of beta cells to elevated glucose concentrations leads to beta
cell apoptosis. Culturing MIN6 cells in low glucose or with AICAR resulted in mi-
tochondrial dysfunction and increased production of ROS, which led to initiation
of mitochondrial apoptotic pathway, suggesting that activation of AMPK might
contribute to beta cell apoptosis (Cai et al., 2007). Similarly, overexpression of
constitutively active AMPK construct (AMPK-CA) in MIN6 beta cells and CD1
mouse islets, or exposure of MIN6 cells to cytokines (TNF-α, interleuking-1β,
interferon-γ) induced beta cell apoptosis (Riboulet-Chavey et al., 2008; Xavier
et al., 2003). However, the cytokine induced apoptosis was prevented by over-
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expression of dominant negative form of AMPK (AMPK-DN) (Riboulet-Chavey
et al., 2008). AMPK probably induces apoptosis via activation of JNK that leads
to caspase-3 release and DNA fragmentation as a JNK inhibitor prevented AICAR
induced apoptosis (Kefas et al., 2003, 2004). However it seems that a short term
activation of AMPK might protect cells agains apoptosis, but a long term acti-
vation might lead to increased apoptosis (Hinke et al., 2007). On the other hand,
Jambal et al. (2003) and Inoki et al. (2003) showed that inhibition of PKB and
mTOR by AMPK leads to inhibition of an anti-apoptotic pathway (Riboulet-
Chavey et al., 2008). Hence, discrepancies exist about the role of AMPK in
regulation of apoptosis and more research is needed to properly assess the role of
AMPK on cell survival and apoptosis.
1.10.5 The controversial role of AMPK in beta cell insulin
secretion
The role of AMPK in insulin secretion has remained controversial and unclear.
In general, some studies have shown that activation of AMPK (expression of con-
stitutively active (CA) AMPK construct, AICAR, metformin, alpha-lipoic acid)
decrease glucose-stimulated insulin secretion, whereas others have shown the op-
posite. On the other hand, similar discrepancies have been shown upon inhibi-
tion of AMPK activity (expression of dominant negative (DN) AMPK construct,
amino acids, compound C). The factors that most likely aﬀect the inconsisten-
cies between the diﬀerent studies are the cell/islet types used, experimental set
up and normalisation of data. Also, the concentration of AICAR that is used to
activate AMPK varies between 200 and 1000 µM, which can possibly aﬀect the
specificity of AICAR acting on AMPK.
The eﬀect of AMPK on insulin secretion also seems to vary depending on glucose
concentration (low vs. high). As AMPK is mainly activated when the cellular AT-
P/AMP ratio is low, one would assume that AMPK is in an inactive state when
glucose concentration is high and insulin secretion is elevated. Indeed, Leclerc
et al. (2004) have shown that high glucose concentration and amino acids such
as leucine, arginine and glycine reduce AMPK activity markedly and that insulin
secretion and AMPK activity are inversely correlated with each other (Leclerc
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et al., 2004). The higher the AMPK activity, the lower the insulin secretion and
vice versa (Leclerc and Rutter, 2004). Therefore, overexpression of CA AMPK
for instance, does not necessarily provide any useful information about AMPK in
relation to insulin secretion in high glucose concentration, as in normal situation
AMPK would not be activated. The results of the studies that have looked at
the role of AMPK in insulin secretion have been summarised in Table 1.1.
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1.10.6 Knowledge from transgenic AMPK animals
Transgenic mouse models of the AMPK pathway have provided some new infor-
mation about the role of this pathway in beta cells, but even these studies have
been inconclusive and controversial. AMPKα2 -global-null mice were not reported
to have any intrinsic beta cell defect, even though they showed impaired glucose
homeostasis and reduced glucose-stimulated insulin secretion in vivo. Deletion
of the AMPK upstream kinase, LKB1, in beta cells (RIPCreLKB1KO, Pdx-
CreLKB1KO) leads to enhanced insulin secretion and improved glucose tolerance
in vivo (Granot et al., 2009; Sun et al., 2010b). In vitro GSIS was normal in the
LKB1 KO islets but beta cell mass, and islet- and beta cell size were increased
and islet architecture altered (Sun et al., 2010b; Xue and Kahn, 2006). The gen-
eral consensus is that AMPK does have a pivotal role in beta cells. Based on the
knowledge from cell culture studies its role includes regulation of gene expression,
beta cell survival and insulin secretion.
1.10.7 AMPK in peripheral tissues
Activation of AMPK in peripheral tissues leads to regulation of metabolic pro-
cesses that improve cellular and whole-body glucose- and lipid homeostasis. Exer-
cise also induces AMPK activation in these tissues (See Figure 1.6). For example,
IL-6, which is produced and released from contracting skeletal muscle, activates
AMPK by raising intracellular cAMP levels and secondly the AMP/ATP ratio
(Kelly et al., 2009). Peripheral AMPK is also activated by two adipocyte derived
hormones, leptin and adiponectin, highlighting a role for AMPK in the regula-
tion of whole-body energy homeostasis (Cool et al., 2006b). The most commonly
used oral anti-diabetic drug metformin is thought improve blood glucose levels
by activation of AMPK in peripheral tissues such as muscle, liver and adipocytes.
1.10.7.1 Skeletal muscle
Muscle glucose uptake constitutes about 80-85 % of the peripheral blood glucose
uptake (DeFronzo, 2004). Insulin receptor signalling stimulates glucose uptake
in the muscle. However, as muscle insulin resistance is often manifest in pre-
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diabetic and diabetic individuals, activation of AMPK in skeletal muscle pro-
vides an alternative way to stimulate glucose uptake into the muscle (Holmes
et al., 1999). This is thought to be achieved by AMPK mediated upregulation
of GLUT4 gene expression and GLUT4 translocation to the plasma membrane
(Kurth-Kraczek et al., 1999; Zheng et al., 2001).
AMPK activity also enhances muscle fatty acid oxidation, directly by phosphory-
lation and inhibition of acetyl-CoA carboxylase (ACC) that catalyses the conver-
sion of acetyl-CoA to malonyl-CoA (Merrill et al., 1997). Inhibition of ACC re-
sults in the reduction in malonyl-CoA, which inhibits the entry of fatty acids into
the mitochondria, facilitated by carnitine:palmitoyl-CoA acyltranserase (CPT I).
Hence, the reduction in malonyl-CoA levels results in the entry of fatty acid
into the mitochondria for β-oxidation (Hardie and Carling, 1997). AMPK also
stimulates muscle β-oxidation indirectly by increasing the mRNA expression of
peroxisome proliferator-activated receptor-α (PPARα) and transcription regulator
peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α), which ac-
tivates expression of genes involved mitochondrial biogenesis such as β-oxidation
(Lee et al., 2006).
AMPK is involved in the regulation of mitochondrial biogenesis but the exact
mechanisms have remained unclear. However, it has been thought to involve di-
rect phosphorylation or increased expression of the transcription regulator PGC-
1α, which induces the expression of genes involved in mitochondrial and lipid
metabolism (Canto´ et al., 2009). Activation of PGC-1α involves its deacetyla-
tion, a process mediated by AMPK and NAD+ -dependent type III deacetylase
(SIRT1). AMPK induces mitochondrial β-oxidation that leads to increased mito-
chondrial NAD+ levels and increased NAD+/NADH ratio, thus inducing SIRT1
activity and deacetylation of PGC-1α (Canto´ et al., 2009). It is also possible
that AMPK- and SIRT1-dependent deacetylation is one mechanism to activate
another transcription regulator FoxO that is also involved in the transcriptional
regulation of energy expenditure (Canto´ et al., 2009). Muscle protein and glyco-
gen synthesis are also inhibited by AMPK. AMPK acts as a negative regulator of
mTOR signalling in skeletal muscle by activation of TSC2, which inhibits mTOR
activity and leads to decreased protein synthesis (Deshmukh et al., 2008; Glea-
son et al., 2007). AMPK also directly phosphorylates glycogen synthase (GS) that
30
leads to the inactivation of GS (Jørgensen et al., 2004; Lage et al., 2008).
1.10.7.2 Liver
The main role for liver in glucose homeostasis is the regulation of hepatic glu-
coneogenesis. Insulin receptor signalling inhibits the gluconeogenic pathway, but
again in insulin resistant state, this is blunted. This usually leads to increased
hepatic glucose output and further increase in blood glucose levels. Activation of
AMPK in liver inhibits gluconeogenesis, independently from insulin, by phos-
phorylation of transducer of regulated CREB (cyclic AMP response element
binding protein) activity 2 (TORC2) (Andreelli et al., 2006). Phosphorylation
of TORC2 prevents its translocation from the cytoplasm to the nucleus where
TORC2 mediates the transcription of gluconeogenic genes phosphoenolpyruvate
carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) (Xue and Kahn,
2006). Hence, activation of AMPK also leads to the inhibition of gluconeogenesis
in liver by downregulating the expression of two gluconeogenic enzymes PEPCK
and glucose-6-phosphatase (Cool et al., 2006b).
Transgenic mouse models of AMPK have also demonstrated the importance of
hepatic AMPK in the regulation of glucose homeostasis. For example, liver spe-
cific AMPKα2KO mice displayed fasted hyperglycaemia and glucose intolerance
and endogenous glucose production in these mice was increased by 50 % (An-
dreelli et al., 2006). On the other hand, short term overexpression of AMPKα2
in mouse liver leads to mild hypoglycaemia in wt mice, and improves blood glu-
cose levels in streptozotocin-induced and ob/ob diabetic mice due to enhanced
suppression of gluconeogenesis (Foretz et al., 2005).
1.10.8 AMPK in the hypothalamus
AMPK has become one of the key regulators of whole-body energy homeosta-
sis. As mentioned earlier, the adipokines leptin and adiponectin that regulate
whole-body energy homeostasis in the hypothalamus, activate AMPK in pe-
ripheral tissues. However, in the hypothalamus, leptin inhibits AMPK activity
(Bjørbaek and Kahn, 2004; Okamoto et al., 2008). Leptin is produced and se-
creted from adipocytes in proportion to adipocyte mass and is a key signalling
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molecule in the hypothalamus in the regulation of energy storage and expendi-
ture and food intake (Obici, 2009). AMPK activity is increased upon fasting in
the hypothalamus, which leads to increased food intake and body weight. Vice
versa, feeding inhibits hypothalamic AMPK activity, leading to a reduction in
food intake and loss in body weight (Xue and Kahn, 2006).
1.10.9 AMPK in the regulation of whole-body energy home-
ostasis
AMPKα1 -global-null and AMPKα2 -global-null mice were created to study the
role of the AMPK catalytic subunits isoforms in whole-body physiology (Viollet
et al., 2003a). Glucose homeostasis was normal in AMPKα1 -global-null mice, and
no other obvious phenotype was observed in these mice. In contrast, AMPKα2 -
global-null mice displayed abnormal glucose homeostasis. In the fed state the
AMPKα2 -global-null mice were hyperglycaemic and hypoinsulinaemic. A glucose
tolerance test showed that the mice were glucose intolerant and glucose-stimulated
insulin secretion (GSIS) was impaired (Viollet et al., 2003a). However, isolated
islets from the AMPKα2 -global-null mice did not show any intrinsic beta cell
defect in glucose- or arginine-stimulated insulin secretion. Additionally, insulin
sensitivity and muscle glycogen synthesis were both reduced, and free fatty acids
were elevated in the AMPKα2 -global-null mice. Urine catecholamine levels in
these mice were increased, which suggested that alterations in the autonomic
nervous system accounts for the defects in glucose handling, insulin sensitivity
and insulin secretion exhibited by these animals (Viollet et al., 2003a,b).
The role of AMPKα2 in hypothalamic AgRP and POMC neurons of the arcuate
nucleus was studied by specific deletion of AMPKα2 in these neurons by cre-
loxP system. AgRPα2KO mice developed an age-dependent lean phenotype,
whereas POMCα2KO mice were obese due to decreased energy expenditure and
increased food intake. Both the AgRPα2KO and POMCα2KO neurons were
unable to respond to changes in extracellular glucose; lack of AMPKα2 prevented
hyperpolarisation in response to reduced glucose concentration. These findings
suggest a key role for AMPK in hypothalamic function and glucose sensing (Claret
et al., 2007) (Figure 1.6).
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1.10.10 AMPK as a drug target
Metformin (N,N -dimethylbiguanide) is a commonly used oral drug that is used in
the treatment of T2DM (Canto´ et al., 2009; Hinke et al., 2007; Rutter and Leclerc,
2008). It mainly works by inhibiting hepatic gluconeogenesis (Hinke et al., 2007;
Viollet et al., 2009). It is thought that many of the beneficial eﬀects of metformin
are achieved in part by activation of AMPK in peripheral tissues (Hinke et al.,
2007). However, early this year Foretz et al. (2010) reported that metformin
inhibits gluconeogenesis independently of LKB1/AMPK pathway. Another oral
T2DM drug rosiglitazone (thiazolidinedione) is an insulin sensitiser that improves
peripheral glucose uptake and has been thought to act partially via activation of
AMPK (Viollet et al., 2009). However, due to increased risk of cardiovascular
complications, rosiglitazone has been withdrawn from the clinical use (Agency,
2010). Yet both metformin and rosiglitazone have also been shown to activate
AMPK in MIN6 beta cells and human or rat islets respectively (Chang et al.,
2009; Viollet et al., 2009). However, whereas activation of AMPK by metformin
inhibited glucose-stimulated insulin secretion, rosiglitazone activated AMPK was
linked to stimulation of insulin secretion (Leclerc et al., 2004). Therefore, it is
unclear whether cellular AMPK activation is actually involved in the treatment
of T2DM. In addition, whether activation of AMPK by the current anti-diabetic
drugs, or potential new drugs that might activate AMPK, are beneficial for beta
cells is still unknown.
1.11 Insulin signaling in pancreatic beta cells
All insulin target tissues contain insulin receptors that initiate insulin receptor
signalling cascades inside the cell, which lead to regulation of multiple cellular
processes from cell growth and survival to cell metabolism. The insulin recep-
tor signalling pathway has been originally described in traditional insulin target
tissues such as liver, muscle and fat. However, insulin also possess an autocrine
eﬀect on beta cells and there is clear evidence that insulin and insulin-like growth
factor pathways regulate beta cell function. I will now describe insulin recep-
tor signalling and its downstream pathways. I will also talk about how insulin
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receptor pathways regulates beta cell function.
1.11.1 Insulin action on insulin secretion
Studies about the role of insulin autocrine eﬀect on beta cells have shown that
insulin modulates insulin gene transcription via insulin receptor-A. However, con-
troversies exist whether insulin negatively or positively regulates insulin secretion
from beta cells (Khan et al., 2001). It has been shown that insulin activates
KATP -channels in rat hypothalamic neurons, single mouse pancreatic beta cells
and islets. This then leads to hyperpolarisation of the plasma membrane, and in
case of beta cells, reduces calcium oscillations, thus inhibiting insulin secretion
(Khan et al., 2001). In both cases, non-selective phosphoinositide 3-kinase (PI3K)
inhibitors wortmannin and LY-294002 prevented insulin induced KATP -channel
activation. Hence, these studies suggested that insulin might have a negative
impact on islet physiology and it is possible that insulin achieves this through
PI3K-dependent pathway (Khan et al., 2001). In contrast, another study has
shown that insulin positively stimulates beta cell insulin secretion by stimulation
of calcium release from intracellular ER calcium stores. Increase in intracellular
calcium stimulates insulin granule exocytosis. It has been shown previously that
IRS-1 is required for insulin stimulated increase in intracellular calcium levels and
subsequent insulin exocytosis (Aspinwall et al., 2000). PI3K was shown to have
a similar role in promoting calcium release from calcium stores and insulin secre-
tion. Beta cells treated with the PI3K inhibitor wortmannin, failed to increase
intracellular calcium levels and insulin exocytosis (Khan et al., 2001). Hence these
results suggest that insulin mediates a positive feedback loop to stimulate intra-
cellular calcium release and insulin exocytosis. This eﬀect seems to be dependent
on IRS-1 and PI3K. However, production of PIP3 by PI3K and possible activation
of PLC-γ that can stimulate opening of IP3-sensitive calcium store, are not in-
volved (Aspinwall et al., 2000). Therefore, discrepancies about the role of insulin
autocrine eﬀect remain to be solved. However, it is clear that insulin signalling
in pancreatic beta cells is important for functional cells.
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1.11.2 The role of insulin receptor in beta cells
Insulin receptor -global-null mice die within days after birth due to ketoacidosis
associated with severe diabetes, thus demonstrating the importance of insulin
receptors in the regulation of whole-body glucose homeostasis (Accili et al., 1996;
Joshi et al., 1996). In contrast, mice that lack insulin or IGF-1 receptor specifi-
cally in pancreatic beta cells (RIPCreIRKO and RIPCreIGF1KO) are viable, but
develop progressive impaired glucose tolerance due to a loss of first-phase insulin
secretion in response to glucose (Kulkarni, 2002). These mice demonstrate the im-
portance of IR and IGF-1 receptor signalling in the regulation of beta cell glucose
homeostasis and insulin secretion. The results also suggest that insulin resistance
within beta cells might lead to the loss of glucose-stimulated insulin secretion
from beta cells (Kulkarni et al., 1999). Studies using the RIPCreIRKO islet also
demonstrated that insulin receptor, not IGF-1 receptor is responsible for high
glucose or insulin induced upregulation of endogenous insulin gene transcription
(Leibiger and Berggren, 2008). This insulin stimulated insulin gene expression is
dependent on PI3K and its downstream target p70S6K (Leibiger et al., 2002). Us-
ing a beta cell line, obtained from RIPCreIRKO mice, it has been possible to
show that glucose is unable to activate PI3K and Akt, and stimulation of mTOR
is reduced in insulin receptor lacking beta cells. Furthermore, glucose induced
anti-apoptotic property is lost in insulin receptor KO beta cells and glucose and
insulin induced GLUT2 expression is diminished (Assmann et al., 2009).
1.11.3 The role of insulin receptor substrates in beta cells
IRS-1 -global-null mice showed growth retardation and are insulin resistant. How-
ever, due to increased insulin secretion and expansion of beta cell mass, these mice
do not progress to develop diabetes (Araki et al., 1994; Tamemoto et al., 1994). In
contrast, IRS-2 -global-null mice displayed marked glucose intolerance, peripheral
insulin resistance and reduced beta cell mass, which eventually led to the devel-
opment of severe diabetes (Withers et al., 1998). Mice with a deletion of IRS-2
in pancreatic beta cells show impaired glucose tolerance and reduced beta cell
mass Cantley et al. (2007); Choudhury et al. (2005). While RIPCreIrs2KO mice
also show reduced fasted blood glucose levels and increased fasted insulin levels,
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PdxCreIrs2KO mice have normal fasted glucose and insulin levels, but display
increased fed glucose levels (Cantley et al., 2007). Interestingly, RIPCreIrs2KO
mice also had a significant hypothalamic phenotype (increased leptin levels, body
weight, food intake) due to a deletion of IRS-2 in insulin expressing hypothalamic
neurons. Hypothalamic phenotype might also explain why the RIPCreIrs2KO
mice were insulin resistance, as altered CNS function can aﬀect whole-body in-
sulin sensitivity Choudhury et al. (2005). Hence, PdxCreIrs2KO mice can be
considered to be a better mouse model for the study of IRS-2 function specifi-
cally in beta cells as PdxCre only deletes in the pancreas. These mice had normal
insulin sensitivity and did not display any hypothalamic phenotype. As men-
tioned above, these mice were glucose intolerant due to a significant reduction in
glucose-stimulated insulin secretion observed in vivo and in vitro. Loss of IRS-2
in beta and alpha cells also resulted in reduced beta cell mass, reduced pancreatic
insulin content and reduced insulin mRNA expression, and beta cell proliferation
was reduced over 50 %. GLUT2 and FoxO1 mRNA expression was also decreased
and IRS-2 KO beta cells displayed reduced glucose-stimulated increase in calcium
uptake. Hence these results suggested that IRS-2 signalling has an essential role
in the maintenance of beta cell mass and regulation of glucose-stimulated insulin
secretion (Cantley et al., 2007).
1.11.4 The role of PI3K in beta cells
Numerous studies have demonstrated the importance of insulin receptor signalling
pathway for functional beta cells. Phosphoinositide 3-kinases (PI3K) are lipid
kinases that generate lipid second messengers called phosphatidylinositols (Pt-
dIns), located on the plasma membrane. Upstream and downstream signalling
molecules of PI3K have been shown to be important in beta cells, especially for
the maintenance of beta cell mass, which involves regulation of cell proliferation,
size and apoptosis. Most of the upstream and downstream molecules of PI3K
pathway have been subjected to targeted gene deletion, and further studies us-
ing siRNA technique in beta cell lines have provided important insight to the
function of these proteins. Stimulation of pancreatic beta cells with glucose leads
to increased insulin secretion, which subsequently leads to activation of beta cell
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insulin receptor signalling pathway, including PI3K (Barker et al., 2002). Glucose
stimulates activation of PI3K, Akt and mTOR in beta cells. Glucose, together
with insulin also stimulates expression of GLUT2 in beta cells. All these actions
of glucose have been suggested to be dependent on PI3K signalling, as PI3K in-
hibitor LY-294002, prevented them.
The exact role for PI3K in beta cells is however not well understood. As the
p110α-global-null and p110β-global-null mice were not viable, and single or dou-
ble heterozygous p110α-global-null and p110β-global-null mice did not show any
obvious phenotype, genetic targeting of PI3K catalytic subunits p110α and p110β
have not provided us any clues about the role of these isoforms in beta cells. Be-
cause both the upstream and downstream eﬀectors of the PI3K pathway have
shown to be important for beta cells, one would expect that the p110α and
p110β isoforms also have important role in this regulation.
Using relatively non-selective PI3K inhibitors wortmannin and LY-294002 that
do not target specific PI3K catalytic isoforms in inhibiting PI3K in beta cells have
suggested that PI3K has a role in stimulating insulin secretion by regulation of
intracellular calcium levels and insulin exocytosis. However, as these inhibitors
also inhibit other kinases downstream of PI3K such as mTOR, the specificity of
the inhibitors towards PI3K in these studies has remained unclear (Al-Qassab
et al., 2009). Therefore, studies that have employed the use of PI3K inhibitors
should be regarded with caution.
The studies employing inhibitors have shown for example that a novel thiazo-
lidinedione, BLX-1002, potentiated insulin secretion at high glucose concentra-
tion, but this eﬀect was blocked by treatment with PI3K inhibitors wortman-
nin and LY-294002 (Zhang et al., 2009). Another thiazolidinedione, rosiglita-
zone (RSG), enhanced insulin secretion and stimulated first- and second phase of
glucose-stimulated insulin secretion, but again this eﬀect was blocked by LY294002,
which prevented stimulation of insulin secretion (Yang et al., 2001a).
Glucagon-like peptide-1 (GLP-1) is an insulinotropic agent that is secreted from
the gut cells. It can stimulate beta cell insulin secretion by binding to the GLP-1
receptors on the surface of beta cells. It also inhibits apoptosis by upregulating
the expression of anti-apoptotic proteins such as Bcl-2 and Bcl-xL. The anti-
apoptotic property of GLP-1 is thought to be achieved via PI3K as treatment
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with the PI3K inhibitor LY-294002, prevented GLP-1 protecting MIN6 cells from
H2O2 induced apoptosis (Hui et al., 2003).
1.11.5 The role of Pdk1 in beta cells
Phosphatidylinositol dependent kinase 1 (Pdk1) is a serine/threonine protein ki-
nase that binds to PIP3 and phosphorylates Akt, thus mediating signals down-
stream from insulin receptor and PI3K. Deletion of Pdk1 in mouse pancreatic
beta cells leads to a progressive hyperglycaemia and reduced plasma insulin lev-
els and finally to death between the ages of 12-24 weeks due to uncontrollable
diabetes (Hashimoto et al., 2006). This is due to reduced beta cell number and
size, as well as reduced islet density. FoxO1 haploinsuﬃciency helped to restore
the blood glucose levels to normal by increasing islet density and beta cell num-
ber, but not the size, by increasing the proliferation of beta cells (Hashimoto
et al., 2006).
1.11.6 The role of Akt in beta cells
Protein kinase B, also known as Akt, is a serine/threonine protein kinase that is a
member of the AGC protein family. Three Akt isoforms exist, each encoded by a
diﬀerent gene (Elghazi et al., 2007). Akt2 is the main isoform involved in the reg-
ulation of glucose homeostasis (Hirsch et al., 2007). In resting cells, Akt is mainly
cytosolic, but upon stimulation and generation of PIP3, Akt is recruited to the
plasma membrane via its interaction with PIP3 where it becomes activated upon
phosphorylation of Thr308 by Pdk1, and on Ser473, probably by TORC2. Acti-
vated Akt is then able to translocate to the nucleus where it phosphorylate its
various downstream targets (Elghazi et al., 2007; Hirsch et al., 2007).
Akt regulates a wide variety of cellular processes and has a critical role in mediat-
ing signals downstream from insulin receptor via PI3K and Pdk1. For example, it
inactivates glycogen synthase kinase-3 (GSK3) by phosphorylation, which relieves
the inhibition on glycogen synthase (GS) and leads to increased glycogen synthe-
sis (Taniguchi et al., 2006). It stimulates glucose uptake by phosphorylation and
inhibition of the Rab-GTPase-activating protein (AS160), which then activates
Rab-GTPases that stimulates translocation of GLUT2 to the plasma membrane
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(Taniguchi et al., 2006). Akt also stimulates protein synthesis by phosphoryla-
tion and inhibition of tuberous sclerosis complex-2 (TSC2), which then leads
to activation of mTOR pathway that results in phosphorylation of p70 riboso-
mal protein S6 kinase (p70 S6K) and eukaryotic translation initiation factor 4E
binding protein-1 (4EBP1) (Taniguchi et al., 2006). Akt has also been shown
to possess anti-apoptotic properties by modulation of FoxO1 and GSK3β activ-
ity, and direct phosphorylation and inhibition of pro-apoptotic enzymes Bad and
Caspase 9 (Elghazi and Bernal-Mizrachi, 2009; Molina et al., 2009).
Mice deficient in Akt2 develop glucose intolerance and insulin resistance, and
some progress to develop diabetes. Mice overexpressing a kinase-dead Akt in
beta cells (RIP-KdAkt) have a defective insulin secretion due to defective exocy-
tosis but surprisingly, the islet morphology and beta cell mass were unchanged
(Elghazi and Bernal-Mizrachi, 2009). On the other hand, transgenic mice that
express a constitutively active Akt in beta cells have increased beta cell mass,
cell proliferation and size, and increased neogenesis (Bernal-Mizrachi et al., 2004;
Tuttle et al., 2001). One might assume that the kinase-dead Akt mice would have
decreased beta cell mass, as expression of constitutively active Akt resulted in in-
creased beta cell mass. The discrepancies could be caused by diﬀerence in genetic
background in mice. However, overexpression of kinase-dead Akt was detected in
80 % of mouse beta cells (Tuttle et al., 2001). Therefore it is also possible that
20 % of the beta cells with residual Akt expression are able to maintain the beta
cell mass within normal limits.
1.11.7 The role of FoxO1 in beta cells
Forkhead trasnscription factor member FoxO regulates transcription of genes in-
volved in cell proliferation, apoptosis, diﬀerentiation and metabolism and is neg-
atively regulated by Akt (Accili and Arden, 2004). Akt phosphorylates FoxO,
which leads to the translocation of FoxO from the nucleus to the cytoplasm
where it is inactivated and labelled for protein degradation (Elghazi and Bernal-
Mizrachi, 2009). In murine islets and cultured beta cells, FoxO1 is the main form
of FoxOs expressed (Kitamura et al., 2002). FoxO1 haploinsuﬃciency rescues
IRS-2 -global-null mice from diabetes and restores beta cell area to about 80 % of
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normal wt levels by increasing beta cell proliferation via increased Pdx1 expres-
sion (Kitamura et al., 2002). Phosphorylation of FoxO1 is regulated by glucose,
but is dependent on plasma membrane depolarization, calcium influx and au-
tocrine eﬀect of insulin receptor signalling through PI3K. Glucose starvation of
MIN6 insulinoma cells results in FoxO1 dephosphorylation and translocation to
the nucleus. Glucose treatment of starved cells leads to rapid phosphorylation
and nuclear exclusion of FoxO1 (Martinez et al., 2006).
1.12 Phosphoinositide 3-kinase
Earlier I discussed the importance of insulin signalling pathway in beta cells.
In the following section, I will give a more general overview of PI3K as it is a
topic of the study described in Chapter 4. Phosphoinositide 3-kinases (PI3K) are
lipid kinases that phosphorylate the position D3 hydroxyl on the inositol ring of
the phosphatidylinositols (PtdIns) (See Figure 1.7). PtdIns consist of a glycerol
that has two fatty acid chains attached at positions one and two, and an inositol
1-phosphate group at position three (Vanhaesebroeck and Alessi, 2000). Phos-
phorylated PtdIns are lipid second messengers that amplify signals downstream
from the cell surface. This leads to triggering of intracellular processes such as
regulation of cell proliferation, survival and growth, membrane traﬃcking, cell
migration and metabolism (Hirsch et al., 2007). PI3Ks are divided into three
classes (PI3K Class I, II and III) depending on the mechanism they are activated
and which PtdIns they phosphorylate. Of the three classes, only class IA and
class II are activated by insulin (Creveaux et al., 2010). The class I PI3Ks are
the best characterised of the three classes. Therefore, I will only concentrate on
the description of the class I PI3K from now on as these are thought to be the
most critical mediators of insulin signalling (See Figure 1.8).
1.12.1 Class IA PI3K
Class I PI3Ks are responsible for the formation of PtdIns 3,4,5-trisphosphate
(PI(3,4,5)P3) by phosphorylation of PtdIns 3,4-bisphosphate (PI(3,4)P2). They
are heterodimers that consist of a catalytic and a regulatory/adaptor subunit.
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Figure 1.7: Structure of PtdIns(4,5)P2 and PtdIns(3,4,5)P3. Class I PI3Ks phos-
phorylate position 3 hydroxyl on the inositol ring of PIP2 to generate PIP3. Pro-
tein phosphatase PTEN can remove the position 3 phosphate from PIP3. Thus
PTEN functions as a negative regulator of PI3K by generation of PIP2 from PIP3.
Adapted from Hirsch et al. (2007).
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Figure 1.8: Class I PI3K subunit composition. Adapted from Vanhaesebroeck
et al. (2005).
Mammals express four class I PI3K catalytic subunit genes: Pik3ca, Pik3cb, Pik3cg
and Pik3cd, although they are generally termed as PI3Kα, β, γ and δ. Pik3ca
and Pik3cb are ubiquitously expressed whereas Pik3cg and Pik3cd are mainly
expressed in leukocytes (Hirsch et al., 2007; Taniguchi et al., 2006). The catalytic
subunits are highly homologous and their molecular mass is approximately 110
kDa, hence they are usually called p110 catalytic subunits. They all contain a
C-terminal kinase domain, and a Ras and a p85 binding domains towards the N-
terminus (Shepherd et al., 1998). The class I PI3Ks are further divided into two
sub-categories: IA and IB. The sub-categories are defined in terms of diﬀerent
adaptor/regulatory subunits that are associated with the catalytic subunits.
The class IA PI3Ks are activated by tyrosine kinase receptors and Ras, and
consists of PI3Kα, β and δ (Hirsch et al., 2007). They bind to highly homologous
p85 family of regulatory subunits that consists of three genes Pik3r1, Pik3r2
and Pik3r3. Due to alternative splicing, Pik3r1 gene encodes for p85α, p55α
and p50α. Pik3r2 encodes for p85β and Pik3r3 for p55γ. p85α and p85β are
ubiquitously expressed whereas p55α and p50α are expressed in fat, muscle, liver
and brain. p55γ is mainly present in the brain (Hirsch et al., 2007). The PI3K
adapter/regulatory proteins all consist of two Src-homology-2 (SH2)-domains, a
P2-domain and a p110-binding domain. The SH2-domains facilitate the binding
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to phosphorylated tyrosine residues in the YXXM motif of the tyrosine receptor,
or receptor associated adaptor proteins such as insulin receptor (IR) and insulin
receptor substrate (IRS) (Hirsch et al., 2007).
1.12.2 Class IB PI3K
PI3Kγ is the only member of the class IB PI3K family. Whereas the class IA
PI3Ks are activated by tyrosine kinase receptors, PI3Kγ is activated when both
the catalytic subunit and the adapter subunit p101 bind to the βγ subunit of
heterotrimeric G protein-coupled receptors (GPCR) (Shepherd et al., 1998). The
adaptor/regulatory proteins p101 and p84/87 also assist in the activation of
PI3Kγ by docking it to the plasma membrane (Hirsch et al., 2007).
1.12.3 PI3K in insulin signalling
Activation of the insulin receptor and subsequent phosphorylation of tyrosine
residues of the insulin receptor substrates (IRS) leads to activation of the class
IA PI3Ks. The p85 adapter/regulatory proteins of PI3K bind to phospho-tyrosine
motifs on IRS proteins via two SH2 domains (Taniguchi et al., 2006). This recruits
the p110 catalytic subunits to close proximity to the plasma membrane where ac-
tivated PI3K phosphorylates PI(3,4)P2, which leads to the formation of a lipid
second messenger PI(3,4,5)P3 i.e. PIP3. Various proteins, such as the serine/thre-
onine kinases of the AGC protein family (Pdk1, PKB/Akt, PKC, p70S6K and
SgK) are recruited and docked to the plasma membrane by binding to PIP3 via
plextrin homology (PH) domain, which then leads to their activation (Taniguchi
et al., 2006). Thus formation of PIP3 leads to activation of numerous downstream
eﬀectors that participate in the regulation of various metabolic processes such as
stimulation of glucose uptake, glycogen and protein synthesis, and inhibition of
gluconeogenesis and lipolysis (Hirsch et al., 2007).
PI3K activity is negatively regulated by two protein phosphatases. Phosphatase
and tensin homologue (PTEN) and SH2-domain containing tyrosine phosphatase-
2 (SHIP2) are protein phosphatases that dephosphorylate PIP3. PTEN removes
phosphates from the 3-position and SHIP2 from the 5-position hydroxyl of the
phosphoinositides, thus leading to inactivation of PIP3 and generation of PIP2
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(Taniguchi et al., 2006).
1.12.4 Transgenic mouse models of PI3K
In order to understand and determine the role of class IA PI3Ks in cellular and
whole-animal physiology, various approaches ranging from PI3Ks inhibitors, mi-
croinjection of antibodies targeting specific subunits of PI3Ks and transgenic
animal models have been used (Foukas and Okkenhaug, 2003). Each of the class
I PI3Ks catalytic subunits and regulatory subunits p85α and p85β have been
subjected to inactivation by gene targeting in transgenic mouse models (Van-
haesebroeck et al., 2005). Surprisingly, most of the transgenic mouse models of
PI3K with a total or tissue specific loss of PI3K subunits have revealed changes
in expression levels and activities in non-targeted subunits in addition to the
targeted one, hence complicating the conclusion that can be drawn from these
studies (Vanhaesebroeck et al., 2005).
It has been shown that p85 adaptor/regulatory subunits are in abundance over
p110 catalytic subunits, and that there might be a cellular pool of free p85 sub-
units available that compete with p85-p110 complexes over the phospho-tyrosine
binding sites. Adaptor/regulatory subunits also have an inhibitory role over p110
catalytic subunits which is relieved upon p85 binding to phospho-tyrosines (Geer-
ing et al., 2007).
1.12.4.1 Targeting of regulatory subunits
Four class I PI3K knock-out mouse models exist that are targeted against the p85
regulatory subunits. The metabolic phenotypes reported are summarised in Table
1.2. In general, pan-p85α-global-null mice (disrupted expression of Pik3r1 gene
products; p85α, p55α and p50α) show perinatal lethality and are hypoglycaemic
and hypoinsulinaemic. They also have reduced p110α and p110β expression lev-
els, and elevated p85β expression levels (Vanhaesebroeck et al., 2005). Heterozy-
gous pan-p85α-global-null mice are viable and display increased glucose tolerance
and increased insulin sensitivity. Mouse embryonic fibroblasts (MEFs) from these
mice have increased PIP3 levels upon IGF-1 stimulation (Vanhaesebroeck et al.,
2005). The other transgenic knock-out mice with a disruption of one of the reg-
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ulatory subunits p85α, p85β or p55α and p50α are also viable (Vanhaesebroeck
et al., 2005). In general, these transgenic mice show increased insulin sensitiv-
ity, hypoglycaemia, increased glucose transport in adipocytes and skeletal muscle
and increased insulin induced PIP3 generation (Aﬀourtit and Brand, 2008; Ter-
auchi et al., 1999). Liver specific p85α KO mice have improved peripheral insulin
sensitivity, which is probably due to increased PIP3 levels and increased insulin-
stimulated Akt phosphorylation, even though PI3K activity is reduced. Reduced
PTEN activity in these mice, probably explains why the PIP3 levels were in-
creased. Hence, p85α functions not only as a regulatory subunit for PI3Ks but
also as a regulator of PTEN activity (Vanhaesebroeck et al., 2005).
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1.12.4.2 Targeting of catalytic subunits
p110α-global-null or p110β-global-null mice die at embryonic stage E10.5 and
E3.5 respectively (Vanhaesebroeck et al., 2005). Interestingly, heterozygous p110α-
global and/or p110β-global knockin (KI) mice were viable (Foukas and Okken-
haug, 2003). Mice heterozygous for a p110α-global knockin (KI) mutation (D933A)
that disrupts the kinase activity are insulin resistant and glucose intolerant. They
are also smaller in size and are hyperleptinaemic and hyperphagic (Foukas et al.,
2006). Mice expressing kinase dead p110β become insulin resistance and glucose
intolerant at 6-months of age which might be linked to changes in Akt phospho-
rylation (Ciraolo et al., 2008).
p110δ-global-null mice are viable and do not display any metabolic phenotype,
but display a complicated immunological phenotype. Similar phenotype is seen
in p110δ kinase-dead animals (Vanhaesebroeck et al., 2005). Deletion of p110γ
results in decreased glucose-stimulated insulin secretion but increased pancreatic
beta cell mass and increased insulin tolerance (MacDonald et al., 2004). These
mice also display altered immunological phenotype.
Inactivation of p110α in mouse endothelial cells leads to embryonic lethality due
to defects in the development of vasculature. In contrast, mice with a deficiency
of p110β or p110δ were viable and fertile, and did not display any vascular ab-
normalities (Graupera et al., 2008).
Conditional knockout of p110β in mouse liver caused impaired glucose home-
ostasis and decreased insulin sensitivity. However, phosphorylation of Akt in
response to insulin and epidermal growth factor (EGF) was almost unchanged,
but cell proliferation was slowed down, implicating that p110β possesses a kinase-
independent role upon insulin stimulus that is involved in cell proliferation (Jia
et al., 2008). The metabolic phenotypes reported are summarised in Table 1.3.
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1.12.5 Isoform specific diﬀerences in insulin receptor sig-
nalling in diﬀerent tissues
Several studies have looked at the isoform specific roles for the class IA PI3K
catalytic isoforms in tyrosine kinase receptor signalling and shown that in most
tissues, p110α is the dominant PI3K isoform and p110β is the main PI3K iso-
form in inducing signals downstream of GPCR. It has also been shown that p110α
is the main PI3K isoform that is recruited to insulin stimulated IRS-1/2 com-
plexes, and that p110β lipid kinase activity is not present in these complexes
(Foukas et al., 2006; Guillermet-Guibert et al., 2008; Hooshmand-Rad et al.,
2000). For example, in endothelial cells, p110α is the main PI3K isoform in
mediating signals downstream from tyrosine kinase receptors such as vascular en-
dothelial growth factor (VEGF) whereas p110β activity is concentrated on GPCR
(Graupera et al., 2008). Inhibition of p110β and p110γ in bone marrow derived
macrophages (BMMs) did not prevent tyrosine kinase induced phosphorylation
of Akt and Erk. However, the GPCR agonist complement 5a (C5a) stimulated
Akt phosphorylation was abolished upon p110β or p110γ inhibition. These re-
sults further confirm that p110β and p110γ isoforms are not the main signalling
molecules downstream form tyrosine kinase receptors, but are coupled to the
GPCR (Guillermet-Guibert et al., 2008).
Studies that have used isoform specific inhibitors of p110α (PIK-75, PIK-90),
p110β (TGX-115, TGX-286) and p110γ (IC87114, PIK-23), have also shown
that p110α is the predominant PI3K isoform in two insulin responsive cell types,
3T3-L1 adipocytes and L6 myotubes (Knight et al., 2006). Insulin stimulated
glucose uptake and phosphorylation of Akt, p70S6K and rpS6 were blocked by
p110α inhibitors, but not with p110β or p110γ inhibitors. Insulin stimulated de-
cline in blood glucose levels in vivo was also prevented by p110α inhibitors, as
assessed by an insulin tolerance test in mice. No eﬀect on blood glucose levels
was observed in mice treated with p110β inhibitors (Knight et al., 2006).
On the contrary, we have previously shown in mouse POMC and AgRP neu-
rons that in the arcuate nucleus, p110β isoform has a more dominant role over
p110α in the regulation of energy homeostasis. Mice with an inactivation of p110β
in POMC neurons were hyperphagic, hyperleptineamic and had increased adi-
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posity on normal chow and increased sensitivity to high-fat feeding (Al-Qassab
et al., 2009). Electrical activity in response to insulin or leptin was blunted in
POMCp110βKO neurons. In contrast, POMCp110αKO mice had a relatively nor-
mal body weight phenotype during chow diet, but did display hyperleptinaemia
and increased adiposity on a HFD. However, insulin stimulated hyperpolarisa-
tion of POMC neurons was also prevented in p110α deficient neurons (Al-Qassab
et al., 2009). Mice with an inactivation of p110β in AgRP neurons developed an
age-dependent lean phenotype and were resistant to obesity induced by hight-fat
feeding (Al-Qassab et al., 2009). Overall, it seems that in hypothalamic insulin
signalling, p110β is the dominant PI3K isoform and in peripheral tissues p110α
is responsible for mediating insulin receptor signalling.
1.13 General insulin receptor signalling
1.13.1 Insulin receptor
All insulin target tissues contain insulin receptors that initiate insulin signalling
cascades inside the cell, which lead to regulation of multiple cellular processes
from cell growth and survival to cell metabolism (See Figure 1.9). There are
two types of insulin receptors: insulin receptor type A (IR-A) and insulin re-
ceptor type B (IR-B). At high concentrations, insulin also binds to insulin-like
growth factor-1 receptor (IGF-1) (Taniguchi et al., 2006). In order to function,
insulin receptors form dimers with each others and as each receptor can func-
tion as homoreceptors (IR-A, IR-B and IGF-1) and hybrid-receptors (IR-A/IR-
B, IR-A/IGF-1, IR-B/IGF-1), the insulin receptors can form six diﬀerent type of
combinations of functional receptor pairs (Leibiger and Berggren, 2008). Insulin
receptors are tetrameric proteins that contain two extracellular, insulin binding α-
subunits and two intracellular β-subunits that are linked together by disulphide-
bonds (DeFronzo, 2004). Insulin binds to insulin and IGF-1 receptors (IR) and
stimulates intrinsic tyrosine kinase function that leads to autophosphorylation of
tyrosine residues within the receptor (Taniguchi et al., 2006). Receptor associ-
ated adapter proteins, such as insulin receptor substrates (IRS), Gab-1 and Shc,
bind to phosphorylated tyrosine residues on the receptors, and are subsequently
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tyrosine phosphorylated by the receptors (Leibiger and Berggren, 2008). Phos-
phorylated adapter proteins then facilitate downstream signalling cascade from
the receptor, leading to activation of PI3K/AKt and MAPK pathways (DeFronzo,
2004; Morris et al., 2009).
1.13.2 Insulin receptor substrates
There are six insulin receptor substrate (IRS) isoforms, termed IRS-1 to 6 (Taniguchi
et al., 2006). IRS-1 and IRS-2 are the most widely expressed, including the insulin
target tissues. The N-terminus of IRS proteins contains both plextrin homology
(PH) domain and phosphotyrosine-binding (PTB) domain that are needed for the
high aﬃnity association with the insulin receptor (Taniguchi et al., 2006). Mul-
tiple tyrosine phosphorylation sites are located in the middle and C-terminus
of the proteins that are phosphorylated by the receptor, and can be bound by
Src-homology-2-domain (SH2) containing proteins such as p85-regulatory protein
of phosphoinositide 3-kinase (PI3K) and son-of-sevenless (SOS) associated adap-
tor protein Grb2 that leads to the activation of PI3K and Ras-MAPK pathways
respectively (Taniguchi et al., 2006).
1.13.3 Insulin signalling via MAPK pathway
Mitogen-activated protein kinase (MAPK) signals downstream of insulin recep-
tors. Two receptor associated adaptor proteins Grb2 and Shc bind to tyrosine-
phosphorylated IRS-1 and IRS-2 molecules that are associated with insulin ac-
tivated receptor. This signalling cascade leads to activation of MAPK-pathway,
which stimulates gene expression of a range of transcription factors that stimulate
cell growth, diﬀerentiation and proliferation (DeFronzo, 2004).
1.14 Summary and aims of investigation
1.14.1 Rationale for study: AMPK
Understanding the mechanisms regulating whole-body glucose homeostasis is im-
portant in order to understand what happens in a disease state such as T2DM.
51
p85IRSIRS
p110 PIP3 Pdk1
PIP3
Akt
AS160
GLUT4
Glucose
Glucose
uptake
Rab
GTPase
P
AS160
P
FoXO1
FoXO1
FoXO1
P
mTOR
Rheb Raptor
TSC1/2
TSC1/2
P
PKC
Insulin
Insulin receptor
S6K
S6
4EBP1
EIF4E
Protein synthesis
Growth
GSK3
GS
GSK3
P
Glycogen
synthesis
P
P P
Cell proliferation
Figure 1.9: Insulin receptor signalling network. Insulin binding to insulin receptor
activates the receptor, which leads to recruitment of an insulin receptor substrate
(IRS) docking protein to the receptor and phosphorylation of IRS. Phosphory-
lated IRS recruits regulatory protein p85 subunit and catalytic p110 subunit of
PI3K near the plasma membrane and activation of the PI3K pathway. PI3K
stimulates production of PtdIns(3,4,5)P3 (PIP3). Serine/threonine kinases of the
AGC protein family such as Pdk1, Akt, and PKC are recruited and docked to
the plasma membrane by binding to PIP3 via plextrin homology (PH) domain,
which then leads to their activation. Activation of Akt by phosphorylation by
Pdk1 leads to regulation and activation of multiple cellular processes such as
protein and glycogen synthesis, cell proliferation, growth and metabolism. Acti-
vation of Akt as well as PKC also leads to stimulation of glucose uptake. Adapted
from Hirsch et al. (2007) and Taniguchi et al. (2006).
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Pancreatic beta cells play a central part in the regulation of glucose homeostasis.
It is eventually the beta cell dysfunction and subsequent failure that leads to the
development of type 2 diabetes. Tight control of beta cell metabolic coupling and
production of ATP, as well as insulin receptor signalling pathway are all essential
for functional beta cells and regulation of glucose-stimulated insulin secretion.
AMPK functions as a cellular energy regulator and its activity is linked to changes
in cellular ATP/AMP ratio. Therefore, it seems obvious that it could have a key
role in the regulation of beta cell function and insulin secretion. The role of
AMPK in pancreatic beta cells has been of great interest for several years. How-
ever, despite the numerous studies conducted over the years, no clear conclusion
has been made yet, and discrepancies between studies exists, especially about
the role of AMPK in the regulation of insulin secretion. Anti-diabetic drugs met-
formin and rosiglitazone are thought to activate AMPK in peripheral tissues that
leads to a reduction in blood glucose levels. Whether activation of AMPK in beta
cells by these or new drugs is beneficial is still unclear. Because AMPK is a known
drug target for the treatment of T2DM, it is important to understand the cellu-
lar function of AMPK in beta cells and how this translates to the regulation of
whole-body glucose homeostasis. This could also aid in the development of a new
generation of drugs that are more specific and with less side-eﬀects. Even though
the AMPKα2 -global-null mice had impaired glucose homeostasis and reduced in
vivo GSIS, surprisingly no intrinsic beta cell defect was found and defective GSIS
was argued to be caused by increased catecholamine levels. No other transgenic
mouse model exists that would have studied the in vivo role of AMPK in beta
cells. Thus it would be of great benefit to conduct an extensive study about the
role of AMPK in the beta cell by means of a transgenic approach.
1.14.2 Hypothesis and experimental plan
Bases on previous studies, I propose the following hypothesis: AMPK in pan-
creatic beta cells is central for the maintenance of normal whole-body glucose
homeostasis by regulation of insulin secretion from the beta cells. To determine
the specific role of AMPK in beta cell function, transgenic mice will be gener-
ated, employing the cre-loxP system. Firstly, to study the role of AMPKα2 in
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beta cells, RIPCreα2KO mice are created, in which floxed AMPKα2 catalytic
subunit (Prkaa2 ) is deleted by recombination with Cre-recombinase, expressed
from rat insulin promoter (RIP). Expression of cre from rat insulin promoter oc-
curs only in pancreatic beta cells and in a population of hypothalamic neurons.
To combine the deletion of AMPKα2 with a deletion of AMPKα1 (Prkaa1 )
in beta cells, RIPCreα2KO mice are crossed with AMPKα1 -global-null mice to
create α1KORIPCreα2KO mice.
1.14.3 Rationale for study: PI3K
Class I PI3Ks have been shown to have a central role in insulin receptor signalling.
All viable transgenic mouse models of class IA PI3K regulatory or catalytic sub-
units have highlighted an important role for PI3K in the regulation of glucose
homeostasis. Recent studies have implicated diﬀerential roles for class IA cat-
alytic subunit isoforms p110α and p110β. In peripheral tissues, p110α has been
shown to be the dominant isoform in insulin receptor signalling (Foukas et al.,
2006). On the other hand, we have shown previously that p110β has a more im-
portant role in regulation of whole-body energy homeostasis in POMC and AgRP
neurons and insulin- and leptin receptor signalling (Al-Qassab et al., 2009). All
viable transgenic mouse models of class IA PI3K regulatory or catalytic subunits
have highlighted an important role for PI3K in the regulation of glucose home-
ostasis. However, no previous studies exist that have directly studied the catalytic
subunits of class IA PI3K isoforms specifically in pancreatic beta cells. Current
studies have involved using relatively non-selective inhibitors such as wortman-
nin and LY-294002. Results from these studies have provided indications that
inhibition of PI3K in beta cells results in alterations in glucose-stimulated insulin
secretion, KATP -channel activity and intracellular calcium signalling (Aspinwall
et al., 2000; Khan et al., 2001). However, the results have been controversial and
inconclusive. Beta cell specific roles of upstream and downstream molecules of
the PI3K pathway, such as insulin receptor, IRS, Pdk1 and Akt have provided
invaluable information about the role of the insulin receptor signalling pathway
in the regulation of beta cell function. In general, these studies have shown that
loss of these molecules leads to a diabetes-like phenotype at the whole-animal
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level, which usually results in reduced beta cell mass, change in islet morphology
or alteration in glucose sensing and stimulation of glucose uptake and metabolism
(Bernal-Mizrachi et al., 2004; Cantley et al., 2007; Hashimoto et al., 2006; Tuttle
et al., 2001). However, the role of PI3K catalytic isoforms in beta cells remains
unknown. In the light of the previous studies, it would be likely to expect a sig-
nificant role for the PI3K in the regulation of glucose homeostasis and insulin
secretion.
1.14.4 Hypothesis and experimental plan
Bases on previous studies, I propose the following hypothesis: PI3K in pancreatic
beta cells and insulin expressing hypothalamic neurons is essential for the main-
tenance of normal whole-body energy- and glucose homeostasis. To determine the
specific role of PI3K in beta cells and RIPCre expressing neurons, transgenic mice
will be generated by the cre-loxP system. RIPCrep110αβKO mice are created,
in which floxed p110α and floxed p110β catalytic subunits are both deleted by
recombination with cre-recombinase, expressed from rat insulin promoter (RIP).
Expression from rat insulin promoter occurs only in pancreatic beta cells and in
a population of hypothalamic neurons.
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Chapter 2
Materials and Methods
2.1 Animals
All animal procedures were approved by the British Home Oﬃce Animals Sci-
entific Procedures Act 1986 (Project License no. 0971) and UCL Animal Users
Ethics Committee. Animals were maintained at 20-23◦C with 12 hour light-dark
cycle, with ad libitum access to standard mouse chow (RM1 diet SDS UK Ltd)
and water. Mice had free access to water during all the studies. Animals were
tail tipped for genotyping purpose at 15 days of age using ethyl chloride as local
anaesthesia. At 21 days of age mice were weaned and housed with the same sex
with a maximum of 8 mice per cage.
2.1.1 RIPCre mice
The RIPCre mice, which express cre-recombinase driven by the Rat Insulin
2 promoter (Postic et al., 1999) were obtained from the Jackson laboratory
(http://www.jax.org/).
RIPCre specific expression occurs in pancreatic beta cells and in RIPCre express-
ing population of hypothalamic neurons.
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2.1.2 AMPKα2flox mice
AMPKα2flox were obtained from Dr. Benoit Viollet (Institut Cochin, Universite´
Rene´ Descartes, Paris) and were generated using conditional gene targetting of
Prkaa2 gene (Jørgensen et al., 2004). These mice were maintained on a mixed
129Sv x C57BL/6 genetic background.
2.1.3 AMPKα1 -global-null mice
AMPKα1 -global-null mice (Prkaa1 ) were obtained from Dr. Benoit Viollet (In-
stitut Cochin, Universite´ Rene´ Descartes, Paris) and were generated using condi-
tional gene targetting (Jørgensen et al., 2004). These mice were maintained on
a mixed 129Sv x C57BL/6 genetic background.
2.1.4 Generation ofRIPCreα2KO and α1KORIPCreα2KO
mice
RIPCreAMPKα2KO mice were generated, named as RIPCreα2KO, to study the
role of AMPKα2 specifically in pancreatic beta cells, and also in RIP express-
ing neurons. Briefly, RIPCre transgenic mice were crossed with the AMPKα2flox
mice to generate heterozygous RIPCreα2flox mice. The heterozygous mice (Cre+
flox+/−) were intercrossed to generate RIPCreα2KO (Cre+ flox+/+) and rele-
vant control mice of all genotypic combinations. The same breeding cycle was per-
formed to obtain α1KORIPCreAMPKα2KO mice, named as α1KORIPCreα2KO,
by starting with homozygous mice for RIPCreα2flox crossed with
AMPKα1 -global-null mice. Hence, two transgenic AMPK KO mouse lines were
generated: RIPCreα2KO, lacking AMPKα2 in RIPCre expressing cells (beta
cells and a population of hypothalamic neurons ) and α1KORIPCreα2KO, lack-
ing AMPKα1 globally and AMPKα2 in RIP Cre expressing cells.
The oﬃcial gene names for AMPKα1 and AMPKα2 are Prkaa1 and Prkaa2
respectively. However, AMPKα1 and AMPKα2 are commonly used instead of
the oﬃcial gene names. Therefore, I will be using AMPKα1 and AMPKα2
through out in this thesis.
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2.1.5 P110αflox mice
P110αflox mice were generated in the laboratory of Professor Vanhaesebroeck
(Institute of Cancer, Queen Mary, University of London) using conditional gene
targeting of the Pik3ca gene (Graupera et al., 2008). Cre-mediated recombina-
tion of floxed p110α results in a kinase-dead p110α protein without changing
the stoichiometry of PI3Kp110α and p85 signalling complexes (Al-Qassab et al.,
2009). The mice were maintained on a mixed 129Sv x C57BL/6 genetic back-
ground.
2.1.6 P110βflox mice
P110βflox mice were generated in the laboratory of Professor Vanhaesebroeck (In-
stitute of Cancer, Queen Mary, University of London) using conditional gene tar-
geting of the Pik3cb gene (Guillermet-Guibert et al., 2008). Cre-mediated recom-
bination of floxed p110β results in a kinase-dead p110β protein without changing
the stoichiometry of PI3Kp110β and p85 signalling complexes (Al-Qassab et al.,
2009). The mice were maintained on a mixed 129Sv x C57BL/6 genetic back-
ground.
2.1.7 Generation of RIPCrep110αβKO mice
RIPCrep110αβKO mice were generated to study the role of PI3K signalling
specifically in pancreatic beta cells and RIP expressing neurons. Briefly, mice
homozygous for p110αflox and mice homozygous for p110βflox were crossed
together to generate mice heterozygous for loxP sites at both alleles. These
p110αflox+/− p110βflox+/− mice were crossed with RIPCre transgenic mice. The
resulting RIPCrep110αflox+/− p110βflox+/− oﬀspring were subsequently mated
with p110αflox+/− p110βflox+/− mice to generate RIPCrep110αβKO mice and
relevant control mice of all genotypic combinations.
The oﬃcial gene names for p110α and p110β are Pik3ca and Pik3cb respec-
tively. However, p110α and p110β are commonly used instead of the oﬃcial gene
names. Therefore, I will be using p110α and p110β through out in this thesis.
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2.2 Genotyping of mice
2.2.1 DNA extraction
Animals were tail tipped for genotyping purpose at 15 days of age using ethyl
chloride as local anaesthesia, and DNA extracted from these tail tips. Each tail
tip was put in a 1.5 ml eppendorf tube and boiled in 600 µl of 0.1 mol/L NaOH
for 10 minutes and allowed to cool down for 10 minutes at room temperature.
100 µl of 1 mol/L Tris (pH 6.8) was then added to each tail sample.
2.2.2 Determination of genotype using PCR
For the determination of mouse genotype 1-3 µl of DNA extract, depending on
the gene of interest, was used per polymerase chain reaction (PCR) in a 96-well
plate. Two types of PCR master mix was used, depending on PCR cycle: 1X
Reddy Mix (Thermo Scientific # AB-00575/LD/B) and 2X Goldstar Red Master
Mix (Eurogentec # PK-0064-02R). All primers are oligo primers from Eurogen-
tec. PCR products were resolved with 2-3 % agarose gel electrophoresis in TAE
buﬀer (See Appendix A - Solutions), and visualised by UV excited fluorescence
of ethidium bromide stained DNA (1 in 50,000 dilution).
2.2.3 RIPCre genotyping
RIPCre genotyping was performed to determine whether the mice were expressing
Cre by using a set of four primers. One pair was used to amplify a promoter
specific 550 bp sequence (Cre present): RIPCre Forward (RIP3) 5￿ CTC TGG
CCA TCT GCT GAT CC 3￿ and RIPCre Reverse (Cre 102) 5￿ CGC CGC ATA
ACC AGT GAA AC 3￿. The second pair was used to amplify the interleukin-2
(IL2 ) gene 100 bp sequence, as an internal control: IL2 Forward 5￿ CTA GGC
CAC AGA ATT GAA AGA TCT 3￿ and IL2 Reverse 5￿ GTA GGT GGA AAT
TCT AGC ATC ATC C 3￿. See Figure 2.1 for RIPCre PCR cycle and reaction.
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RIPCre PCR reaction
Reddy mix 10 μl
Rip3 primer 0.6 μl
Cre 102 primer 0.6μl
IL2 primers 0.4 μl
DNA template 1.2 μl
RIPCre PCR cycle
94 ℃ for 2 minutes
94 ℃ for 1 minutes
60 ℃ for 30 seconds
72 ℃ for 30 seconds
72 ℃ for 7 minutes
X 39
Figure 2.1: RIPCre PCR reaction
2.2.4 AMPKα2flox genotyping
AMPKα2 genotyping was performed to determine whether the mice were wild
type, heterozygous or homozygous for the targeted allele. Genotyping was per-
formed using the following two primers α2flox-F 5￿ GCT TAG CAC GTT ACC
CTG GAT GG 3￿ and α2flox-R 5￿ GTT ATC AGC CCA ACT AAT TAC AC 3￿.
A 250 bp homozygous band is amplified if the locus is targeted with loxP sites
and a 200 bp wild type band if untargeted. If a mouse is a heterozygous for the
floxed AMPKα2 both a 250 bp and a 200 bp bands are detected. See Figure 2.2
for AMPKα2 PCR cycle and reaction.
AMPKα2 PCR reaction
Reddy mix 10 μl
a2floxR primer 0.6 μl
a2floxF primer 0.6μl
DNA template 2.0 μl
AMPKα2 PCR cycle
94 ℃ for 4 minutes
94 ℃ for 20 seconds
52 ℃ for 20 seconds
72 ℃ for 30 seconds
72 ℃ for 7 minutes
X 29
Figure 2.2: AMPKα2 PCR reaction
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2.2.5 AMPKα1 genotyping
Two individual PCR reactions were required to determine if mice were wild type,
heterozygous or homozygous for global deletion of AMPKα1.
To detect the presence of a wild type AMPKα1 allele, the following primers
were used: AMPKα1wtF 5￿ A GCC GAC TTT GGT AAG GAT 3￿ and
AMPKα1wtR 5￿ CC CAC TTT CCA TTT TCT CCA 3￿. The generation of a
500bp indicated the presence of a wild type allele.
To detect the deletion of an AMPKα1 allele, the following primers were used:
AMPKα1IRESFa 5￿ GGG CTG CAG GAA TTC GAT ACA AGC 3￿ and
AMPKα13.0Ra 5￿ CC TTC CTG AAA TGA CTT CTG TGC 3￿. The amplifica-
tion of a 300bp indicated deletion of AMPKα1 allele. If a mouse is a heterozygous
for the AMPKα1 both a 300 bp and a 500 bp bands are detected. See Figure 2.3
for AMPKα1 PCR cycle and reaction.
AMPKα1 wt PCR reaction
Gold mix (2X) 12.5 μl
ddH2O 7.5 μl
MgCl2 (25 mmol/l) 1.5 μl
AMPKa1wtF primers 0.75 μl
AMPKa1wtR primers 0.75 μl
DNA template 2.5 μl
AMPKα1 wt PCR cycle
94 ℃ for 4 minutes
94 ℃ for 30 seconds
58 ℃ for 40 seconds
72 ℃ for 90 seconds
72 ℃ for 7 minute
X 30
AMPKα1 null PCR reaction
Gold mix (2X) 12.5 μl
ddH2O 7.5 μl
MgCl2 (25 mmol/l) 1.5 μl
AMPKa1ResFa primers 0.75 μl
AMPKa13.0Ra primers 0.75 μl
DNA template 2.5 μl
AMPKα1 null PCR cycle
94 ℃ for 4 minutes
94 ℃ for 30 seconds
58 ℃ for 40 seconds
72 ℃ for 90 seconds
72 ℃ for 7 minute
X 30
Figure 2.3: AMPKα1 PCR reaction
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2.2.6 P110αflox genotyping
P110αflox genotyping was performed to determine whether the mice were wild
type, heterozygous or homozygous for the targeted allele. Genotyping was per-
formed using the following two primers: FE1 5￿ GGA TGC GGT CTT TAT
TGT C 3￿ and FE5 5￿ GCA TGC TGC CGA ATT 3￿. This resulted in a 718 bp
product for the wild-type allele and/or a 782 bp product for the p110αflox allele.
See Figure 2.4 for P110αflox PCR cycle and reaction.
P110αflox PCR reaction
Gold mix (2X) 12.5 μl
ddH2O 7.5 μl
MgCl2 (25 mmol/l) 1.5 μl
FE1 primers 0.75 μl
FE1 primers 0.75 μl
DNA template 2.5 μl
P110αflox PCR cycle
94 ℃ for 3 minutes
94 ℃ for 30 seconds
59 ℃ for 30 seconds
72 ℃ for 1 minute
72 ℃ for 1 minute
X 30
Figure 2.4: P110αflox PCR reaction
2.2.7 P110βflox genotyping
P110βflox genotyping was performed to determine whether the mice were wild
type, heterozygous or homozygous for the targeted allele. Genotyping was per-
formed using the following two primers: B3 5￿ AGT GAA CGC TAT GCA TCA
CAC CAG C 3￿ and B98 5￿ AAG TAC AAA CAT CCA AGC AA 3￿. This
resulted in a 304 bp product for the wild-type allele and/or a 372 bp product for
the p110βflox allele. See Figure 2.5 for P110βflox PCR cycle and reaction.
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P110βflox PCR reaction
Gold mix (2X) 12.5 μl
ddH2O 7.5 μl
MgCl2 (25 mmol/l) 1.5 μl
B3 primers 0.75 μl
B98 primers 0.75 μl
DNA template 2.5 μl
P110βflox PCR cycle
94 ℃ for 3 minutes
94 ℃ for 30 seconds
59 ℃ for 30 seconds
72 ℃ for 1 minute
72 ℃ for 1 minute
X 30
Figure 2.5: P110βflox PCR reaction
2.3 Analysis of tissue specific gene deletion by
PCR
To confirm the tissue specificity of the cre recombinase and to ensure that the
recombination of floxed alleles occurs in the correct tissues, a tissue specific gene
deletion by PCR was performed. Briefly, DNA was extracted from islets, hy-
pothalamus, cortex, liver, muscle and fat and PCR performed using a set of
primers that amplify a region of DNA when two loxP sites are joined together
after a recombination event catalysed by Cre recombinase.
2.3.1 DNA extraction of tissues
A snap frozen tissue weighing approximately 100 mg was homogenized with a
motorised probe in a 2 ml sterilin tube with 500 µl of tissue extraction buﬀer (See
Appendix A - Solutions). The homogenate was removed to a 1.5 ml eppendorf
tube and 700 µl of chloroform:isoamylalcohol (24:1) added. The sample was
allowed to mix for 2 hours at 4 ◦C by shaking, after which it was centrifuged at
10,000 RPM for 10 minutes at 4 ◦C. The upper aqueous layer was removed to a
new 1.5 ml eppendorf tube and 700 µl of isopropanol added and the sample mixed
by gently inverting the tube. DNA was pelleted by centrifugation at 10,000 RPM
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for 10 minutes at 4 ◦C. The pellet was washed with 300 µl of 70 % ethanol, air
dried and resuspended in 50 µl of nuclease-free H2O overnight at 4 ◦C.
Islet DNA extraction was performed by re-suspending a snap frozen islet pellet
in 150 µl of 0.1 mol/L NaOH and boiling the sample for 10 min at 100 ◦C. The
sample was then cooled down for 10 minutes at room temperature and 25 µl of 1
mol/L Tris (pH 6.8) added.
2.3.2 Detection of AMPKα2 deletion
AMPKα2 deletion was identified using the following primers: AMPKfloxF1 5￿
GCT TAG CAC GTT ACC CTG GAT GG 3￿ and AMPKneoR 5￿ GCA TTG
AAC CAC AGT CCT TCC TC 3￿. The amplification of a 974 bp band indicated
that recombination had occurred between the loxP sites, resulting in tissue spe-
cific inactivation of AMPKα2. See Figure 2.6 for AMPKα2 deletion PCR cycle
and reaction.
AMPKα2 deletion
 PCR reaction
Reddy mix 10 μl
a2delR primer 0.75 μl
a2delF primer 0.75μl
IL2 primers 0.25μl
DNA template 2.0 μl
AMPKα2 deletion
PCR cycle
94 ℃ for 4 minutes
94 ℃ for 30 seconds
56 ℃ for 40 seconds
72 ℃ for 50 seconds
72 ℃ for 7 minutes
X 40
Figure 2.6: AMPKα2 deletion PCR reaction
2.4 In vivo physiological studies
2.4.1 Determination of body weights
Mice body weights were measured with Sartorius BP60 balance during early light
phase between 9 am and 11 am.
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2.4.2 Determination of body length
Post-mortem body lengths (naso-anal) were measured in cm with a standard
ruler.
2.4.3 Determination of body composition
Dual-energy X-ray absorptiometry (DEXA) scanning was used to determine the
body composition of mice studied. Mice were culled using a CO2 chamber and
their body composition determined using a PIXImus DEXA scanner (Lunar, GE
Healthcare, USA), designed for scanning small rodents. A mouse is placed on
a luminescent panel and exposed to high and low energy X-rays and radiation
hitting the luminescent panel is measured with a CCD (charged coupled device)
camera. Bone mineral density (g/cm2), bone mineral content (g), lean tissue mass
(g), fat tissue mass (g) and body fat (%) are then determined depending on the
ability of diﬀerent tissue types to absorb and reflect X-rays.
2.4.4 Feeding studies
2.4.5 Analysis of food intake
Mice were singly caged and allowed to acclimatise for a week before starting
the food intake experiment. A pre-weighed amount of standard chow (≈ 100 g)
was given to each mouse and ad libitum feeding allowed. Food intake and body
weights were measured daily during early light phase (9 am-11 am) for a duration
of seven days using a Sartorius BP60 balance.
2.4.6 Response to fasting
Singly caged mice were fasted overnight for 16-hrs with free access to water. Next
morning a pre-weighed amount of chow (≈100 g) was given to each mouse during
early light phase (≈ 9 am). Food was then measured 1 hr, 2 hrs, 4 hrs, 8 hrs and
24 hrs after re-feeding using a Sartorius BP60 balance.
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2.4.7 Response to peripheral MT-II treatment
Mice were singly caged for two weeks before starting the study. They were sham
injected with 100 µl of saline each morning at 9 am for a week before the study.
Food was removed from the cages and mice were fasted overnight for 16-hr the
night before starting the study. Next morning mice were given an i.p. injection
of either 100 µl of vehicle (saline) or 100 µl of MT-II (Bachem, # H-3902) (0.5
µg/µl in PBS) and then a pre-weighed amount of food was given to each mouse.
Food was then measured 1 hr, 2 hr, 4 hr, 8 hr and 24 hr post-injection using a
Sartorius BP60 balance. After a week of recovery the study was repeated in a
cross-over fashion i.e. the mice that were given MT-II injection on the first week
were now given vehicle injection and vice versa.
2.4.8 Response to peripheral leptin treatment
Mice were singly caged before starting the study. They were sham injected daily
with 100 µl of saline at around 6 pm for three days before the start of the study.
To check that mice were not stressed and were eating normally, daily food intake
and body weight were measured at the same time with sham injections. Leptin
(recombinant mouse leptin 5mg, R&D Systems, # 498-OB) was reconstituted in
HCL/NaOH (See Appendix A - Solutions) as 1.85 mg/ml. Leptin concentration
used for i.p. injection was 5 µg/g (≈100 µl volume). Vehicle (saline) was injected
in 100 µl volume (i.p.).
The study was carried out as follows. Animals were weighed and controls and
KOs were randomly divided into two treatment groups (vehicle and leptin). Mice
were injected with leptin or vehicle at 6 pm (late light phase) and a pre-weighed
amount of food (≈ 50 g) was added to each cage. The following day, food and
body weight were measured at 9 am, and the mice were injected with leptin or
vehicle (as before) at 6 pm. The following day, food and body weight were again
measured at 9 am, and mice received their final injection of leptin or vehicle (as
before) at 6 pm. On the final day, food and body weight were measured at 9 am.
This study was done using a cross-over design, meaning that both control and
KO groups were divided into two groups: one group to receive leptin and one to
receive vehicle (saline) injections. Animals were allowed to recover for a week
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after finishing the study, after which treatment groups were changed over.
2.5 In vivo metabolic studies
For experiments requiring execution under fasted conditions (GTT, fasting blood-
/insulin/leptin levels, GSIS) mice were fasted for 24 hrs (RIPCreα2KO and
α1KORIPCreα2KO) or over night for a duration of 16 hours (RIPCrep110αβKO).
2.5.1 Determination of fasting blood glucose levels
Mice were fasted and blood glucose levels were measured with a Glucometer Elite
(Bayer) via tail bleed.
2.5.2 Determination of fasting serum insulin levels
Mice were fasted and blood samples were collected via tail bleed using capillary
blood collection tubes (Sarstedt Microvette 300). Blood samples were kept on ice
and then centrifuged for 20 min at 2,000 RPM. Serum supernatant was removed
to a fresh 0.5 ml eppendorf tube and stored at -80 ◦C. Serum insulin levels were
measure with a Rat/Mouse Insulin ELISA kit (Millipore, # EZRMI-13K).
2.5.3 Determination of fasting serum leptin levels
Mice were fasted and blood samples were collected via tail bleed using capillary
blood collection tubes (Sarstedt Microvette 300). Blood samples were kept on ice
and then centrifuged for 20 min at 2,000 RPM. Serum supernatant was removed
to a fresh 0.5 ml eppendorf tubes and stored at -80 ◦C. Serum leptin levels were
measure with a Rat/Mouse Leptin ELISA kit (Millipore, # EZML-82K).
2.5.4 Glucose tolerance test (GTT)
Mice were fasted and fasting blood glucose levels measured as described above.
Mice were then injected intraperitoneally (i.p. ) with 2g/kg of 20 % D-glucose and
blood glucose levels measured at 15, 30, 60, 90 and 120 minutes after injection.
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2.5.5 Insulin tolerance test (ITT)
Mice were studied in the middle of the light phase with free access to food and
water prior start of the study. During the study, food was not available but free
access to water was provided. Blood glucose levels were measured as described
earlier prior to injection with insulin. Mice were then i.p. injected with 0.75 mU of
insulin/kg. Blood glucose levels were measured at 15, 30, 60, 90 and 120 minutes
after injection.
2.5.6 In vivo glucose-stimulated insulin secretion (GSIS)
Mice were fasted and fasting blood glucose levels measured and blood samples
were collected using capillary blood collection tubes (Sarstedt Microvette 300)
prior to injection with glucose. Mice were injected i.p. with 2g/kg of 20 % D-
glucose and blood glucose levels measured and blood samples collected at 3, 15
and 30 minutes or 3, 7 and 20 minutes after injection. Blood samples were kept
on ice and after finishing the study, samples were centrifuged for 20 min at 2,000
RPM. Serum supernatants were removed to fresh 0.5 ml eppendorf tubes and
stored at -80 ◦C. Serum insulin levels were measure with a Rat/Mouse Insulin
ELISA kit (Millipore, # EZRMI-13K).
2.5.7 Determination of basal metabolic rate (BMR)
Basal metabolic rate was measured in male mice at 22 ◦C during light phase
by indirect calorimetry using an OXYMAX system (Columbus Instruments Inc.)
as previously described (Al-Qassab et al., 2009). The average of the lowest 3
consecutive measurements (heat as kcal/hr) were used as an estimate for BMR.
2.6 Islet isolation and primary culture
2.6.1 Islet isolation
Mice were killed by cervical dislocation and a laparotomy was performed. The
bile duct and hepatic portal vein were clamped adjacent to liver. A 25 G needle
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was inserted into the bile duct immediately before the junction of duodenum/-
bile duct. The pancreas was perfused with 2 ml of ice-cold pancreatic digestion
solution (See Appendix A - Solutions) and immediately dissected out and placed
in a 15 ml falcon tube containing 2.5 ml of ice-cold pancreatic digestion solu-
tion. The pancreas was then incubated at 37 ◦C water bath for 11 minutes. After
incubation the sample was placed on ice and 20 ml of ice-cold quenching buﬀer
(See Appendix A - Solutions) was added and the tube was shaken vigorously to
dissociate exocrine tissue from the islets. The digest was poured through a mesh
well into a 50 ml falcon tube. The tissue digest was centrifuged at 1,000 RPM for
1 minute at 4 ◦C. The supernatant was discarded and the pellet was resuspended
in 20 ml of quenching buﬀer. The centrifugation step was repeated two more
times but after the last spin the pellet was resuspended in 15 ml of Ficoll-Paque
PLUS (GE Healthcare #17-1440-02) and the sample vortexed. Another 15 ml of
Ficoll was added carefully along the side of the tube. 10 ml of ice-cold quenching
buﬀer was carefully added along the side of the tube and the sample centrifuged
at 2510 RPM for 22 minutes at 10 ◦C. After the centrifugation step islets were
floating between the Ficoll and quenching buﬀer layers. Using a 25 ml serological
pipette the supernatant along with the islets was collected and passed though a
70 µm cell strainer (BD Falcon #734-0003) that was place upside down on top
of a conical flask. Islets stayed on top of the cell strainer and they were washed 3
times with 20 ml of quenching buﬀer. After washing, the cell strainer was put on
a petri dish, islet side facing the bottom of the dish and washed on to dish with
15 ml of quenching buﬀer. The islets were then picked to a fresh petri dish from
where they were collected for tissue culture or frozen down for other assays.
2.6.2 Islet picking
If islets were to be used for DNA/RNA or protein extraction, quenching buﬀer
with 0.5 % BSA was used. Islets were picked keeping the islets cold at all times,
washed once in BSA free KRB (1X), pelleted and snap frozen and stored at -80
◦C.
If islets were to be used for primary culture, quenching buﬀer with 10 %
NCS (new-born calf serum) was used. Islets were picked on to a petri dish and
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incubated in overnight culture medium (See Appendix A - Solutions) at 37 ◦C
with 21 % O2, 5 % CO2 and high humidity for 24 to 48 hours before study.
2.7 In vitro glucose-stimulated insulin secretion
(static incubation)
Islets were isolated and cultured for 24 to 48 hours in overnight culture medium
as described above.
Islets were picked to a fresh petri dish and incubated in quenching buﬀer (See
Appendix A - Solutions) supplemented with 0.5 % BSA (2 mmol/l D-glucose) at
37 ◦C for 1 hour before the start of the experiment. Batches of 5 size-matched
islets were picked in a volume of 5 µl and plated into a v-shaped bottom 96-well
plate. From each mouse diﬀerent islet batches were used for incubation in either 2
mmol/L glucose or 20 mmol/L glucose. Six replicates of 5 islet batches were used
per given glucose concentration. Once all the islets were picked for each condition,
125 µl of secretion buﬀer (with appropriate glucose concentration) was added with
a multichannel pipette. Islets were incubated for 1 hour at 37 ◦C with 21 % O2,
5 % CO2. After the incubation the plate was swirled gently and centrifuged at
1,000 RPM for 1 minutes to ensure that the islet were all settled down at the
bottom of the wells. 100 µl of secretate was removed with a multichannel pipette
to a fresh 96-well plate and the samples immediately frozen at -80 ◦C. The insulin
concentration in each sample was measured with Rat/Mouse Insulin ELISA kit
(Millipore, # EZRMI-13K). The samples from 2 mmol/L glucose conditions were
diluted 1/2 with assay buﬀer (from the Elisa kit) and the samples from 20 mmol/L
glucose condition were diluted 1/10.
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2.8 Pancreatic immunocytochemistry and mor-
phometric analysis
2.8.1 Preparation of pancreata and Bouin’s fixation
Mice were killed by cervical dislocation and laparotomy performed. The pancreas
were quickly dissected out, rinsed in phosphate buﬀered saline (PBS) solution,
blotted dry with tissue and weighed with a fine balance. The pancreas were spread
on to histology cassettes and fixed in Bouin’s fixative (See Appendix A - Solutions)
for 3 hours at room temperature. After 3 hours the samples were rinsed in 70 %
ethanol and then left in 70 % ethanol for overnight (16 hours).
2.8.2 Tissue processing for paraﬃn embedding
Tissues were processed as described below. Steps 1 to 6 were performed at room
temperature and 7-8 at 60 ◦C. After processing the tissues were embedded in
paraﬃn and cooled on ice.
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1. 90 % ethanol, 1 hour
2. 95 % ethanol, 1 hour
3. 100 % ethanol, 1 hour
4. 100 % ethanol, 2 hours
5. Histoclear I, 1 hour
6. Histoclear II, 2 hours
7. Paraﬃn wax I, overnight
8. Paraﬃn wax II, 2 hours
2.8.3 Immunostaining for fluorescent detection
Paraﬃn embedded tissues were sliced with a microtome to obtain 5 µm sections.
The sections were float mounted on to a poly-lysine coated cover slides and dried
at 37 ◦C overnight. De-paraﬃnisation of the sections was performed as described
below.
• Histoclear I, 5 minutes
• Histoclear II, 1 minute
• 100 % ethanol, 30 seconds
• 90 % ethanol, 30 seconds
• 70 % ethanol, 30 seconds
• ddH2O, 5 minutes
• PBS, 5 minutes
• PBS + 0.05 % Tween20, 5 minutes
• PBS + 1 % Triton X-100, 5 minutes
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• PBS + 0.05 % Tween20, 3 X 5 minutes
Following deparaﬃnisation, sections were incubated at room temperature for
30 min with blocking solution (See Appendix A - Solutions). Blocking solution
was removed and the sections were placed in a hydration chamber and incubated
overnight at 4 ◦C in blocking solution containing primary antibody (See Table
2.1 for a complete list of primary and secondary antibodies used). Next day the
sections were washed three times for 5 min with PBS + 0.05 % Tween20. The
sections were incubated at room temperature in darkness for 1 hour with PBS
+ 2 % BSA + secondary antibody, and then washed three times for 5 min with
PBS + 0.05 % Tween20. Lastly, the sections were mounted with DAPI mounting
media.
2.9 Pancreatic morphometry
Images for measurement of pancreatic beta cell area were captured using an
Olympus fluorescent microscope and either a 10X or 20 X objective lens. Flu-
orescent filter channels DAPI, FITC (for Alexa fluor 488 nm) and TRITC (for
Alexa fluor 594 nm) were used. Images of whole pancreas sections with a calibra-
tion slide were captured with a Sony Cyber-shot DSC-W30 digital camera, which
was mounted to a dissection microscope (Nikon SMZ645). Simple PCI software
(C Imaging) was used to measure beta cell area (stained with insulin) and ex-
ocrine area (whole pancreas section) from each pancreas section (4 sections per
mouse). Relative beta cell volume was calculated by dividing the total beta cell
area of each section with the corresponding exocrine area. The average of the four
sections was then calculated. Beta cell mass (mg) was calculated by multiplying
the average relative beta cell volume by pancreas weight.
2.9.1 Immunofluorescence imaging
A Zeiss LSM700 inverted confocal microscope with 20X air objective or 40X
oil objective was used to capture fluorescent images of immunostained pancreas
sections. Alexa fluor 594 nm conjugated secondary antibody (against insulin) was
excited at 594 nm and light emitted above 617 nm was collected. Alexa fluor 488
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nm conjugated secondary antibody (against glucagon) was excited at 488 nm and
light emitted between 500 and 540 nm was collected. The DAPI nuclear stain was
excited at 405 nm and light emitted between 420 and 480 nm was collected.
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2.10 Western blotting
2.10.1 Tissue lysis
Islets were isolated and snap frozen as a pellet as described earlier. Islet pellet was
resuspended in 40 µl of RIPA lysis buﬀer (Sigma, # R0278) (See Appendix A -
Solutions). Islets were lysed by vortexing and carefully passing the islet suspension
through an insulin syringe 15 times avoiding air bubbles. The lysate was left
on ice for one hour, centrifuged at 12,000 RPM for 5 minutes and the protein
concentration measured by Bradford assay (Bio-Rad 1998).
2.10.2 Immunoblotting
35 µg of islet protein was resuspended in 2 x Laemmli buﬀer (See Appendix A
- Solutions) (Laemmli, 1970), boiled for ten minutes, cooled on ice and pulse
spun. 75 µl of protein suspension was loaded onto a 12 % SDS-polyacrylamide
gel (See Appendix A - Solutions) and run at 120 volts for one and half hours at
room temperature with a Tris-glycine-SDS running buﬀer (See Appendix A - So-
lutions). Proteins were transferred to 0.2 µm nitrocellulose membrane (Invitrogen
# LC2000) using a Tris-glycine transfer buﬀer (See Appendix A - Solutions).
The membrane was blocked for 30 minutes shaking at room temperature with
blocking solution and then incubated overnight at 4 ◦C in blocking solution (See
Appendix A - Solutions) with primary antibody. After this incubation with the
primary antibody, the membrane was washed 3 times for 5 minutes with wash-
ing buﬀer and then incubated with a horseradish peroxidase (HRP) conjugated
secondary antibody at room temperature for 1 hour. After the incubation, the
membrane was washed 5 times for 10 minutes with washing buﬀer and the sec-
ondary antibody was detected using an ECL plus detection system (Amersham).
When a membrane was used for detection of multiple proteins it was stripped
of antibodies by incubating the membrane for 15 min at 37 ◦C shaking using
stripping buﬀer (Thermo Scientific #21059). The membrane was then washed
once with 1X TBST and then blocked for 30 min with blocking solution (See
Table 2.2 for a complete list of primary and secondary antibodies used).
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2.11 Gene expression studies
2.11.1 Reverse transcription
RNA was extracted as described below depending on the tissue source (islet or
hypothalamus). Once extracted, mRNA was quantified using a NanoDrop (Ther-
moScientific) and reverse transcribed using the TaqMan Retrotranscription Kit
(Applied Biosystems # N808-0234) in order to generate complementary DNA
(cDNA) templates for RT-PCR quantification. Briefly, each sample contained
2.5 µl of RT Buﬀer (10X), 5.5 µl of MgCl2, 5 µl of dNTPs, 1.25 µl of oligo-DT,
0.5 µl of RNAse inhibitor and 0.5 µl of reverse transcriptase with 1 µg of RNA
used as a template. Each reaction was set-up in 0.2 ml reaction tubes (BioRad)
and the total volume in each tube made up to 25 µl with nuclease free water.
Samples were incubated at 37 ◦C for 60 minutes, and the reverse transcriptase
subsequently inactivated by heating the samples to 95 ◦C for 5 minutes. The
resulting cDNA was then stored at -20 ◦C until PCR analysis.
2.11.2 Quantitative PCR cycling conditions
A pool of cDNA was prepared from control samples and a standard curve (ar-
bitary) prepared from the pool of cDNA by serial dilution (usually six points, the
first being undiluted). A separate standard curve was prepared for each probe
(gene of interest) used. cDNA from each sample was diluted 1/2 with nuclease
free water. A separate mastermix for each probe was prepared (See Table 2.3 for
the TaqMan probes used).
Each sample was run in duplicate, in 10 µl volume, using TaqMan Gene
Expression Master Mix (Applied Biosystems # 4369016) on a MicroAmp Optical
384-well reactive plate (Applied Biosystems # 4309849). An ABI Prism 7900 HT
thermocycler (Applied Biosystems) sequence detection system with integrated
488 nm argon laser with SDS2.1 software was used (See Figure 2.7 for the qPCR
programme).
78
2.11.3 Islet gene expression analysis
Islets were isolated as described above. RNA was extracted immediately after
the islet isolation using an RNeasy Micro Kit (Qiagen # 74004). 0.5-1 µg of islet
RNA was reverse transcribed into cDNA as described above. Quantitative PCR
was performed as described above using fluorescent FAM/TAMRA probes from
Applied Biosciences. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
used as an internal control and mRNA levels were normalised to GAPDH levels.
2.11.4 Hypothalamic gene expression analysis
Hypothalami were dissected and immediately frozen in flat-bottomed 5 ml sterilin
tubes in liquid nitrogen. RNA was extracted by homogenising each hypothalamus
on ice in a 5 ml sterilin tube with 0.5 ml of cold phenol-guanidine isothiocyanate
solution according to the manufacturers instructions (TRIzol Reagent, Invitrogen
#15596-018). The precipitated RNA was dissolved in 40 µl of nuclease-free wa-
ter. 1 µg of hypothalamic RNA was reverse transcribed into cDNA as described
above. Quantitative PCR was performed as described above using fluorescent
FAM/TAMRA probes from Applied Biosciences. Hypoxanthine-guanine phos-
phoribosyltransferase (HPRT) (Mm99999915 g1) was used as an internal control
and mRNA levels were normalised to HPRT levels.
qPCR reaction 
(per sample)
Master mix 5.5 μl
Nuclease free water 0.55 μl
Probe 0.55μl
diluted cDNA 5.5 μl
qPCR cycle
50 ℃ for 2 minutes
95 ℃ for 10 minutes
95 ℃ for 15 seconds
60 ℃ for 1 minutes
72 ℃ for 5 minutes
X 40
Figure 2.7: qPCR reaction and cycle
A Ct-value for each sample was obtained from the SDS2.1 software. A stan-
dard curve was plotted for each gene: arbitary cDNA concentrations were plotted
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on a logarithmic scale against the Ct-values. The unknown sample values (aver-
age Ct-value) were extrapolated from the standard curve and anti-log calculated.
Relative expression (arbitary concentration) to the housekeeping gene was calcu-
lated for each sample for the gene of interest. Relative mRNA expression in KO
samples was calculated as a % of control expression.
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Table 2.3: Table of TaqMan probes.
Gene name/symbol Gene symbol Primer product name
Agouti-related protein AgRP Mm00475829 g1
AMP-activated protein kinase, alpha 1 catalytic subunit AMPKα1 Mm01296695 m1
AMP-activated protein kinase, alpha 2 catalytic subunit AMPKα2 Mm01264786 g1
Forkhead box O1 Foxo1 Mm00490672 m1
Glucokinase GK Mm00439129 m1
Glutathione peroxidase 4 GPX4 Mm00515041 m1
Glyceraldehyde-3-phosphate dehydrogenase GAPDH Mm99999915 g1
Heme oxygenase (decycling) 1 HMOX1 Mm00516004 m1
Hexokinase 1 HK1 Mm01145241 m1
Hexokinase 2 HK2 Mm00443395 m1
Hexokinase 3 HK3 Mm01341937 m1
Hypoxanthine guanine phosphoribosyl transferase HPRT Mm00446968 m1
Insulin II Ins2 Mm00731595 gH
Insulin receptor substrate 1 IRS-1 Mm01278327 m1
Neuropeptide Y NPY Mm00445771 m1
Nuclear respiratory factor 1 Nrf1 Mm00447996 m1
Peroxisome proliferator-activated receptor, gamma, coactivator 1 alpha PGC-1α Mm00731216 s1
Phosphatase and tensin homolog PTEN Mm00477210 m1
Phosphatidylinositol 3-kinase catalytic subunit p110α p110α Mm00435669 m1
Phosphatidylinositol 3-kinase catalytic subunit p110β p110β Mm00659576 m1
Phosphatidylinositol 3-kinase regulatory subunit p85 p85 Mm01282780 m1
Pro-opiomelanocortin POMC Mm00435874 m1
Protein kinase B Akt Mm01331624 m1
Pyruvate dehydrogenase kinase, isoenzyme 1 PDK1 Mm00554306 m1
Solute carrier family 2 (facilitated glucose transporter) member 2 (GLUT2) Slc2a2 Mm11446224 m1
Sulfonylurea receptor 1 SUR1 Mm00803450 m1
Superoxide dismutase 2, mitochondrial SOD2 Mm00449726 m1
Transcription factor A, mitochondrial Tfam Mm00447485 m1
Uncoupling protein 2 UCP2 Mm00627598 m1
2.12 Measurement of islet reactive oxygen species
(ROS) generation
Islets were isolated as described earlier and incubated overnight in overnight
culture media at 37 ◦C. Next day, islets were picked into a 2 ml petri dish and
incubated for 1 hr at 37 ◦C in 1X KRB with 2 mmol/L D-glucose and 0.5 %
BSA. After 1 hr islets were picked again to a new 2 ml petri dish and incubated
for 30 min in 1X KRB with either 2 mmol/L or 20 mmol/L D-glucose and 1
µmol/L CM-H2DCFDA (5-(and 6)-chloromethyl-2,7-dicholorodihydrofluorescein
diacetate, acetyl ester) (Molecular Probes, UK # 6827). After incubation, media
was removed and replaced with 1X KRB with either 2 mmol/L or 20 mmol/L
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D-glucose and islets incubated for 15 min at 37 ◦C. After 15 min islets were
placed on ice and H2O2 derived CM-H2DCFDA fluorescence was measured with
Olympus fluorescent microscope with Simple PCI software (C Imaging) and 10X
objective lens.
2.13 Statistical analysis of data
Data are presented as mean values with standard error of the mean (SEM) unless
otherwise indicated. n = indicates sample size and is represented as control
vs KO in figure text. Unpaired two-tailed Student’s t-tests were used on all
statistical analysis except analysis of glucose- and insulin tolerance test and in
vivo GSIS that were analysed with 2-way ANOVA with Bonferroni post-test. P
values <0.05 (∗), <0.01 (∗∗) and <0.001 (∗∗∗) were recorded as significant. Raw
data were collected in Microsoft Excel and calculations of mean and SEM values,
statistical analysis and graphical representation were done using GraphPad Prism
5 (GraphPad software).
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Chapter 3
Physiological characterisation of
RIPCreα2KO and
α1KORIPCreα2KO mice
3.1 Introduction
1AMPK has been shown to be important in the regulation of glucose homeosta-
sis, but as described in Chapter 1, controversies remain about its role in beta
cell function. Understanding the role of AMPK in beta cells is important as
a commonly used oral T2DM drug metformin is thought to achieve its blood
sugar lowering eﬀect via activation of AMPK in peripheral tissues. Activation
of AMPK in liver and skeletal muscle improves glucose uptake and metabolism
and inhibits hepatic gluconeogenesis (Fryer et al., 2002). However, it is unclear
whether metformin possess a beneficial eﬀect for beta cells in terms of AMPK
activation, specifically because the role of AMPK in beta cells has yet to be fully
determined.
AMPKα2 -global-null andAMPKα1 -global-null mice did not show that AMPK
deficiency caused any intrinsic beta cell defect, even though the AMPKα2 -global-
null mice demonstrated impaired glucose homeostasis. At the time when this re-
1This chapter, and the following Chapter 4, were published in Biochemical Journal (Beall
et al., 2010) where the author of this PhD thesis (KP) and C. Beall share the first authorship.
See Appendix C - Publications.
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search project was started, no other studies existed that would have employed
transgenic mouse models in the assessment of the role of AMPK specifically in
the beta cells.
In order to fully understand the role of AMPK in beta cell function, the fol-
lowing transgenic mouse models were generated: RIPCreα2KO and
α1KORIPCreα2KO. RIPCreα2KO mouse lacks functional AMPKα2 specifically
in the pancreatic beta cells and in a population of hypothalamic RIPCre ex-
pressing neurons. Because there was a concern about potential upregulation of
AMPKα1 we combined the deletion of AMPKα2 in beta cells with a global
deletion of AMPKα1, which previously has not been shown to have an eﬀect
on whole-body glucose homeostasis, hence creating α1KORIPCreα2KO mouse,
which does not have any functional AMPK catalytic subunits expressed in the
beta cells. I hypothesise that deletion of AMPK in beta cells will aﬀect the
whole-body glucose homeostasis and glucose-stimulated insulin secretion in the
RIPCreα2KO and α1KORIPCreα2KO transgenic mice.
The results in this chapter confirm the specificity and eﬃcacy of AMPKα2
deletion in order to establish the suitability of RIPCreα2KO and
α1KORIPCreα2KO mouse models for studying the role of AMPK in beta cells.
Secondly hypothalamic function, whole-body glucose homeostasis and glucose-
stimulated insulin secretion are examined in both mouse models.
3.2 Analysis of deletion
The following experiments were performed in order to confirm the specificity and
eﬃcacy of RIPCre-mediated deletion of AMPKα2 in pancreatic beta cells and
RIPCre expressing neurons of the hypothalamus.
3.2.1 Specificity of AMPKα2 deletion
RIPCre has been reported to delete genes in the pancreatic beta cells and also
in a small population of hypothalamic neurons (Choudhury et al., 2005). To test
for the specificity of AMPKα2 gene deletion, recombination of floxed alleles was
assessed (Figure 3.1). DNA was isolated from islets, hypothalamus, and insulin
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target tissues of RIPCreα2KO and control mice and amplified with PCR. Islets
and hypothalamus from RIPCreα2KO mice showed a 750 bp band indicating a
recombination of two loxP sites flanking a part of the AMPKα2 catalytic subunit
gene, thus indicating the deletion of AMPKα2 catalytic subunit. No recombina-
tion could be detected in other tissue of RIPCreα2KO or control mice.
La La T L M F C Hy I T L M F C Hy I
Control RIPCreα2KO
IL2 control
AMPKα2 gene deletion 
Figure 3.1: Tissue specific deletion of AMPKα2 using RIPCre. DNA was ex-
tracted from diﬀerent tissues (T, tail; L, liver; M, skeletal muscle; F, fat; C,
cerebral cortex; H, hypothalamus; I, islet of Langerhans) and recombination of
the floxed AMPKα2 allele detected by PCR. The presence of the 750 bp band
indicates a deletion of AMPKα2. Recombination was only detected in the islets
of Langerhans and hypothalamus of RIPCreα2KO mice. A PCR reaction with
IL2 as internal control shows the presence of DNA template in all the samples.
La, denotes DNA ladder.
3.2.2 Eﬃcacy of AMPKα2 deletion
To determine whether deletion of AMPKα2 resulted in the anticipated reduction
in mRNA level, real time quantitative PCR (qRT-PCR) was performed (Figure
3.2). RNA isolated from islets and hypothalamus of RIPCreα2KO and control
mice was reverse transcribed to cDNA, which was then amplified with RT-PCR.
A 50 % reduction in islet, and a 20 % reduction in hypothalamic AMPKα2
mRNA expression was detected in RIPCreα2KO mice in comparison to con-
trols. In mice, beta cells only represent ≈70 % of the cell types present in islets,
therefore the islets also consist of other cell types, such as alpha cells, in which
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the deletion of AMPKα2 does not occur. Therefore a 50 % reduction in the to-
tal islet AMPKα2 mRNA levels is consistent with the deletion event driven by
the RIPCre-recombinase. As with the islets, only a small population of neurons
within the hypothalamus are RIPCre expressing neurons, therefore only a 20 %
reduction (not significant, P = 0.1705) in total hypothalamic AMPKα2 mRNA
was detected.
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Figure 3.2: Eﬃciency of deletion of AMPKα2 in islets (A) and hypothalamus
(B). Quantitative RT-PCR was performed to analyse the expression of AMPKα2
mRNA extracted from islets and hypothalamus of RIPCreα2KO and control mice
(n = 6). Data shown is mean ± SEM, ∗∗∗P<0.001.
To confirm that deletion of AMPKα2 results in reduced AMPKα2 protein
levels, Western blotting against AMPKα2 was performed (Figure 3.3). Western
blot for AMPKα2 from RIPCreα2KO and control islets showed a clear reduction
in AMPKα2 protein levels confirming a loss of AMPKα2 protein expression in
RIPCreα2KO islets.
In summary it can be concluded that recombination of floxed AMPKα2 cat-
alytic subunit occurs only in pancreatic beta cells and in a population of hypotha-
lamic neurons when cre-recombinase is expressed from the rat insulin promoter.
A significant reduction (≈ 50 %) in AMPKα2 mRNA levels, as well as a clear
reduction in AMPKα2 protein levels is detected in RIPCreα2KO islets.
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Figure 3.3: Analysis of AMPKα2 protein levels in RIPCreα2KO and control
islets. Islet lysates were run on SDS-PAGE and western blotted against a sheep
anti-AMPKα2 antibody.
3.3 Metabolic studies in RIPCreα2KO mice
As described before, the RIPCre transgene deletes in a small population of hy-
pothalamic neurons. Therefore to exclude for the fact that the RIPCreα2KO mice
do not have a hypothalamic phenotype due to a deletion of AMPKα2 in RIPCre
neurons, body weight and food intake were measured. RIPCreα2KO mice exhib-
ited normal body weight in comparison to control littermates at young and old
age (Figure 3.4). 24-hr food intake analysis showed that RIPCreα2KO mice have
a normal feeding behaviour (Figure 3.5). Normal body weight and food intake
suggest that the deletion of AMPKα2 in RIPCre neurons does not aﬀect the hy-
pothalamic function in RIPCreα2KO mice, which could otherwise have an eﬀect
on whole-body glucose homeostasis.
In conclusion, the data indicates that deletion of AMPKα2 in beta cells and
in RIPCre expressing hypothalamic neurons does not lead to a major central
nervous system phenotype such as altered feeding behaviour and body weight
(Heinrichs, 2001).
3.4 Glucose homeostasis in RIPCreα2KO mice
Blood glucose concentrations of fasted, random fed and post-glucose injected
RIPCreα2KO and control mice were measured to investigate glucose handling in
these animals. Insulin sensitivity of peripheral tissues was investigated in order to
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Figure 3.4: Body weight curve for male RIPCreα2KO and control mice. Data
shown are mean ± SEM (n = 5 vs 8).
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Figure 3.5: 24-hr food intake in RIPCreα2KO and control mice. 8-months old
male mice were used (n = 7 vs 9). Data shown are mean ± SEM.
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determine whether RIPCreα2KO mice were to suﬀer from insulin resistance, and
fasted and fed plasma insulin levels measured to see whether the RIPCreα2KO
beta cells were hypo/hyper-secreting insulin. In vivo glucose-stimulated insulin
secretion was performed to assess insulin secretory function of pancreatic beta
cells.
3.4.1 Fasting/fed blood glucose
Fasted and fed blood glucose levels in male RIPCreα2KO mice were normal in
comparison to control mice at 12- and 20-weeks of age on a chow diet (Figure
3.6).
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Figure 3.6: Fasted and fed blood glucose levels in RIPCreα2KO and control mice.
(A) Blood glucose levels after a 24-hr fast in 12-week old (n = 13 vs 14), and (B)
random fed blood glucose levels in 20-week old male mice (n = 9 vs 7). Bloods
were collected from tail bleeds. Data shown are mean ± SEM.
3.4.2 Glucose tolerance
Glucose tolerance testing was performed on male RIPCreα2KO mice and their
littermate controls (Figure 3.7). At 14-weeks of age RIPCreα2KO mice display
mild glucose intolerance, especially from 30 minutes post-injection onwards.
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Figure 3.7: Glucose tolerance in RIPCreα2KO and control mice. Blood glucose
concentrations were measured from tail bleeds at indicated times after an i.p.
injection of 20 % D-glucose (2 g/kg). 14-week old male mice (n= 8 vs 8) were
used. Data shown are mean ± SEM, ∗P<0.05, ∗∗P<0.01 and ∗∗∗P<0.001
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3.4.3 Insulin sensitivity
Insulin sensitivity was assessed in RIPCreα2KO and control mice. Fasted insulin
levels were measured to establish whether RIPCreα2KO mice are hypo/hyper-
secreting insulin (Figure 3.8). The fasted insulin levels were found to be nor-
mal. Next an insulin tolerance test was performed to measure insulin sensitivity
of insulin target tissues, and to establish that the mice are not suﬀering from
insulin resistance. If the mice were to suﬀer from insulin resistance, injection of
insulin would not lead to a reduction in blood glucose levels. Glucose clearance
in response to insulin was equivalent in RIPCreα2KOs compared to control ani-
mals (Figure 5.6). Together these results indicated normal insulin sensitivity for
RIPCreα2KO mice.
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Figure 3.8: Fasted plasma insulin levels in RIPCreα2KO and control mice.
Plasma insulin levels after a 24-hr fast in 10-week old mice (n = 7 vs 7). Bloods
were collected from tail bleeds and plasma insulin levels were measured with a
Rat/Mouse Insulin Elisa Kit. Data shown are mean ± SEM.
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Figure 3.9: Insulin sensitivity in RIPCreα2KO and control mice. Blood glucose
concentrations were measured from tail bleeds at indicated times after an i.p.
injection of insulin (0.75 mU/kg). Random fed, 20-week old male mice were used
(n = 7 vs 7). Data shown are mean ± SEM.
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3.4.4 Glucose-stimulated insulin secretion in vivo
To detect any insulin secretory defects in RIPCreα2KO mice, a glucose-stimulated
insulin secretion test was performed. This revealed that even though fasted in-
sulin levels were equivalent to those measured in control mice, RIPCreα2KO
mice had significantly impaired insulin secretory function in response to a glu-
cose challenge (Figure 3.10). GSIS performed for a cohort of 10-week old male
RIPCreα2KO and control mice showed a significant diﬀerence in insulin secretion
between the control and KO groups in response to glucose injection.
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Figure 3.10: In vivo glucose-stimulated insulin secretion (GSIS) in RIPCreα2KO
and control mice. Bloods were collected from tail bleeds at indicated times after
an i.p. injection of 20 % D-glucose (2 g/kg) and plasma insulin levels were mea-
sured with a Rat/Mouse Insulin Elisa Kit. 10-week old male mice were used (n=
6 vs 7). Data shown are mean ± SEM, ∗∗P<0.01.
Taken together, the data from the glucose tolerance test and from the in
vivo GSIS indicates that the RIPCreα2KO mice are more glucose intolerant in
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comparison to their control littermates, with a concomitant defect in glucose-
stimulated insulin secretion.
3.5 Metabolic studies in α1KORIPCreα2KO mice
It has been reported that in some tissues, deletion of AMPKα2 is compen-
sated for by increased AMPKα1 expression (Jørgensen et al., 2004). Hence we
combined the deletion of AMPKα2 with a global deletion of AMPKα1 to cre-
ate α1KORIPCreα2KO mice that do not express any functional AMPKα1 or
AMPKα2 subunits in islet beta cells. AMPKα1 -global-null mice were used be-
cause AMPKα1 floxed mice were not available at the time of these studies, and
because the AMPKα1 -global-null mice are reported not to have a metabolic phe-
notype (Viollet et al., 2003a).
0
10
20
30
Control α1KORIPCreα2KO
B
od
y 
w
ei
gh
t (
g)
Figure 3.11: Body weight in α1KORIPCreα2KO and control mice. 8-week old
male mice were used (n = 6 vs 6). Data shown are mean ± SEM.
To confirm that α1KORIPCreα2KO mice do not have a hypothalamic phe-
notype due to the deletion of AMPKα2 in RIPCre neurons and deletion of
AMPKα1 in all tissue types, body weight and food intake were measured in
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α1KORIPCreα2KO mice. 8-week old male α1KORIPCreα2KO mice had a nor-
mal body weight in comparison to control mice (Figure 3.11). 24-hr food in-
take and feeding behaviour after a 16-hr fast were also indistinguishable between
α1KORIPCreα2KO and control mice (Figures 3.12, 3.13). Because it has al-
ready been shown that AMPKα1 -global-null mice (Viollet et al., 2003a) and
RIPCreα2KO mice have normal peripheral insulin sensitivity, determined by in-
sulin tolerance test, insulin sensitivity was not determined in α1KORIPCreα2KO
mice.
0
1
2
3
4
5
6
24
-h
r 
fo
od
 in
ta
ke
 (g
)
Control α1KORIPCreα2KO
Figure 3.12: 24-hr food intake in α1KORIPCreα2KO and control mice. 16-week
old male mice used (n = 4 vs 4). Data shown are mean ± SEM.
3.6 Glucose homeostasis in α1KORIPCreα2KO
mice
3.6.1 Fasted glucose and insulin
Blood glucose concentrations of fasted and post-glucose injected α1KORIPCreα2KO
and control mice were measured to investigate glucose handling and its clearance.
95
02
4
6
8
10
1 2 4 8 24
Time after re-feeding (h)
Control
α1KORIPCreα2KO
C
um
ul
at
iv
e 
fo
od
 in
ta
ke
 (g
)
Figure 3.13: Feeding behaviour over a 24-hr period after a 16-hr fast in
α1KORIPCreα2KO and control mice. 20-week old male mice used (n = 5 vs
5). Data shown are mean ± SEM.
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Figure 3.14: Fasted blood glucose levels in α1KORIPCreα2KO and control mice.
Blood glucose levels after a 24-hr fast in 5-week old (n = 9 vs 12). Bloods were
collected from tail bleeds. Data shown are mean ± SEM.
Fasted blood glucose levels in male α1KORIPCreα2KO mice were normal in
comparison to control mice at 5-weeks of age (Figure 3.14). This means that the
mice are able to correctly regulate their blood glucose concentration at fasted
state. The fasted plasma insulin levels were also normal when measured in 10-
week old male α1KORIPCreα2KO and control mice (Figure 3.15).
3.6.2 Glucose tolerance
A glucose tolerance test was performed on the male α1KORIPCreα2KO mice and
their littermate controls at 5-weeks of age. At 5-weeks of age, a clear and signifi-
cant diﬀerence in glucose tolerance between the α1KORIPCreα2KO and control
mice was measured (Figure 3.16). The data shows that the α1KORIPCreα2KO
mice have a clear defect in their glucose handling.
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Figure 3.15: Fasted plasma insulin levels in α1KORIPCreα2KO and control mice.
Plasma insulin levels after a 24-hr fast in 10-week old male mice (n = 9 vs 12).
Bloods were collected from tail bleeds and plasma insulin levels were measured
with Rat/Mouse Insulin Elisa Kit. Data shown are mean ± SEM.
3.6.3 Glucose-stimulated insulin secretion in vivo
To detect any insulin secretory defects in α1KORIPCreα2KO mice, a glucose-
stimulated insulin secretion test was performed. This revealed that even though
fasted insulin levels were indistinguishable from the control values, at 10-weeks
of age the α1KORIPCreα2KO mice exhibited significantly impaired insulin se-
cretory function in response to a glucose challenge (Figure 3.17).
These results clearly demonstrate that α1KORIPCreα2KO mice exhibit sig-
nificant glucose intolerance, which is due to a severe defect in glucose-stimulated
insulin secretory function. The impaired glucose homeostasis in α1KORIPCreα2KO
mice occurred at an earlier age and was more severe than in RIPCreα2KO mice.
In summary, investigation of glucose homeostasis in α1KORIPCreα2KO mice
shows that the KO mice have normal fasted blood glucose levels. However, they
have highly impaired glucose tolerance. Even though their fasted plasma insulin
levels are normal in comparison to control mice, glucose-stimulated insulin se-
cretory behaviour is significantly impaired which explains the marked glucose
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Figure 3.16: Glucose tolerance in α1KORIPCreα2KO and control mice. Blood
glucose concentrations were measured from tail bleeds at indicated times after an
i.p. injection of 20 % D-glucose (2 g/kg). 5-week old male mice (n= 8 vs 8) were
used. Data shown are mean ± SEM, ∗P <0.05 and ∗∗∗P<0.001.
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Figure 3.17: In vivo glucose-stimulated insulin secretion (GSIS) in
α1KORIPCreα2KO and control mice. Bloods were collected from tail bleeds at
indicated times after an i.p. injection of 20 % D-glucose (2 g/kg) and plasma
insulin levels were measured with Rat/Mouse Insulin Elisa Kit. 10-week old male
mice were used (n= 6 vs 6). Data shown are mean ± SEM, ∗∗∗P<0.001.
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intolerance in α1KORIPCreα2KO mice.
3.7 Summary
The results presented in this chapter demonstrate that both the RIPCreα2KO
and α1KORIPCreα2KO are suitable models for investigation of AMPK function
in pancreatic beta cells. RIPCre mediated deletion of AMPKα2 was confirmed
in islets and hypothalamus but not in other tissues. AMPKα2 mRNA and pro-
tein levels were significantly reduced in the islets of RIPCreα2KO mice. Even
though AMPKα2 is also deleted in a population of hypothalamic neurons in
these mice, and additionally AMPKα1 is deleted globally in all tissues of the
α1KORIPCreα2KO mice, these models do not demonstrate any significant de-
fects in hypothalamic function such as alteration in body weight or food intake
that could aﬀect the assessment of whole-body glucose homeostasis and in vivo
glucose-stimulated insulin secretion. Insulin sensitivity in peripheral tissues was
also normal in these mice, further confirming that insulin resistance or increased
peripheral insulin sensitivity does not influence glucose homeostasis and insulin
secretion from the beta cells.
Fasted blood glucose and plasma insulin levels were normal in both transgenic
AMPK KO lines. Mice with a deletion of AMPKα2 in beta cells developed mild
glucose intolerance by 3 months of age, as assessed by glucose tolerance testing.
This phenotype was exacerbated when both catalytic subunits AMPKα2 and
AMPKα1 were deleted. α1KORIPCreα2KO mice exhibited a marked glucose
intolerance which is apparent already at 5-weeks of age. Assessment of glucose-
stimulated insulin secretion (GSIS) in vivo in RIPCreα2KO mice demonstrated
that the mice had a defective GSIS as insulin secretion in response to glucose
was significantly reduced. Again a more marked defect in GSIS was seen in
α1KORIPCreα2KO mice as the insulin secretion in response to glucose was not
increased above basal insulin levels. Because the fasted blood glucose and plasma
insulin levels were normal, but upon glucose stimulation defect in glucose han-
dling and insulin secretion was observed, these results give an indication that
AMPK might be involved specifically in beta cell glucose sensing and regulation
of insulin secretion in response to glucose stimulation. In conclusion, these results
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demonstrate that AMPK is important for maintaining functional whole-body glu-
cose homeostasis and glucose-stimulated insulin secretion. Defective GSIS could
result in alteration in beta cell mass and defect in intrinsic beta cell function such
as insulin secretion. These aspects are examined further in Chapter 4.
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Chapter 4
AMPK regulated beta cell
function in vitro
4.1 Introduction
1In Chapter 3 data were presented that showed that mice with a deletion of
the AMPKα2 catalytic subunit in beta cells developed mild glucose intolerance
by three months of age caused by decreased glucose-stimulated insulin secre-
tion. This phenotype was exacerbated when both the catalytic isoforms (α1 and
α2 ) were deleted in beta cells. Mice with no functional AMPK catalytic subunit
in beta cells had a marked glucose intolerance, and glucose-stimulated insulin
secretion was reduced to basal insulin secretion levels. Even though these mice
also had a deletion of AMPKα2 in a population of hypothalamic neurons, no
significant hypothalamic phenotype was observed in these animals. The mice also
had normal insulin sensitivity. In this chapter, the role of AMPK in regulation
of beta cell function in vitro is discussed. Results from the whole-animal physi-
ology suggest that the observed decrease in glucose-stimulated insulin secretion
could be caused by alterations in beta cell mass, or by functional defect within
the beta cells. The studies in this chapter examine beta cell mass and islet mor-
1This chapter, and the previous one, were published in Biochemical Journal (Beall et al.,
2010) where the author of this PhD thesis (KP) and C. Beall share the first authorship. See
Appendix C- Publications. Some of the published data, produced by C. Beall has been included
in this chapter with the permission of C. Beall.
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phology together with an examination of islet glucose-stimulated insulin secretion
capacity in vitro. To further determine the reasons for defective insulin secretion,
gene expression analysis of key beta cell genes involved in glucose sensing and
metabolism was conducted, and islet reactive oxygen species (ROS) production
and expression of anti-oxidant enzymes were also measured. Electrophysiologi-
cal characterisation of control and RIPCreα2KO and α1KORIPCreα2KO beta
cell were done by C. Beall, and the summary of the results are included in this
chapter.
4.2 Beta cell morphology
Pancreatic sections from RIPCreα2KO and control mice were stained with in-
sulin and glucagon antibodies to assess any alterations in islet structure and beta
cell mass. Beta cell mass was determined by morphology in RIPCreα2KO and
control pancreases, and no significant diﬀerence was measured between the geno-
types (Figure 4.1). The whole pancreatic mass was also unaltered (Figure 4.1).
Qualitative comparison of pancreas sections also showed no structural diﬀerences
between RIPCreα2KO and control mice 4.2. Hence, it can be concluded that the
defect in insulin secretion is not caused by alterations in pancreatic or beta cell
mass, or islet organisation.
4.3 Analysis of glucose-stimulated insulin secre-
tion in vitro
Normal beta cell mass seen in RIPCreα2KO mice suggested that impaired glucose-
stimulated insulin secretion (GSIS) observed in vivo, is caused by functional
rather than anatomical defects. Hence, islets were isolated from RIPCreα2KO
and α1KORIPCreα2KO mice and islet GSIS was examined in vitro (ex vivo),
thus avoiding possible inter-tissue interaction such as increased sympathetic ner-
vous activity that can aﬀect islet insulin secretion.
Over a 10-fold increase over basal secretion (2 mmol/L glucose) was measured
in control islets in response to a stimulatory glucose (20 mmol/L) concentration.
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Figure 4.1: Pancreatic and beta cell mass in RIPCreα2KO and control mice.
Pancreas mass (mg) (A) and beta cell mass (mg) (B) in 10-week old male mice
(n = 4 vs 4). Data shown is mean ± SEM.
105
Control RIPCreα2KO
20 μm20 μm
Figure 4.2: Pancreatic sections from RIPCreα2KO and control mice. 10-week
male mice were used. Sections co-stained with insulin (red), glucagon (green)
and DAPI (blue).
In RIPCreα2KO and α1KORIPCreα2KO islets there was a significant increase
in insulin secretion in response to low glucose when compared to insulin secre-
tion from control islets, i.e. an increased basal insulin secretion. However, the
increase in insulin secretion over the basal secretion was reduced around 50 % in
RIPCreα2KO islets (Figure 4.3) and around 90 % in α1KORIPCreα2KO islet
(Figure 4.4).
In conclusion, RIPCreα2KO and α1KORIPCreα2KO islets showed a significant
increase in insulin secretion at basal (2 mmol/L) glucose concentration. At stimu-
latory (20 mmol/L) glucose concentration, RIPCreα2KO and α1KORIPCreα2KO
islets showed a significant reduction in insulin secretion. These results suggest
that impaired glucose-stimulated insulin secretion is due to an intrinsic beta cell
defect within the islets of RIPCreα2KO and α1KORIPCreα2KO mice. These
results indicate that expression of AMPK in beta cells is important for normal
glucose-stimulated insulin secretion.
4.4 Glucose sensing in AMPK deficient beta cells
Impaired GSIS could be caused by a defect in beta cell electrical activity. Nor-
mal beta cells are electrically active at >10 mmol/L glucose concentration, char-
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Figure 4.3: In vitro glucose-stimulated insulin secretion in RIPCreα2KO and
control islets. Groups of 5 islets were incubated either in 2 or 20 mmol/L glucose
for 1 hour and the amount of insulin secreted (as pg/islet/hour) was measured
(A). (B) represent the same data as a fold increase in insulin secretion over basal
secretion. Islets were isolated from 6 mice per genotype. 16-week old male mice
were used. Data shown are mean ± SEM, ∗P<0.05, ∗∗P<0.01 and ∗∗∗P<0.001.
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Figure 4.4: In vitro glucose-stimulated insulin secretion in α1KORIPCreα2KO
and control islets. Groups of 5 islets were incubated either in 2 or 20 mmol/L
glucose for 1 hour and the amount of insulin secreted (as pg/islet/hour) was
measured (A). (B) represent the same data as a fold increase in insulin secretion
over basal secretion. Islets were isolated from 6 mice per genotype. 16-week old
male mice were used. Data shown are mean ± SEM, ∗∗∗P<0.001.
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acterised by calcium action potential firing, reflected by plasma membrane de-
polarisation (Rorsman, 1997). When the glucose concentration is reduced to 2
mmol/L, beta cells become electrically silent, characterised by a loss of action
potentials and hyperpolarisation of the plasma membrane. RIPCreα2KO and
α1KORIPCreα2KO beta cells failed to become electrically silent when glucose
concentration was reduced from 10 to 2 mmol/L glucose, with continuous ac-
tion potential firing and depolarisation of the plasma membrane even at low
glucose concentration1 (Figure 4.5). This suggests that the RIPCreα2KO and
α1KORIPCreα2KO beta cells are unable to sense glucose properly. The continu-
ous electrical activity at low glucose concentration could also explain the increased
insulin secretion observed at low glucose concentration.
4.4.1 Gene expression analysis of Glut2 and hexokinases
in RIPCreα2KO islets
Loss of hypoglycaemic sensing could be caused by altered expression levels of the
GLUT2 glucose transporter, or the beta cell glucose sensor glucokinase.To deter-
mine whether the expression of genes, involved in glucose transport and glucose
sensing, is altered in RIPCreα2KO islets, Glut2 and Glucokinase mRNA levels
were measured using qRT-PCR (Figure 4.6). GLUT2 is the predominant glucose
transporter in beta cells. Glucokinase is a high Km hexokinase (hexokinase IV),
regarded as a beta cell glucose sensor as it phosphorylates glucose and initiates
glycolysis. However, no changes in Glut2 or Glucokinase mRNA expression levels
were detected.
Three low Km hexokinases are also expressed in beta cells, although at very low
levels. Hence mRNA levels of Hexokinases I, II and III were measured to see
whether altered glucose sensing could be due to changes in the low Km hexokinase
levels. However, no change in mRNA expression was detected (Figure 4.7).
1This experiment was conducted by C. Beall at University of Dundee in isolated islets from
mice that I generated.
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Figure 5 Loss of hypoglycaemic sensing in isolated β-cells from
RIPCreα2KO mice
WT (A) and RIPCre (B) mouse cultured β-cells respond, reversibly, to the reduction of glucose
from 10 to 2 mM by hyperpolarization and cessation of firing. (C) RIPCreα2KO β-cells are
unresponsive to a reduction of glucose concentration from 10 to 2 mM. The histograms in (A–C)
are the mean values for membrane potential in β-cells exposed to 10, 2 and 10 mM glucose for
each condition. Values were derived from seven to 19 individual β-cell recordings per group
and are shown as means+− S.E.M. **P < 0.01, ***P < 0.001.
Altered AMPK levels or activity do not modify ATP levels, glucose
uptake or GK activity
Changing AMPK activity may regulate the expression,
localization or activity of GK and GLUT2 [25–28]. Therefore we
explored whether altered AMPK activity modified glucose uptake
or metabolism in β-cells, using RIPCreα2KO islets and a rat β-
cell line. Although AMPKα2 mRNA was significantly reduced in
RIPCreα2KO compared with control islets, levels of GLUT2 or
GK mRNA were unchanged (Figure 7A and Supplementary Fig-
ure S2D at http://www.BiochemJ.org/bj/429/bj4290323add.htm).
Additionally, there was no change in the levels of mRNA for
the low-Km hexokinase isoforms (HK I–III) in RIPCreα2KO
islets compared with control islets (Supplementary Figures
S2A–S2C). The CRI-G1 cell line was used to examine the
actions of AMPK activity modification because it demonstrated
significant GK expression and an innate hypersensitivity to
glucose, whereby reducing glucose from 10 mM to 2 mM did
not affect cell membrane potential or firing frequency, although
lower glucose (<1 mM) levels caused hyperpolarization and
inhibition of firing (Supplementary Figures S3A and S3B
at http://www.BiochemJ.org/bj/429/bj4290323add.htm). CRI-G1
cells exhibited unchanged GLUT2 or GK protein expression,
GK localization (results not shown) and glucose uptake
(Supplementary Figure S3C) following stimulation or inhibition
of AMPK activity with AICAR (1 mM) or compound C
(40 µM) respectively. We next considered the possibility that
AMPKα2 acts as a negative regulator of GK activity. GK is
the primary glucose sensor of β-cells [29] and pharmacological
activation of β-cell GK with GKA50 increases insulin secretion
at 2 mM glucose [30], mimicking the RIPCreα2KO β-cell
phenotype. Indeed, exposure of WT β-cells to 100 nM GKA50
prevented hyperpolarization and inhibition of electrical activity
by hypoglycaemic challenge (Figure 7B). Furthermore, CRI-G1
cells displayed a glucose concentration-dependent increase in GK
activity (Figure 7C), significantly higher than for INS-1 cells
(CRI-G1 cells, ∼90–100 milli-units/mg of protein; INS-1
cells, 8–10 milli-units/mg of protein at 100 mM glucose [31]).
This is consistent with CRI-G1 insensitivity to low glucose as high
GK activity should raise cellular ATP and maintain KATP in the
closed state, analogous to activating GK mutations, which are also
characterized by hypersecretion of insulin at basal glucose levels
[32]. Our initial studies appeared to corroborate this hypothesis,
as AICAR (1 mM) caused significant inhibition (∼30%) of
GK activity in CRI-G1 cells, at glucose concentrations above
0.5 mM, and compound C prevented this effect (Figures 7C
and 7D). Although an attractive explanation for modification of
glucose sensing by AMPK, the inhibition of GK activity was
not replicated when AMPK activity was stimulated with the
direct AMPK activator [33], A-769662 (Figure 7E). Additionally,
the [ATP]/[ADP] ratio of CRI-G1 cells following stimulation or
inhibition of AMPK was unaffected (Figure 7F).
RIPCreα2KO islets also displayed unaltered mitochondrial
mass reflected by unchanged levels of ATP synthase (Figure 7G)
and mRNA levels of transcription factors involved in
mitochondrial energy metabolism, PGC1α, Tfam and Nrf were
unaltered (Figure 7A). In contrast, the mRNA level for the KATP
channel subunit, SUR1 (Figure 7A) was reduced, raising the
possibility that altered KATP current levels or ATP sensitivity
may underlie the lack of responsiveness to hypoglycaemia by
AMPKα2 deletion. However, the maximal KATP current and
ATP-sensitivity (Figures 8A and 8B) were unaltered between
RIPCreα2KO and RIPCre control β-cells. Overall, we could not
identify any alteration to glucose uptake, coupling of glucose
metabolism to mitochondrial ATP production or deficiency in
KATP channel function, which would explain the hypersecretion
of insulin at low glucose or the reduction in GSIS in AMPKα2-
deficient β-cells.
Islets lacking AMPKα2 have reduced UCP2, and UCP2 inhibition
causes glucose insensitivity of β-cells
Increased UCP2 activity has been reported to impair GSIS in islets
[34,35]. Conversely, UCP2 reduction increases GSIS [36,37],
and pharmacological inhibition of UCP2 with genipin stimulates
insulin secretion [38]. UCP2 mRNA was markedly suppressed
in RIPCreα2KO islets (Figure 7A). Furthermore, exposure of
WT β-cells to genipin prevented the hyperpolarization associated
with hypoglycaemic challenge (Figure 8C), but did not influence
c© The Authors Journal compilation c© 2010 Biochemical Society© 2010 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.
Figure 4.5: Loss of hypoglycaemic sensing in isolated beta cells fromRIPCreα2KO
mice. WT (A) and RIPCre (B) mouse cultured beta cells respond to the reduction
of glucose from 10 to 2 mmol/L by hyperpolarisation and cessation of firing. (C)
RIPCreα2KO beta cells are unresponsive to a reduction of glucose concentration
from 10 to 2 mmol/L. The histograms in (A-C) are the mean values f membrane
potential in beta cells exposed to 10, 2 and 10 mmol/L glucose for each condition.
Values were derived from seven to 10 individual beta cell recordings per group
and are shown as mean ± SEM, ∗∗P <0.01, ∗∗∗P<0.001. 14-week old male mice
were used. Figure from Beall et al. (2010), produced by C. Bea l.
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Figure 4.6: Expression levels of Glut2 (solute carrier family 2 [facilitated glucose
transporter], member 2 gene, Slc2a2) and Glucokinase in RIPCreα2KO and con-
trol islets. 20-week old male mice were used (n = 7-8). Data shown are mean ±
SEM.
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Figure 4.7: Expression of hexokinase isoforms (I-III) in RIPCreα2KO and control
islets. 20-week old male mice were used (n = 7-8). Data shown are mean ± SEM.
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4.5 Mitochondrial function in RIPCreα2KO islets
Because proper mitochondrial biogenesis is essential for functional beta cells, es-
pecially in terms of insulin secretion, mRNA expression levels of three genes,
Nrf1, Tfam and Pgc-1α, involved in the regulation of mitochondrial biogenesis,
respiration and mitochondrial DNA transcription were also measured (Scarpulla,
2008, 2002). However, the expression of these genes remained unchanged in
RIPCreα2KO islets (Figure 4.8).
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Figure 4.8: Expression of mitochondrial biogenesis regulating genes in
RIPCreα2KO and control islets. Nrf1 (Nuclear respiratory factor 1 gene), Pgc-
1α (Peroxisome proliferator-activated receptor gamma coactivator-1 alpha gene),
Tfam (Transcription factor A, mitochondrial gene). 20-week old male mice were
used (n = 5-6). Data shown are mean ± SEM.
Previous studies have indicated a link between AMPK and UCP2 expression.
For example, UCP2 expression was reduced in the aortas of AMPKAα2 -global-
null mice, and decreased in response to AMPK activation (Xie et al., 2008).
UCP2 has also been shown to aﬀect islet GSIS, although whether it is involved in
stimulating or inhibiting GSIS has remained unclear (Pi et al., 2009; Zhang et al.,
2001). Therefore, mRNA expression of Ucp2 was measured in RIPCreα2KO and
control islets, and was found to be significantly downregulated (Figure 4.9). To
confirm that reduction in Ucp2 expression was not caused by reduced mitochon-
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drial mass, mitochondrial mass was estimated by examining the expression of
mitochondrial protein ATP synthase. No change in mitochondrial mass observed
reflected by unchanged ATP synthase levels (Figure 4.10).
0
50
100
***
Control RIPCreα2KO
U
cp
2 
m
R
N
A
 e
xp
re
ss
io
n
(%
 o
f m
ea
n 
co
nt
ro
l)
Figure 4.9: Gene expression levels of Ucp2 (Uncoupling protein 2 ) gene in
RIPCreα2KO and control islets. 20-week old male mice used (n = 5-6). Data
shown is mean ± SEM, ∗∗∗P<0.001.
Control RIPCreα2KO
ATP synthase
Actin
Figure 4.10: Immunoblot for ATP synthase from RIPCreα2KO and control islets.
4.5.1 Production of reactive oxygen species in
RIPCreα2KO and α1KORIPCreα2KO islets
UCP2 is an important regulator of mitochondrial reactive oxygen species (ROS)
production. Previous studies have shown that reduction of UCP2 in beta cells
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can lead to increased ROS production and impaired GSIS (Joseph et al., 2002).
Hence, H2O2 production (as an indicator of ROS generation) determined by CM-
H2DCFDA fluorescence was measured at 2 and 20 mmol/L glucose concentrations
in control, RIPCreα2KO and α1KORIPCreα2KO islets (Figure 4.11). However,
no diﬀerences in CM-H2DCFDA fluorescence was detected.
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Figure 4.11: H2O2-derived fluorescence in RIPCreα2KO, α1KORIPCreα2KO and
control islets at 2 and 20 mmol/L glucose concentration. Islets were isolated from
3 mice per genotype (n = 16-23 islets in each condition). Data shown are mean
± SEM.
To investigate whether increased anti-oxidant enzyme levels could have ex-
plained why ROS levels remained unchanged between control and RIPCreα2KO
and α1KORIPCreα2KO islets, mRNA expression levels of Gpx4, Hmox1 and
Sod2 were measured in RIPCreα2KO and control islets. However, no change in
Gpx4 and Hmox1 expression levels were detected, and surprisingly, Sod2 levels
showed a minor reduction between RIPCreα2KO and control islets (Figure 4.12).
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Figure 4.12: Expression of antioxidant enzymes in RIPCreα2KO and control
islets. Gpx4 (Glutathione peroxidase 4 gene), Hmox1 (Heme oxygenase (decycling
1) gene), Sod2 (Superoxide dismutase 2 gene). 20-week old male mice were used
(n = 8-10). Data shown are mean ± SEM, ∗P<0.05.
4.6 KATP -channel function inRIPCreα2KO beta
cells
As the RIPCreα2KO beta cells remained electrically active at low glucose con-
centration and insulin secretion was significantly elevated, it was postulated that
the KATP -channels remain closed at low glucose (Beall et al., 2010). Loss of func-
tion mutations of KATP -channel subunits or reduced expression of KATP -channels
on the plasma membrane have been shown to cause increased electrical activity
and insulin secretion at low glucose (Ashcroft, 2005; Miki et al., 1998; Seghers
et al., 2000). Previous studies have shown that deletion of Sur1 leads to alter-
ations in insulin secretion(Chan et al., 2004a). Hence, mRNA expression of Sur1,
a subunit of the KATP -channel was measured. Surprisingly, expression of Sur1
was significantly downregulated (Figure 4.13). Reduced Sur1 expression levels
could indicate an alteration in KATP -channel function or ATP-sensitivity, which
could explain altered insulin secretion at basal, hypoglycaemic levels. However,
voltage-clamped whole-cell currents in control and RIPCreα2KO beta cells at
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various ATP concentrations were unaltered1 (Figure 4.14). These results indicate
that even though Sur1 expression is reduced, the KATP -channels in RIPCreα2KO
beta cells have a normal decreased channel conductivity in response to increased
ATP concentration, and voltage-clamped currents are also normal.
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Figure 4.13: Gene expression level of KATP -channel subunit gene Sur1 (Sulfony-
lurea receptor 1 gene) in RIPCreα2KO and control islets. 20-week old male mice
used (n = 5-6). Data shown are mean ± SEM, ∗∗∗P<0.001.
4.7 Summary
Deletion of AMPK catalytic subunits in beta cells caused glucose intolerance and
impaired glucose-stimulated insulin secretion in vivo. Even though these animals
had a normal hypothalamic function and normal peripheral insulin sensitivity,
more detailed examination of AMPK deficient islets in vitro was necessary in
order to obtain a better understanding of the role of AMPK in regulation of beta
cell function.
Impaired GSIS could result from a change in beta cell mass or beta cell dys-
function. Recently, an AMPK upstream kinase, LKB1, has been implicated in
1This experiment was conducted by C. Beall at University of Dundee
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Figure 4.14: Loss of AMPKα2 does not alter beta cell KATP current or ATP sen-
sitivity. (A) Current-voltage relationship for voltage-clamped currents of RIPCre
control (black symbols) and RIPCreα2KO (grey symbols) cultured beta cells.
Mean currents were measured at various membrane potentials shortly after at-
taining whole-cell recording (i.e. prior to significant washout of cell ATP; filled
squares) and 20 min later (following maximal washout of cellular ATP; filled
circles. (B) Mean slope conductance values for current-voltage relationships as
shown in (A) as a function of [ATP] (0, 0.5, 1.0 or 3.0 mM in the pipette solu-
tion). Lines of best fit (dose-response) are shown for RIPCre control (black filled
squares) and RIPCreα2KO (grey filled circles) beta cells (n = 3-6). Figure from
Beall et al. (2010), produced by C. Beall.
117
regulation of beta cell mass. Deletion of LKB1 in beta cells led to increased beta
cell mass and cell proliferation, and change in cell polarity (Granot et al., 2009;
Sun et al., 2010b). Therefore it could be possible that loss of AMPK in beta cells
could also lead to changes in islet beta cell mass. However, no change in beta cell
mass was observed in RIPCreα2KO mice. Because the beta cell mass was found
to be normal, it was even more likely that impaired GSIS was due to an intrinsic
beta cell defect.
In vitro GSIS was assessed in RIPCreα2KO and α1KORIPCreα2KO islets. The
increase in insulin secretion over basal secretion level was significantly reduced
in RIPCreα2KO and α1KORIPCreα2KO islets at 20 mmol/L glucose. These
results further confirm that the impaired GSIS observed in vivo is due to an
intrinsic beta cell defect in the RIPCreα2KO and α1KORIPCreα2KO mice. In-
terestingly, at a low glucose concentration both the AMPK single and double KO
islets secreted significantly more insulin in response to 2 mmol/L glucose. This
eﬀect was more profound in the double KO islets. In vitro GSIS results suggest
that AMPK could be involved in sensing low and high glucose concentrations and
regulating insulin secretion correspondingly.
To further examine whether there could be a change in beta cell glucose sensing,
electrical activity in control and RIPCreα2KO beta cells was measured by C.
Beall. In RIPCreα2KO beta cells, plasma membrane was not hyperpolarised and
action potentials could still be recorded when glucose concentration was reduced
to 2 mmol/L. Continuous electrical activity at low glucose concentration could
also explain the increased insulin secretion measured at basal glucose level.
Therefore AMPK seems to be involved in glucose sensing and regulation of in-
sulin secretion. Loss of low glucose sensing could be caused by altered expression
levels of glucose transporter Glut2 and Glucokinase (hexokinase IV), which acts
as a rate-limiting enzyme of the glycolysis. However, both Glut2 and Glucoki-
nase mRNA levels were normal in RIPCreα2KO islets in comparison to control
islets. Expression levels of three low Km hexokinases (Hexokinase I, II and III )
were also found normal in RIPCreα2KO islets.
Impaired mitochondrial function, including defect in key genes regulating mito-
chondrial biogenesis was assessed. However, mRNA expression of Nrf1, Tfam and
Pgc-1α were all normal in RIPCreα2KO islets. Previous studies have indicated
118
that UCP2 might have a role in regulating beta cell glucose-stimulated insulin se-
cretion. Furthermore, reduced UCP2 expression has been reported in the aortas
of AMPKα2 -global-null mice, indicating a link between AMPK and UCP2 (Xie
et al., 2008). Interestingly, mRNA expression of Ucp2 in RIPCreα2KO islets was
significantly reduced, and it was confirmed that the reduction was not caused by
decreased mitochondrial mass but genuine reduction in Ucp2 gene expression.
Genetical knockdown of Ucp2, and inhibition of UCP2 activity by genipin has
been shown to result in increased glucose-stimulated insulin secretion (Zhang
et al., 2006). To further examine the relationship between reduced Ucp2 expres-
sion in RIPCreα2KO islets, and increased electrical activity and insulin secretion
at low glucose concentration, we showed (Beall et al., 2010) that treatment of
wt beta cells with the UCP2 inhibitor genipin resulted in a similar electrophysio-
logical phenotype that was observed in RIPCreα2KO beta cells with a failure to
hyperpolarise the plasma membrane at low glucose concentration. These results
suggest that loss of glucose sensing and increased insulin secretion at low glucose
might result from UCP2-dependent mechanism.
Mitochondrial uncoupling proteins are linked to generation of reactive oxygen
species (ROS). ROS generation has been linked to regulation of glucose-stimulated
insulin secretion. Previous studies have shown that reduced UCP2 levels result
in increased ROS production, which could stimulate insulin secretion from beta
cells (Pi et al., 2010). Hence ROS production was measured in RIPCreα2KO
and α1KORIPCreα2KO islets. However, no diﬀerence in ROS generation was
measured between control and KO islets. Hence, the defective GSIS observed was
not due to alterations in ROS generation.
The RIPCreα2KO beta cells failed to hyperpolarise the plasma membrane in re-
sponse to hypoglycaemia and basal insulin secretion was elevated. Loss of func-
tion mutations of KATP -channel subunits or reduced expression of KATP -channels
on the plasma membrane have been shown to cause increased electrical activity
and insulin secretion at low glucose (Ashcroft, 2005; Miki et al., 1998; Seghers
et al., 2000). Furthermore, deletion of the KATP -channel subunit Sur1 has been
shown to cause impaired islet insulin secretion (Seghers et al., 2000). Hence,
Sur1 mRNA expression levels were measured in RIPCreα2KO islets and found
to be significantly reduced. This indicated that perhaps KATP -channels in the
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RIPCreα2KO beta cells had a change in ATP-sensitivity or channel conductance.
However, voltage-clamped currents assessed at various ATP concentrations, mea-
sured by C. Beall were unaltered in RIPCreα2KO beta cells. Hence, even though
Sur1 gene expression was reduced, no defect in ATP-sensitivity or channel con-
ductance was found that could explain the increased electrical activity and insulin
secretion at low glucose.
As a summary, deletion of AMPKα2 and AMPKα1 catalytic subunits in beta
cells causes impaired glucose-stimulated insulin secretion. At a low glucose con-
centration, beta cells deficient in AMPK secrete significantly more insulin, but
at a stimulatory glucose concentration the insulin secretion is reduced. Increased
insulin secretion at low glucose it most likely caused by continuous electrical
activity and maintenance of plasma membrane depolarisation at this concentra-
tion. Our results suggest that AMPK is required in beta cells for glucose sensing
at low and stimulatory glucose concentration, and regulation of insulin secretion
accordingly. It is possible that this regulation is dependent on the mitochondrial
uncoupling protein UCP2 but the more detailed mechanisms remain yet to be
determined.
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Chapter 5
Physiological characterisation of
RIPCrep110αβKO mice and
determination of in vitro beta
cell function
5.1 Introduction
Activation of tyrosine kinase receptors, such as insulin and IGF-1 receptors, leads
to activation of phosphoinositide 3-kinase (PI3K) (Kozma and Thomas, 2002).
Once activated, class IA PI3Ks phosphorylate membrane associated PI(3,4)P2,
which leads to generation of PI(3,4)P3. PIP3 mediates signals downstream from
PI3K by functioning as a docking site and activator for multiple enzymes such
as Pdk1, Akt and PKC (Cantley, 2002). Hence metabolic signalling from insulin
and IGF-1 receptors are mediated via PI3K, and results in a regulation of a
wide variety of diﬀerent metabolic and cellular functions such as cell growth and
survival, and in beta cells insulin secretion (Leibiger and Berggren, 2008).
Previous studies that have studied the class IA catalytic isoforms have highlighted
a key role for catalytic isoforms in insulin signalling. Gene targeting and use of
isoform specific inhibitors have shown that p110α isoform is a predominant class
IA catalytic isoform that associates with IRS-1/2 complexes and mediates signals
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downstream from the insulin receptor (Foukas et al., 2006; Guillermet-Guibert
et al., 2008; Hooshmand-Rad et al., 2000). On the contrary, we have shown a
dominant role for p110β in POMC and AgRP neurons in the regulation of whole-
body energy homeostasis and hypothalamic insulin- and leptin-receptor signalling
(Al-Qassab et al., 2009).
The role of PI3K in pancreatic beta cells has been investigated using non-
specific inhibitors of PI3K catalytic subunits (Aspinwall et al., 2000; Kubota
et al., 2004). However, no research exists that directly examines the role of
both p110α and p110β subunits in pancreatic beta cell function in vivo and
in vitro. Hence we have generated mice that express kinase dead p110α and
p110β subunits (simultaneously) in pancreatic beta cells under rat insulin pro-
moter (RIP) cre-recombinase. The aim was to investigate the whole-body glucose
homeostasis in these mice as well as to look at the in vitro mechanism that results
in dysfunctional PI3K signalling in pancreatic beta cells.
5.2 Analysis of deletion
5.2.1 Eﬃcacy of p110α and p110β deletion
Both p110α and p110β floxed alleles are designed to create a kinase dead catalytic
subunit upon cre-mediated recombination without changing the stoichiometry
between the p110 catalytic and p85 regulatory subunit (Graupera et al., 2008;
Guillermet-Guibert et al., 2008). Hence transcription and translation of both
the subunits should remain normal despite manipulation of kinase activity loop
regions within the subunit genes. In order to confirm that transcription of p110α
and p110β catalytic subunits and p85 regulatory subunit are unchanged, their
islet and hypothalamic1 mRNA levels in RIPCrep110αβKO and control mice
were measured by real time quantitative PCR (qRT-PCR). No change in p110α,
p110β or p85 islet mRNA levels were detected (Figure 5.1).
Significant reduction in the PI3K lipid kinase activity was confirmed in the
RIPCrep110αβKO islets in comparison to controls, demonstrating that RIPCre
1Experiment and figure by H. Al-Qassab at UCL
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Figure 5.1: Expression of catalytic (p110α and p110β) and regulatory (p85 )
subunits of PI3K in RIPCrep110αβKO and control islets (A) and hypothalami
(B). 16-week old male mice were used (n = 8 vs 6). Data shown are mean ± SEM.
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mediated recombination of floxed p110α and p110β alleles is successful1 (Figure
5.2). RIPCrep110αβKO islet protein lysates were treated with isoform selective
inhibitors (PIK75 against p110α and TGX221 against p110β) and relative PI3K
activity was measured. This suggested that in the RIPCrep110αβKO islets, some
of the PI3K p110α specific kinase activity still remained after RIPCre mediated
recombination and disruption of p110α. However, no further reduction in p110β
specific kinase activity was detected.
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A. western blot 
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(A).  Western Blot analysis of total cell lysate from WT islets treated with DMSO or the indicated inhibitor. 
(B) Total class IA activity was immunoprecipitated from WT or KO islets using an antibody recognizing the 
p85 adapter subunit. PI3K activity was then assayed in the presence of 100 nM of the indicated inhibitor. A 
representative TLC profil as well as quantification of PI3K assays performed from independent 
determinations are shown. (n=10 and 11 for KO and WT mice, respectively); Results are expressed relative 
to the activity in the presence of DMSO and presented as mean ± SEM. P-values were calculated using the 
non-parametric one-way ANOVA, followed by Dunnett's Multiple Comparison Test. P-values !0.05 were 
considered to be statistically significant (designated by a single asterisk; double asterisk, P!0.01; triple 
asterisk, P-values !0.001). 
DMSO 
PIK75 
TGX221 
IC87114 
+ 
+ 
+ 
+ 
KO 
+ 
+ 
+ 
+ 
WT 
WT 
KO 
!-actin 
**
*
***
Figure 5.2: Lipid kinase activity in RIPCrep110αβKO and control islets. To-
tal class IA activity was immunoprecipitated with p85 antibody from control
or RIPCrep110αβKO islets. PI3K activity was then assayed in the presence of
100 nM of the indicated inhibitor or DMSO. PIK75 inhibits the p110α isoform,
TGX221 inhibits the p110β i ofo m and IC87114 inhibits the p110δ soform. A
representative TLC profile as well as quantification of PI3K assays performed
from independent determinations are shown (n=10 and 11 for KO and WT mice,
respectively); Results are expressed relative to the activity in the presence of
DMSO and presented as mean ± SEM, ∗P<0.05, ∗∗P<0.01 and ∗∗∗P<0.001. Fig-
ure produced by C. Chaussade.
1Experiment and figure by C. Chaussade at Queen Mary, University of London
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5.3 Glucose homeostasis in RIPCre110αβKO mice
Blood glucose concentrations of fasted, random fed and post-glucose injected
RIPCrep110αβKO and control mice were measured to investigate glucose han-
dling in these animals. In vivo glucose-stimulated insulin secretion was performed
to assess insulin secretory function of pancreatic beta cells. Fasted and fed plasma
insulin levels were measured and insulin tolerance tests performed to investigate
insulin sensitivity in RIPCrep110αβKO mice.
5.3.1 Fasted/fed glucose
Fasted blood glucose levels were significantly increased in 12-week old
RIPCrep110αβKO male mice (Figure 5.3). This indicates that the RIPCrep110αβKO
mice are unable to handle glucose levels properly in fasting conditions. Random
fed blood glucose levels in 8-week old RIPCrep110αβKO male mice were also
significantly elevated, suggesting that blood glucose levels are not controlled suf-
ficiently after feeding and RIPCrep110αβKO mice might be glucose intolerant
(Figure 5.3).
5.3.2 Glucose tolerance
Glucose tolerance tests were performed on the male RIPCrep110αβKO mice and
their littermate controls at 6- and 12-weeks of age (Figure 5.4). At 6-weeks of age
RIPCrep110αβKO mice were significantly less glucose tolerant than control mice.
At 12-weeks of age RIPCrep110αβKO mice displayed marked glucose intolerance:
even 2 hours after glucose challenge the mean blood glucose levels were 18.7
mmol/L compared to 6.5 mmol/L in control mice.
5.3.3 Insulin sensitivity
Insulin sensitivity was assessed in RIPCrep110αβKO and control mice. Fasted
and fed plasma insulin levels were measured to establish whether RIPCrep110αβKO
mice are hypo/hypersecreting insulin. Both the fasted and fed plasma insulin lev-
els were found to be normal, indicating that the RIPCrep110αβKO mice are not
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Figure 5.3: Fasted and fed blood glucose levels in RIPCrep110αβKO and control
mice. (A) blood glucose levels after a 16-hr fast in 12-week old and (B) random fed
blood glucose levels in 8-week old male mice (n = 8 vs 7). Bloods were collected
from tail bleeds. Data shown are mean ± SEM, ∗∗P<0.01.
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Figure 5.4: Glucose tolerance in RIPCrep110αβKO and control mice. Glucose
tolerance test; blood glucose concentrations were measured from tail bleeds at
indicated times after i.p. injection of 20 % D-glucose (2 g/kg); (A) 6-week old
male mice (n= 21 vs 20) and (B) 12-week old male mice (n = 7 vs 8). Data
shown are mean ± SEM, ∗P<0.05, ∗∗P<0.01 and ∗∗∗P<0.001.
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insulin resistant (Figure 5.5). To further confirm this, an insulin tolerance test
was performed to measure insulin sensitivity of insulin target tissues. Glucose
clearance in response to insulin was equivalent in RIPCrep110αβKOs compared
to control animals (Figure 5.6). Together these results demonstrate normal insulin
sensitivity in RIPCrep110αβKO mice.
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Figure 5.5: Fasted and fed plasma insulin levels in RIPCre110αβKO and control
mice. A) Plasma insulin levels after a 16-hr fast in 12-week old and B) random
fed plasma insulin levels in 8-week old male mice (n = 8 vs 7). Bloods were col-
lected from tail bleeds and plasma insulin levels were measured with a Rat/Mouse
Insulin Elisa Kit. Data shown are mean ± SEM.
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Figure 5.6: Insulin sensitivity in RIPCrep110αβKO and control mice. Blood
glucose concentrations were measured from tail bleeds at indicated times after
i.p. injection of insulin (0.75 mU/kg. Random fed, 8-week old male mice were
used (n = 7 vs 8). Data shown are mean ± SEM, ∗∗P<0.01.
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5.3.4 Glucose-stimulated insulin secretion in vivo
As the RIPCrep110αβKO did not show any signs of insulin resistance but were
overly glucose intolerant it is likely that the impaired glucose tolerance is caused
by defective glucose-stimulated insulin secretion from pancreatic beta cells. To de-
tect any insulin secretory defects in RIPCrep110αβKO mice, a glucose-stimulated
insulin secretion (GSIS) test was performed on 8-week old RIPCrep110αβKO and
control mice. The test showed a significant diﬀerence between insulin secretion
in response to glucose injection in RIPCrep110αβKO and control mice (Fig-
ure 5.7). This revealed that even though fasted insulin levels were equivalent to
those measured in control mice, RIPCre110αβKO mice exhibited significantly
impaired insulin secretory function in response to a glucose challenge. Both
the first- and second phase of insulin secretion were significantly decreased in
RIPCrep110αβKO mice, and the familiar secretion profile seen in control mice
was almost completely lost in RIPCrep110αβKO mice.
5.4 Analysis of glucose-stimulated insulin secre-
tion in vitro
RIPCrep110αβKO mice showed a clear defect in their insulin secretory function
in vivo. However, because of the disruption in PI3K signalling in the hypotha-
lamus, and in order to avoid any inter-tissue interaction, it was necessary to
examine RIPCrep110αβKO islet function in vitro in order to confirm that the
impaired glucose homeostasis phenotype observed in vivo was due to a defect
specifically in islet GSIS. Islets isolated from RIPCrep110αβKO control mice
were used to measure static glucose-stimulated insulin secretion (GSIS) in vitro
(ex vivo) (Figure 5.8).
Control islets demonstrated a significant increase in insulin secretion be-
tween basal 2 mmol/L and stimulatory 20 mmol/L glucose concentration, as
expected. RIPCrep110αβKO islets also showed a significant increase in insulin
secretion between 2 mmol/L and 20 mmol/L glucose concentrations. However,
the increase in insulin secretion between basal and stimulatory glucose concen-
trations in RIPCrep110αβKO islets was significantly less than in control islets.
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Figure 5.7: In vivo glucose-stimulated insulin secretion in RIPCrep110αβKO and
control mice. Bloods were collected from tail bleeds at indicated times after i.p.
injection of 20 % D-glucose (2 g/kg) and plasma insulin levels were measured
with a Rat/Mouse Insulin Elisa Kit. 8-week old male mice used (n= 5 vs 6).
Data shown are mean ± SEM, ∗∗∗P<0.001.
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At basal glucose concentration, insulin secretion was also significantly less in
RIPCrep110αβKO islets than in control islets.
0
100
200
300
400 Control  
RIPCrep110αβKO
2 20
Glucose concentration (mmol/L)
2 20 
***
*
*
***
In
su
lin
 s
ec
re
tio
n 
(p
g/
is
le
t/
ho
ur
)
Figure 5.8: In vitro glucose-stimulated insulin secretion from RIPCrep110αβKO
and control islets. Groups of 5 islets were incubated either in 2 or 20 mmol/L
glucose for 1 hour and the amount of insulin secreted (as pg/islet/hour) was
measured. Islets were isolated from 6 mice per genotype. 12-week old male mice
were used. Data shown are mean ± SEM, ∗P<0.05 and ∗∗∗P<0.001.
5.5 Beta cell morphology
The PI3K signalling pathway has been shown to be important for regulation of
cell growth and survival. For example, deletion of the negative regulator of PI3K,
PTEN, in mouse beta cells (RIPCrePTENKO) leads to increased beta cell pro-
liferation, cell size and mass (Elghazi and Bernal-Mizrachi, 2009). On the other
hand lack of IRS-2 in pancreatic beta cells (PdxCreIRS-2KO) decreases beta cell
proliferation and leads to decreased beta cell mass and pancreatic insulin content
(Cantley et al., 2007). Hence pancreatic and beta cell mass in RIPCrep110αβKO
132
and control mice were measured and islet density determined (Figures 5.9, 5.10).
However, no alterations in pancreas or beta cell mass, or in islet density were
found in RIPCrep110αβKO mice.
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Figure 5.9: Pancreatic (A) and beta cell mass (B) in RIPCrep110αβKO and
control mice. 12-week old male mice were used (A; n = 8 vs 7, B; n = 4 vs 4).
Data shown are mean ± SEM.
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Figure 5.10: Islet density in RIPCrep110αβKO and control mice. Number of
islets per mm2 pancreas section. 12-week old male mice used. 12-week old male
mice used (n = 4 vs 4). Data shown is mean ± SEM.
5.6 RIPCre110αβKO islet gene expression
Relative mRNA expression of genes involved in glucose uptake and PI3K sig-
nalling pathway were measured in RIPCrep110αβKO and control islets (Figure
5.11). Transcription of upstream and downstream molecules of the PI3K sig-
nalling cascade such as Irs-1, Pten, Akt, FoxO1 and Ins II was normal. Glut2
(i.e. Slc2a2 ) expression was also unaltered. Small increase in mRNA expression
of pyruvate dehydrogenase kinase 1 (Pdk1 ) was detected in RIPCrep110αβKO
islets.
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Figure 5.11: Expression of key beta cell genes in RIPCrep110αβKO and control
islets. Glut2 (Slc2a2 (solute carrier family 2 [facilitated glucose transporter],
member 2 gene), Ins II (Insulin II gene), Pten (Phosphatase and tensin homolog
gene), Akt (Protein kinase B gene), FoxO1 (Forkhead box O1 gene), Pdk1 (Pyru-
vate dehydrogenase kinase, isoenzyme 1 gene), Irs-1 (Insulin receptor substrate
1 gene). 16-week old male mice used (n = 8 vs 6). Data shown is mean ± SEM,
∗P<0.05.
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5.7 Investigation of energy homeostasis in
RIPCrep110αβKO
5.7.1 Body weight
As described above, the RIPCre transgene deletes in a small population of hy-
pothalamic neurons. RIPCreIRS-2KO mice showed a marked hypothalamic phe-
notype such as increased body weight and body fat, and increased food intake
(Choudhury et al., 2005). Hence it was important to characterise hypothala-
mic function in RIPCrep110αβKO mice as changes in hypothalamic activity was
expected based on previous studies.
RIPCrep110αβKO mice had significantly increased body weight from 8-weeks
of age onwards (Figure 5.12). This was observed both in male and female mice,
however only male data are shown. All other experiments used for assessment
of hypothalamic function were only performed in male mice in order to reduce
animal usage (three Rs, Home Oﬃce Animal Act 1986).
5.7.2 Body length
When just visually inspecting RIPCrep110αβKO mice, they appeared bigger and
longer (Figure 5.13). Measurement of naso-anal body length (cm) showed that
RIPCrep110αβKO mice were significantly longer than control mice (Figure 5.14).
5.7.3 Body composition
Even though RIPCrep110αβKO mice were heavier, they did not just appear
fatter than control mice but bulkier overall, which is usually a sign of a dis-
rupted melanocortin signalling Butler (2006); Huszar et al. (1997). Hence a dual
energy X-ray absorptiometry (DEXA) scan was performed which showed that
RIPCrep110αβKO mice had significantly increased lean and fat tissue mass and
about 28 % increase in body fat % (Figure 5.15). The mice also had significantly
increased bone mineral density (g/cm2) and bone mineral content (g) (Figure
5.15).
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Figure 5.12: Body weight curve for male RIPCrep110αβKO and control mice.
Data shown are mean ± SEM (n = 15-20 mice per genotype), ∗∗P<0.01 and
∗∗∗P<0.001.
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Figure 5.13: Photograph of male (A) and female (B) RIPCre110αβKO (right)
and control (left) mice at 16 weeks and 12 months of age respectively.
138
02
4
6
8
10
12
**
Control RIPCrep110αβKO
B
od
y 
le
ng
th
 (c
m
)
Figure 5.14: Naso-anal body length (cm) in RIPCre110αβKO and control mice.
10-month-old male mice used (n = 8 vs 7). Data shown are mean ± SEM,
∗∗P<0.01.
5.7.4 Expression of neuropeptides in RIPCrep110αβKO
Because of the hypothalamic expression of kinase dead p110α and p110β genes in
RIPCre neurons of RIPCrep110αβKO mice, expression levels of key hypothalamic
neuropeptides AgRP, Npy and Pomc were measured in the hypothalamus of
RIPCrep110αβKO and control mice 1. Both the mRNA expression of AgRP and
Pomc were significantly reduced in the hypothalamus of RIPCrep110αβKO mice
(Figure 5.16).
5.7.5 Fasted leptin
Circulating plasma leptin levels are usually proportional to body fat mass. Be-
cause RIPCrep110αβKO mice had increased body fat %, fasted plasma leptin
levels (ng/ml) were measured, which showed that RIPCrep110αβKO mice had
significantly increased fasted plasma leptin levels (Figure 5.17).
1Experiment and figure produced by H. Al-Qassab at UCL
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Figure 5.15: Body composition analysis by DEXA scan in RIPCrep110αβKO
and control mice. (A) Fat tissue mass, (B) Body fat %, (C) Lean tissue mass (g),
(D) Bone mineral density (g/cm2) (g), (E) Bone mineral content (g). 10-month-
old male mice used (n = 8 vs 7). Data shown are mean ± SEM, ∗P<0.05 and
∗∗∗P<0.001.
140
AgRP Npy Pomc
0
50
100
** **
m
R
N
A
 e
xp
re
ss
io
n
(%
 o
f m
ea
n 
co
nt
ro
l)
Figure 5.16: Expression of hypothalamic neuropeptides in RIPCrep110αβKO and
control hypothalami. AgRP (Agouti-related peptide gene), Npy (neuropeptide
Y gene) and Pomc (pro-opiomelanocortin gene). 16-week-old male mice used (n
= 8 vs 8). Data shown are mean ± SEM, ∗∗P<0.01. Figure produced by H. Al-
Qassab.
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Figure 5.17: Plasma leptin levels after a 16-hr fast in RIPCrep110αβKO and
control mice. 12-week old male mice were used (n = 8 vs 7). Blood was collected
from tail bleeds and plasma leptin levels were measured with a Rat/Mouse Leptin
Elisa Kit. Data shown are mean ± SEM with unpaired student t-test ∗∗∗P<0.001.
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5.7.6 Feeding behaviour
Because RIPCrep110αβKO mice were much heavier and had increased body fat
it was obvious to investigate the feeding behaviour of RIPCrep110αβKO mice.
Interestingly, 24-hr food intake and feeding behaviour for 24-hrs after a overnight
fast were found to be normal in RIPCrep110αβKO mice in comparison to con-
trol mice (Figures 5.18, 5.19). There was significantly decreased food intake
in RIPCrep110αβKO mice 8-hr after re-feeding. However, when considering the
overall feeding behaviour over the 24-hr period it is quite safe to conclude that
there are not any diﬀerence in feeding behaviour in response to an overnight fast.
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Figure 5.18: 24-hr food intake in RIPCre110αβKO and control mice. 12-week
old male mice were used (n = 8 vs 7). Data shown are mean ± SEM.
5.7.7 Basal metabolic rate
Because RIPCrep110αβKO mice were shown to have a normal feeding behaviour
their basal metabolic rate was measured in order to determine whether increased
body weight was due to a slower basal metabolic rate. However, no diﬀerence
was detected between RIPCrep110αβKO and control mice (Figure 5.20).
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Figure 5.19: Feeding behaviour after a 16-hr fast in RIPCrep110αβKO and con-
trol mice. 16-week old male mice were used (n = 8 vs 7). Data shown are mean
± SEM, ∗P<0.05.
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Figure 5.20: Basal metabolic rate in RIPCrep110αβKO and control mice. 16-
week old male mice were used (n = 8 vs 7). Data shown are mean ± SEM.
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5.7.8 Leptin sensitivity
Circulating plasma leptin levels are usually found to be increased in obesity (El-
Haschimi et al., 2000). However, this does not mean that leptin could have a
greater eﬀect in suppressing appetite in obese subject. In fact, it is usually the
opposite as obese subject are often found to be leptin resistant, meaning that
leptin binding to leptin receptors does not activate the leptin receptor signalling
cascade.
Hence, mice were treated with vehicle or leptin and their feeding behaviour
in response to leptin treatment was investigated (Figure 5.21). As can be seen,
both control and RIPCrep110αβKO mice lost body weight and had decreased
food intake when treated with leptin in comparison to vehicle treatment. How-
ever, RIPCrep110αβKO mice ate significantly more when treated with leptin
than control mice, even though the food intake was still less than when treated
with vehicle. This indicates that there is some degree of leptin resistance in
RIPCrep110αβKO mice but leptin still has a significant impact on reducing food
intake in RIPCrep110αβKO mice.
5.7.9 MT-II sensitivity
Melanocortin signalling also has an important role in controlling feeding be-
haviour and adiposity. MT-II is a melanocortin receptor agonist that reduces
food intake (Seeley et al., 2005). RIPCrep110αβKO and control mice were in-
jected with MT-II or vehicle and their food intake was measured for a 24-hr
period after an overnight fast. MT-II had a similar eﬀect of reducing food intake
in both RIPCrep110αβKO and control mice in comparison to vehicle (Figure
5.22). The eﬀect of MT-II was greatest within the first 4 hr after re-feeding,
when there was a significant reduction in food intake in RIPCrep110αβKO and
control mice.
145
-10
-8
-6
-4
-2
0
2
4
6
leptin
vehicle
Control RIPCrep110αβKO
**
*
A)
C
ha
ng
e 
in
 b
od
y 
w
ei
gh
t (
%
)
0
2
4
6
8
10
12
14
16
Control RIPCrep110αβKO
**
**
*
B)
vehicle
leptin
3-
d
ay
 fo
od
 in
ta
ke
 (g
)
Figure 5.21: Leptin sensitivity in RIPCrep110αβKO and control mice. The re-
sponse to 3 day i.p. administration of leptin (5 µg/g) upon (A) body weight and
(B) food intake in 17-week old male mice (n = 8 vs 7). Data shown are mean ±
SEM, ∗P<0.05 and ∗∗P<0.01.
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Figure 5.22: MT-II sensitivity in RIPCrep110αβKO (B) and control (A) mice.
Cumulative food intake at the times indicated after an i.p. administration of
vehicle or MT-II following an overnight fast (0.5 µg/g) in 15-week old male mice
(n = 8 vs 7). Data shown are mean ± SEM, ∗P<0.05, ∗∗P<0.01 and ∗∗∗P<0.001.
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5.8 Summary
5.8.1 Analysis of deletion
RIPCre mediated recombination of floxed p110α and floxed p110β catalytic sub-
units of the PI3K was proven successful. Islet mRNA expression levels of p110α,
p110β and p85 were unchanged in RIPCrep110αβKO mice in comparison to
control mice, confirming that recombination of the loxP sites does not change
transcription of the catalytic or regulatory subunits, and the stoichiometry be-
tween the regulatory and catalytic subunits remains normal. Lipid kinase assay
from RIPCrep110αβKO and control islets showed that kinase activity was sig-
nificantly reduced in RIPCrep110αβKO islets. Hence, it can be concluded that
RIPCrep110αβKO mouse is a suﬃcient model to study the role of PI3K catalytic
isoforms p110α and p110β in pancreatic beta cells and their eﬀect on whole-body
glucose homeostasis. Because the Cre-recombinase expression is driven from the
rat insulin promoter, RIPCrep110αβKO mouse can also give new insight to the
role of PI3K signalling in the insulin expressing neurons of the hypothalamus.
5.8.2 Glucose homeostasis
Glucose homeostasis was severely impaired in RIPCrep110αβKO mice. The mice
showed significant glucose intolerance at an early age, and by 12-weeks of age
the mice had developed a clear diabetic phenotype characterised by fasting hy-
perglycaemia and marked glucose intolerance. Glucose clearance in response to
exogenous insulin was normal, and fasted and fed plasma insulin levels were un-
changed, indicating that impaired glucose homeostasis in RIPCrep110αβKO mice
was not caused by insulin resistance. In vivo glucose-stimulated insulin secretion
was markedly decreased, with a significant reduction in both the first- and sec-
ond phase of insulin secretion, suggesting that glucose intolerance was caused by
reduced insulin secretion.
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5.8.3 Glucose-stimulated insulin secretion in vitro
Static incubation of RIPCrep110αβKO and control islets at basal (2 mmol/L) and
stimulatory (20 mmol/L) glucose concentrations showed that RIPCrep110αβKO
islets secrete significantly less insulin at both glucose concentrations. This also
supports the in vivo findings, meaning that glucose intolerance and impaired in-
sulin secretion is due to an intrinsic defect in insulin secretion in RIPCrep110αβKO
islets.
5.8.4 Pancreas morphology and gene expression of PI3K
signalling molecules in RIPCre110αβKO mice
Pancreas and beta cell mass, as well as islet density, were all normal in RIPCrep110αβKO
mice. Gene expression of upstream and downstream signalling molecules of the
PI3K signalling pathway were unaltered. However, mRNA expression of pyruvate
dehydrogenase kinase-1 (Pdk1) was increased ≈ 20 % in RIPCrep110αβKO in
comparison to control islets.
5.8.5 Metabolic studies
Simultaneous disruption of p110α and p110β catalytic isoforms in RIPCre neu-
rons of the hypothalamus alters energy homeostasis in RIPCrep110αβKO mice.
In general, RIPCrep110αβKO mice are bigger in size and display increased body
weight from 8-weeks onwards. RIPCrep110αβKO mice also have increased body
fat % and increased skeletal and bone mass. Hypothalamic mRNA expression of
Pomc and AgRP neuropeptides is also significantly reduced in RIPCrep110αβKO
mice. However, they have a normal feeding behaviour, and their sensitivity to
melanocortin receptor agonist MT-II is normal. Basal metabolic rate was also un-
changed in these animals. Plasma leptin levels were significantly increased in the
RIPCrep110αβKO mice, and even though intraperitoneal leptin administration
resulted in reduced food intake, the reduction was significantly less than in con-
trol animals, indicating a mild leptin resistance in the RIPCrep110αβKO mice.
Therefore it can be concluded that disruption of p110α and p110β signalling in
RIPCre neurons causes abnormal energy homeostasis within the whole animal,
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characterised by increased body mass, increased plasma leptin levels and mild
leptin resistance.
5.8.6 Conclusion
Results in this chapter establish a vital role for PI3K in whole-body glucose home-
ostasis. To conclude, RIPCrep110αβKO mice are hyperglycaemic and develop
severe glucose intolerance at young age. This is caused by impaired glucose-
stimulated insulin secretion from pancreatic beta cells. Because beta cell mass
and islet density are unchanged in these mice, it seems that the impaired in-
sulin secretion from the RIPCrep110αβKO beta cells is caused by defects in yet
unidentified downstream signalling cascades from PI3K that are involved in the
regulation of insulin secretion, but not in cell growth. RIPCrep110αβKO also
exhibit a significant hypothalamic phenotype that is seen as a general increase in
body size and body fat %. The mice are also hyperleptinaemic and mildly leptin
resistance, however, they have a normal feeding behaviour. Thus, results in this
chapter also highlight a significant role for PI3K in RIPCre expressing neurons
in the regulation of body growth and leptin receptor signalling.
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Chapter 6
Discussion
6.1 The involvement of AMPK in pancreatic
beta cells
AMPK has been the focus of intense investigation to determine its role in whole-
body energy homeostasis. Much of the previous work has investigated the role of
AMPK in distinct cells, tissues and organ systems to determine the specific role
of AMPK in glucose homeostasis. In liver and skeletal muscle AMPK improves
glucose homeostasis by stimulating glucose uptake and oxidation, and inhibiting
hepatic gluconeogenesis (Fryer et al., 2002; Kurth-Kraczek et al., 1999; Lochhead
et al., 2000; Merrill et al., 1997). AMPK is thought to be a target for a com-
monly prescribed anti-diabetic drug metformin which has been shown to activate
AMPK (Fryer et al., 2002). It is believed that many of the beneficial eﬀects, such
as reduced blood glucose levels of metformin is achieved by activation of AMPK,
although recent genetic evidence suggest that AMPK is not a sole eﬀector of
metformin (Foretz et al., 2010; Fryer et al., 2002; Hinke et al., 2007). Neverthe-
less, a direct activator (A-769662) of AMPK has been shown to have beneficial
metabolic eﬀects, for example improvement of plasma glucose and lipid levels
in ob/ob mice (Cool et al., 2006a). Hence AMPK has an interesting role as a
pharmacological target for treatment of T2DM. However, even though activation
of AMPK in peripheral tissues has a positive impact on glucose homeostasis and
on the treatment of T2DM, it is unclear whether its activation in pancreatic beta
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cells has an adverse eﬀect in terms of regulation of insulin secretion and glucose
homeostasis.
AMPK functions as a cellular energy regulator and its activity is linked to
changes in the cellular ATP/AMP ratio. Therefore it seems likely that AMPK
could have a key role in the regulation of beta cell function and insulin secretion
as these are dependent on changes in cellular adenosine nucleotide levels (Carling,
2004). The role of AMPK in pancreatic beta cells has been of great interest for
several years. However, despite the numerous studies conducted over the years, no
clear conclusion has been made yet and discrepancies between the studies exist,
especially about the role of AMPK in the regulation of insulin secretion. The
reasons explaining the discrepancies could be caused by the use of diﬀerent beta
cell lines (INS-1, MIN6) and use of diﬀerent dominant negative forms of AMPK
that might have diﬀerent substrate specificities (Rutter and Leclerc, 2008).
Surprisingly, islets isolated from AMPKα2 -global-null mice did not show any
intrinsic beta cell defect in glucose- or arginine-stimulated insulin secretion despite
glucose intolerance and decreased plasma insulin levels (Viollet et al., 2003a,b).
As increased urine catecholamine levels were measured in these mice, it was ar-
gued that the impaired glucose handling and lower plasma insulin levels were
due to alterations in the sympathetic nervous system (Viollet et al., 2003a,b).
Even though this study did indicate that AMPKα2 is important for whole-body
glucose homeostasis, it did not give specific insight into the role of AMPK in
beta cells. Hence, I generated two transgenic mice lines: RIPCreα2KO and
α1KORIPCreα2KO. The former lacks AMPKα2 in beta cells and in a poorly
defined population of RIPCre expressing hypothalamic neurons, and the latter is
deficient in AMPKα2 as the other created mouse line, but also has global deletion
of AMPKα1.
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6.2 Deletion of AMPK in beta cell - the impact
on whole-body physiology
To achieve deletion of AMPKα2 in beta cells, mice expressing a Cre-recombinase
from Rat insulin promoter 2 (RIP) were crossed with mice carrying a loxP tar-
geted AMPKα2 gene. RIPCre, rather than PdxCre (Cre expression driven from
the Pancreas duodenal homeobox 1 promoter) was used, as at the time when this
study was started, the RIPCre provided the best deletion eﬃciency in the beta
cells. For example a study by Cantley et al. (2009) reported RIPCre mediated
deletion in 95 % of the beta cells and PdxCre mediated deletion only in 70 % of
the beta cells. In addition, RIPCre deletes specifically in the beta cells, whereas
PdxCre deletes also in the other endocrine cells as well as the epithelial cells of
the pancreas (Dessimoz et al., 2005). RIPCre mediated gene deletion also oc-
curs in a population of hypothalamic neurons located in the arcuate, lateral and
ventromedial hypothalamus (Choudhury et al., 2005). Therefore a hypothalamic
phenotype arising in RIPCre mice is always a possibility that has to be accounted
for. However, deletion of AMPKα2 in RIPCre neurons did not cause any sig-
nificant hypothalamic energy homeostasis phenotype in RIPCreα2KO mice, as
no alteration in body weight, food intake or expression of hypothalamic feeding
peptides were observed. Similarly, normal body weight and food intake were
recorded in the α1KORIPCreα2KO mice.
RIPCreα2KO mice display a defective glucose homeostasis with a mild, age-
dependent deteriorating glucose intolerance caused by a marked defect in glucose-
stimulated insulin secretion. Overall the whole body phenotype is mild in the
RIPCreα2KO mice. This could be due to compensation by the AMPKα1 subunit,
alternated regulation by the CNS or by trans-tissue compensation, with glucose
disposal being impaired in other tissues. However, normal peripheral insulin
sensitivity was measured in RIPCreα2KO mice. Hence, α1KORIPCreα2KO mice
were generated to rule out any compensatory eﬀect by AMPKα1.
As with the RIPCreα2KO no hypothalamic phenotype was observed in the
α1KORIPCreα2KO mice as they also had a normal body weight and feeding
behaviour. Deletion of both the AMPK catalytic subunits led to a significant
153
defect in glucose homeostasis. At 5 weeks of age, the α1KORIPCreα2KO mice
exhibited markedly impaired glucose intolerance, caused by a significant defect in
glucose-stimulated insulin secretion (GSIS). The impaired GSIS showed that the
α1KORIPCreα2KO mice secreted significantly less insulin compared to the con-
trol mice in response to glucose, and the mice lacked the commonly distinguish-
able first- and second phases of insulin secretion. As the AMPKα1 -global-null
mice did not have a defect in their glucose homeostasis (Viollet et al., 2003a,b),
it can be concluded that the phenotype reported here is most likely due to the
deletion of both the subunits specifically in beta cells. Hence from the in vivo
data it can be concluded that AMPK participates in the regulation of glucose-
stimulated insulin secretion and lack of AMPK in beta cells impairs GSIS, which
leads to a defect in glucose homeostasis.
When I started to study the RIPCreα2KO and α1KORIPCreα2KO mice,
no other transgenic animal models of beta cell specific AMPK existed. How-
ever, as our study was in the process of being published, Sun et al. (2010a) re-
ported a study of βAMPKdKO mice (AMPKα1 and AMPKα2 deficiency in beta
cells using RIPCre and AMPKα1 -global-null mice). Similarly to my study, Sun
et al. (2010a) reported an impaired glucose homeostasis phenotype along with
a reduced in vivo GSIS. This is consistent with the physiology reported in the
AMPKα2 -global-null mice that had impaired glucose homeostasis and defective
insulin secretion in vivo (Viollet et al., 2003a,b). Sun et al. (2010a) also reported
a normal hypothalamic function in their βAMPKdKO mice, further confirming
that RIPCre is a suitable system to study AMPK function in beta cells at the
whole-body physiological level.
6.3 Normal islet morphology in RIPCreα2KO
mice
Defects in GSIS could reflect either a change in beta cell mass or morphology
or a functional defect within the beta cells. LKB1, the upstream kinase on the
LKB1/AMPK pathway has been implicated in the regulation of beta cell mass
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and islet morphology. For example, deletion of LKB1 in adult mice using in-
ducible PdxCre led to a 65 % increase in beta cell size, and a change in cell
polarity resulting in altered intracellular organisation of the nucleus and cilia in
relation to the capillary blood vessels (Granot et al., 2009). Another study by
Sun et al. (2010b) using the RIPCreLKB1KO mice also showed significantly in-
creased beta cell size, increased cell proliferation and change in cell polarity. The
phosphorylation levels of the LKB1 downstream kinase AMPK were significantly
reduced in both studies. AMPK has been shown to inhibit the mTOR signalling
pathway, the major regulator of cell growth and protein synthesis (Gleason et al.,
2007). Hence the increased beta cell size was thought to be caused by reduced
AMPK activity and subsequently increased mTOR signalling, measured as in-
creased phospho-rpS6 and decreased phospho-4E-BP1 levels (Granot et al., 2009;
Sun et al., 2010b).
In contrast to the LKB1 KO mice, I found no defect in beta cell mass or islet
organisation in the RIPCreα2KO mice suggesting that this did not contribute
in to the beta cell defect. In a separate study by Sun et al. (2010a) using the
βAMPKdKO mice, beta cell mass was also found to be normal. However rather
confusingly, Sun et al. (2010a) reported increased beta cell proliferation but de-
creased beta cell and islet size in βAMPKdKO mice. In contrast to the beta cell
specific LKB1 KO studies, this was not accounted for altered mTOR signalling
as the phosphorylation of rpS6 was unchanged (Sun et al., 2010a).
6.4 Lack of AMPK in beta cells impairs in vitro
GSIS
Normal beta cell mass in RIPCreα2KO mice suggests a functional defect in
terms of glucose sensing and insulin secretion in response to glucose. At basal
(2 mmol/L) glucose concentration, islets isolated from the RIPCreα2KO and
α1KORIPCreα2KO mice secreted significantly more insulin in comparison to
control islets. This may suggest that AMPK has a role in beta cells sensing hy-
poglycaemia, as it is important to suppress insulin release. These data are also
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consistent with the studies, in which beta cells or islets expressing a DN form of
AMPK have increased insulin secretion in response to low glucose (da Silva Xavier
et al., 2000; Leclerc et al., 2004). It has also been shown that in the ventromedial
hypothalamus (VMH), AMPK has a key regulatory role in response to hypogly-
caemia, when it will activate mechanisms that restore glucose concentration back
to normal levels (Mccrimmon et al., 2007).
In contrast to my findings, islets isolated from the AMPKα2 -global-null mice
did not show any significant diﬀerence in insulin secretion at low glucose con-
centration (Viollet et al., 2003a,b). Furthermore, Sun et al. (2010a) reported no
alteration in insulin secretion in response to low glucose in βAMPKdKO islets.
However, if the GSIS data from the AMPKα2 -global-null islets is examined care-
fully, a clear trend towards increased insulin secretion at low glucose can be seen.
Nonetheless, in both of the previous studies, the lowest glucose concentration
used to stimulate insulin secretion was 3 mmol/L, rather than 2 mmol/L that I
have used. Perhaps 1 mmol/L diﬀerence in glucose concentration is an important
factor in this context. Because such a low glucose level is not normally achieved
at whole-body physiological level, unless using a hypoglycaemic clamp, we cannot
detect increased insulin secretion in fasted RIPCreα2KO and α1KORIPCreα2KO
mice. Also, the presence of other nutrients and compensatory mechanisms in vivo
can provide other means for stimulating insulin release.
At a high (20 mmol/L) glucose concentration RIPCreα2KO and α1KORIPCreα2KO
islets secreted significantly less insulin in comparison to control islets. When the
insulin secretion at high glucose was presented as pg/islet/hour in RIPCreα2KO
islets, only a trend towards decreased insulin secretion was seen. However, in the
α1KORIPCreα2KO islets a significant decrease in insulin secretion was measured
as pg/islet/hour. When the insulin secretion at high glucose was represented as
an increment fold change over the basal insulin secretion, over a 10-fold increase
in insulin secretion was measured in control islets. In the RIPCreα2KO and
α1KORIPCreα2KO islets, the fold change is significantly less in comparison to
control islets. This means that the increment in insulin secretion that normally
occurs, is significantly downregulated. The regulation of insulin secretion in beta
cells is a dynamic process that is controlled at many diﬀerent levels. It is de-
pendent on acute changes in metabolic coupling pathways, allosteric activation
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of enzymes regulating the insulin secretory pathway and regulation of gene ex-
pression. However, these changes only occur when the fold change in insulin
secretion is above a certain threshold. In the case of AMPK KO beta cells, the
cells are used to the constantly higher insulin levels. In response to high glucose
concentration, there might be an initial small increase in insulin secretion, but if
the increase is not high enough, the changes in metabolic coupling pathways and
gene expression to further stimulate insulin release do not occur.
Completely opposite to my results, a separate study by Sun et al. (2010a) who
also used the AMPK KO islets (β2AMPKdKO) reported an enhanced insulin se-
cretion in response to high glucose (16.7 mmol/L), even though the β2AMPKdKO
mice that were used in their study exhibited a similar physiological phenotype to
my mice with glucose intolerance and reduced in vivo GSIS. Hence, it is rather
surprising that the findings by Sun et al. (2010a) showed increased insulin secre-
tion at high glucose concentration in βAMPKdKO islets. However, it is possible
that the expression of data as percentage of total insulin secretion is not a suit-
able way to represent the data. In addition, islets from heterozygous mice were
used as controls rather than wt mice (Sun et al., 2010a). Furthermore, when
the insulin secretion in response to 10 mmol/L glucose was measured in the
AMPKα2 -global-null islets, no significant diﬀerence was measured, although if
the data are examined carefully, a trend towards reduced insulin secretion can be
seen (Viollet et al., 2003b).
In conclusion, my results show that the in vitro GSIS confirms that both the
RIPCreα2KO and α1KORIPCreα2KO mice have an intrinsic beta cell defect,
which results in an increased basal glucose-stimulated insulin secretion. At a high,
stimulatory glucose concentration the RIPCreα2KO and α1KORIPCreα2KO islets
are unable to increase their insulin secretion and meet the fold change required
by the normal beta cells. It seems clear that the role of AMPK in beta cells is
to control insulin secretion in response to glucose but it is not involved in the
regulation of beta cell mass. In order to understand the mechanisms how AMPK
regulates GSIS in beta cells, we examined parts of the classical beta cell stimulus-
secretion coupling pathway which can be divided into three diﬀerent parts which
are discussed further in this chapter: glucose sensing, mitochondrial metabolism
and function and KATP -channel activity.
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6.5 Loss of AMPK alters beta cell glucose sens-
ing
When glucose is reduced from 10 to 2 mmol/L beta cells become electrically
silenced with a reduction in action potential which is reflected in by hyperpolar-
isation of the plasma membrane (Beall et al., 2010). However, in RIPCreα2KO
beta cells, there was no electrical silencing at low glucose with a continuous
electrical firing of action potentials and failure to hyperpolarise the plasma mem-
brane, as no change in membrane potential was observed 1. This is the most
likely explanation as to why the KO islets continue to secrete insulin at low glu-
cose. These results suggest that the deletion of AMPK in beta cells aﬀects the
ability of the cells to sense glucose. Similarly in hypothalamic POMC neurons,
plasma membrane hyperpolarisation in response to hypoglycaemia was prevented
in POMCCreAMPKα2KO neurons (Claret et al., 2007). This is why proximal
elements of the mechanisms involved in glucose sensing were analysed by mea-
suring mRNA levels of glucose transporter Glut2 and the rate limiting enzyme
of the glycolysis, Glucokinase (i.e. Hexokinae IV). However, islet mRNA levels
of Glut2 and Glucokinase were normal in RIPCreα2KO islets in comparison to
control islet expression. Furthermore, mRNA expression of low Km hexokinases
(I-III ) was also normal.
6.6 Mitochondrial gene expression analysis in
RIPCreα2KO islets
Because AMPK is a cellular energy sensor whose activity is dependent on changes
in cellular phosphorylated adenosine nucleotides, largely generated in the mito-
chondria, expression of key genes involved in the regulation of mitochondrial
biogenesis was measured as their expression and activity might be aﬀected by
the deletion of AMPK. Nuclear respiratory factor-1 (Nrf1) is a transcription
1Experiments discussed in this section where conducted by C. Beall at University of Dundee
using mice generated by me
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factor that regulates the expression of respiratory proteins and mitochondrial
transcription and replication (Bergeron et al., 2001). It has been shown pre-
viously that increased AMPK activity in skeletal muscle stimulated Nrf1 func-
tion, which led to increased mitochondrial biogenesis (Bergeron et al., 2001).
Apart from Nrf1, AMPK has also been shown to to stimulate the activation of
peroxisome proliferator-activated receptor γ coactivator 1-α (Pgc-1α) and mi-
tochondrial transcription factor A (Tfam) (Irrcher et al., 2003). For example,
Tfam controls mitochondrial function by regulation of mtDNA copy number and
transcription (Wiederkehr and Wollheim, 2006). Pgc-1α on the other hand is a
transcriptional co-activator that regulates the expression of genes that code for
mitochondrial proteins of the respiratory chain (Wredenberg et al., 2006). How-
ever, normal mRNA expression levels of Nrf1, Tfam and Pgc-1α were measured
in RIPCreα2KO islets.
6.6.1 The impact of reduced Ucp2 expression in AMPK
deficient beta cells
Beta cell GSIS is dependent on mitochondrial ATP production that can be reg-
ulated by mitochondrial uncoupling proteins (Produit-Zengaﬃnen et al., 2007).
Mitochondrial uncoupling protein 2 (UCP2) uncouples mitochondrial oxidative
phosphorylation by promotion of proton leakage from the mitochondrial inter-
membrane space back to the matrix (Bordone et al., 2006; Chan et al., 2004b).
The uncoupling dissipates the proton motive force generated across the mem-
brane that is used in the conversion of ADP to ATP, leading to a reduction in
the production of ATP (Chan et al., 2004b). Thus, UCP2 negatively regulates
the production of ATP (Aﬀourtit and Brand, 2008). Previous studies have indi-
cated a link between AMPK and UCP2 expression. A study by Xie et al. (2008)
showed that immunohistochemical staining of AMPKAα2 -global-null mouse aor-
tas had reduced UCP2 expression levels, accompanied by increased superoxide
anion levels. On the contrary activation of AMPK by AICAR, or overexpression
of CA-AMPK was shown to increase Ucp2 mRNA and protein levels in human
umbilical vein endothelial cells and protect them from high glucose induced su-
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peroxide anion levels (Xie et al., 2008). Similarly, overexpression of AMPKα2
in mouse liver, increased UCP2 expression (Foretz et al., 2005). As UCP2 has
also been shown to aﬀect islet GSIS, mRNA expression of Ucp2 was measured in
RIPCreα2KO and control islets. As a matter of fact, the Ucp2 mRNA levels were
found to be significantly decreased, supporting the earlier studies indicating that
reduced AMPK expression leads to reduced UCP2 expression and vice versa. In
order to confirm that reduction in Ucp2 mRNA levels was not a result of reduced
mitochondrial mass, mitochondrial protein ATP synthase levels were measured
to estimate mitochondrial mass. However, no diﬀerence in ATP synthase levels
were detected indicating that there was no diﬀerence in mitochondrial mass and
reduced UCP2 mRNA levels represent a true change at a transcriptional level.
A partial inhibition of Ucp2 using antisense oligonucleotide to Ucp2 in islets
led to increased GSIS (Souza et al., 2007). Similarly a study by Zhang et al. (2001)
demonstrated that mice deficient in Ucp2 on a mixed B6/129 background had
higher plasma insulin and reduced blood glucose levels. In addition, the UCP2
deficient islet exhibited higher ATP content and increased GSIS (Zhang et al.,
2001). A study by Pi et al. (2009) also found similar increased GSIS on islets iso-
lated from UCP2 deficient mice on the same genetic background. However, when
the Ucp2 -global-null mice were crossed back into inbred strains (B6, 129, A/J,
JAX B6), by the eight backcross, a decreased GSIS in the Ucp2 deficient islets
was measured (Pi et al., 2009). No significant hyperglycaemia and hypoinsu-
linemia was present in the backcrossed Ucp2 -global-null mice Pi et al. (2009).
As previous findings have demonstrated that UCP2 facilitates the regulation of
GSIS, they support my data as I have shown that Ucp2 mRNA expression is
reduced in RIPCreα2KO islets, together with impaired GSIS. However, whether
UCP2 acts as a negative or positive regulator of GSIS remain inconclusive. If
Ucp2 deficiency stimulated insulin secretion, it could explain why I see increased
basal insulin secretion in RIPCreα2KO and α1KORIPCreα2KO islets. However,
it would not explain why insulin secretion is reduced in response to high glucose.
On the other hand, if Ucp2 reduction leads to decrease in GSIS, it would explain,
why in the RIPCreα2KO and α1KORIPCreα2KO islets, high glucose induced
insulin secretion is reduced.
Chronic exposure of islets to high glucose has been shown to increase basal in-
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sulin secretion but to decrease GSIS. Treatment with a UCP2 inhibitor, genipin,
rescues islets from high glucose induced suppression of GSIS (Zhang et al., 2006).
Chronic exposure of Ucp2 deficient islets to high glucose did not suppress GSIS,
and no change in GSIS was observed upon genipin treatment, suggesting that
genipin alters GSIS via UCP2 dependent manner (Zhang et al., 2006). Fur-
thermore, treatment of wt beta cells and POMC neurons with genipin caused a
phenotype similar to that seen in RIPCreα2KO beta cells and POMCCreα2KO
neurons, with a failure to hyperpolarise the plasma membrane at low glucose,
suggesting that the low UCP2 expression measured in the RIPCreα2KO islets
may contribute to the electrophysiological phenotype observed in RIPCreα2KO
islets (Beall et al., 2010). In conclusion, my data, as well as previous studies,
suggest that UCP2 is involved in the regulation of GSIS in beta cells (Aﬀourtit
and Brand, 2008).
6.7 Lack of AMPK does not alter the generation
of ROS
Some studies have suggested that beta cell reactive oxygen species (ROS) produc-
tion contributes to glucose sensing behaviour and regulation of insulin secretion.
For example in islets isolated from Zucker rat lean controls (ZLC), high glucose
induced a significant increase in O2− generation (Bindokas et al., 2003). Similarly,
glucose induced increase in H2O2 production in mouse islets and INS-1 cells has
been reported (Pi et al., 2007a). Furthermore, it was demonstrated that insulin
secretion can be stimulated by H2O2, derived from glucose metabolism (Pi et al.,
2007a). However, decrease in GSIS was measured in mouse islets and INS-1 cell
upon exposure to oxidative stressors (Pi et al., 2007a).
As already mentioned above, AMPK and UCP2 activity might play an impor-
tant role in the control of mitochondrial ROS production (Cai et al., 2007). Lack
of UCP2 in beta cells is thought to increase ROS production and impair GSIS
in islets. ROS production was also increased in macrophages of UCP2 deficient
mice (Pi et al., 2010). Therefore H2O2 production, indicative of ROS gener-
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ation was measured in control, RIPCreα2KO and α1KORIPCreα2KO islets.
However, no change in H2O2 production was detected in RIPCreα2KO and
α1KORIPCreα2KO islets in comparison to control islets at 2 or 20 mmol/L
glucose, as assessed by CM-H2DCFDA fluorescence.
Expression levels of antioxidant enzymes in beta cells are low is comparison to
other cell and tissue types (Pi et al., 2010). However, expression of endogenous
antioxidant enzymes might be upregulated, when cellular exposure to oxidative
stress increases. This has been reported to be an indicative of an increased
adaptive response to oxidative stress and potentially impair GSIS (Pi et al., 2007b,
2010). Yet, no increase in mRNA levels of anti-oxidant enzymes, Gpx4 and
Hmox1 was detected, and rather unexpectedly Sod2 mRNA expression was mildly
reduced in RIPCreα2KO islets. Therefore it seems that reduced Ucp2 mRNA
levels measured in RIPCreα2KO islets do not aﬀect ROS production or result in
compensatory alterations in expression of anti-oxidant defence mechanisms. It
can also suggest that it is unlikely that impaired GSIS is not caused by changes
in beta cell oxidative stress in RIPCreα2KO.
6.8 Normal KATP -channel activity in AMPK de-
ficient beta cells
The plasma membrane KATP -channels couple the production of ATP to beta cell
electrical activity which leads to stimulation of insulin secretion. Both the number
of open channels (not bound by ATP) as well as the number of channels present
at the plasma membrane aﬀect the following electrical activity and stimulation of
insulin secretion (Lim et al., 2009). As the RIPCreα2KO beta cells remained elec-
trically active at low glucose concentration and insulin secretion was significantly
elevated, it was postulated that the KATP -channels remain closed at low glucose
(Beall et al., 2010). Loss-of-function mutations of KATP -channel subunits or re-
duced expression of KATP -channels on the plasma membrane have been shown to
cause increased electrical activity and insulin secretion at low glucose (Ashcroft,
2005; Miki et al., 1998; Seghers et al., 2000). Hence, Sur1 mRNA expression
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levels were measured in RIPCreα2KO and control islets. The Sur1 expression
levels were found to be reduced, suggesting that reduced Sur1 expression might
lead to altered KATP -channel activity and defective GSIS.
A study by Lim et al. (2009) showed that AMPK regulates the traﬃcking
of insulin granule vehicles and Kir6.2 subunits of the KATP -channel in response
to low energy status. AMPK activation in response to glucose deprivation was
shown to increase the number of KATP -channels on the plasma membrane and
the channel activity. Islets from Sur1 KO mice have shown that a deletion of Sur1
caused impaired docking and fusion of insulin granules, which lead to decreased
insulin exocytosis (Kikuta et al., 2005). However, Sun et al. (2010a) reported
increased number of docked insulin granules in AMPK KO beta cells.
Perhaps AMPK is needed as a positive regulator of Sur1 expression, and
deletion of AMPK downregulates Sur1 gene expression, thus aﬀecting the in-
sulin secretion. AMPK might also directly phosphorylate SUR1 subunit that
may be important for a functional KATP -channel (Wang et al., 2005). To de-
termine whether deletion of AMPK leads to altered ATP-sensitivity or current
activity of KATP -channels, whole-cell recordings were made with diﬀerent ATP
concentrations in the electrode solution 1. Similar voltage clamped currents were
measured before and after washout of cellular ATP in wt and KO beta cells.
No change in ATP dependent reduction in channel conductance was measured
between wt and KO cells. Hence it can be concluded that deletion of AMPK in
beta cells did not alter KATP -channel ATP sensitivity and current activity. Fur-
thermore, diazoxide, which is a pharmacological agent that opens KATP -channels
even at high, stimulatory glucose concentrations, was able to normally hyper-
polarise the RIPCreα2KO beta cells (Henquin, 2009). In contrast, the AMPK
double KO islets studied by Sun et al. (2010a) were reported to have increased
KATP -channel sensitivity to ATP at low glucose. However, glucose induced KATP -
channel closure and increased intracellular calcium levels remained normal (Sun
et al., 2010a).
1Experiments discussed in this section where conducted by C. Beall at University of Dundee
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6.9 Conclusion
Thus it can be concluded that AMPK is involved in glucose sensing and regula-
tion of insulin secretion from the beta cells, and the insulin secretory response
is tightly coupled to changes in glucose concentration. When glucose levels are
low, such as in a fasted state, the probable role for AMPK is to inhibit insulin
secretion. Failure to do so could lead to severe hypoglycaemia in the worst case.
I have shown that lack of AMPK in beta cells led to increased insulin secretion
at basal glucose levels. However, an increase in insulin secretion in response to
a stimulatory glucose concentration was significantly impaired, demonstrated in
vivo and in static incubation of isolated islets. Consequently, the impaired GSIS
resulted in the development of glucose intolerance. Even though the basal insulin
secretion was enhanced, the AMPK KO islets showed significantly decreased fold
change in insulin secretion over basal secretion. Insulin secretion is a dynamic
process that is dependent on acute changes in metabolic coupling pathways such
as glycolysis and mitochondrial ATP generation via oxidative phosphorylation,
activation of enzymes regulating the insulin secretory pathway, such as positive
and negative phosphorylation of kinesin-I that drives the insulin granule move-
ment along microtubules, and regulation of gene expression such as insulin gene
transcription (Leibiger et al., 1998; McDonald et al., 2009; Wiederkehr and Woll-
heim, 2006).
At basal levels, the metabolic secretion coupling is probably elevated as the
basal insulin secretion is enhanced. However, when the glucose concentration
increases, there is a bigger demand for increased rate of glucose metabolism,
coupled to insulin secretion. It has been shown previously that suppression of
insulin secretion by pharmacological activation of KATP -channels improves glu-
cose tolerance and beta cell function by providing the cells a period of rest from
insulin secretion (Wajchenberg, 2007). Perhaps continuous electrical activity at
low glucose and increased basal insulin secretion desensitises AMPK KO beta
cells as the basal metabolic secretion coupling is probably constantly elevated.
Therefore, when there is a demand to increase glucose metabolism and insulin
secretion, the AMPK KO beta cells fail to detect this or are unable to respond.
As a summary, lack of AMPK in beta cells causes impaired glucose home-
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ostasis and insulin secretion. The AMPK KO beta cells continue to fire action
potentials at low glucose, failing to hyperpolarise the plasma membrane. This
leads to increased insulin secretion at low glucose. The same electrophysiological
eﬀect is seen when wt beta cells are treated with the UCP2 inhibitor genipin.
As UCP2 mRNA levels are reduced in RIPCreα2KO mice, the results suggest
a key role for beta cell AMPK in sensing low glucose levels and suppressing
insulin secretion possibly via a UCP2 dependent mechanism. Therefore lack of
AMPK may result in disconnection of the normal response to nutrient deprivation
whereby AMPK and UCP2 would act to lower insulin secretion at low glucose
and maintain secretion at high glucose levels. In conclusion, the work presented
in this thesis highlights a key role for AMPK in beta cells in glucose sensing and
whole-body glucose homeostasis
6.10 Future studies
Future work should focus on finding the link between UCP2 and AMPK that
results in the defective insulin secretion. First of all, it should be important to
confirm that reduced Ucp2 mRNA levels correlate with reduced protein levels.
Reduced UCP2 levels should lead to increased mitochondrial respiration and
increased production of cellular ATP. Hence if ATP levels are increased, this
should lead to increased insulin secretion. Therefore, future work should put more
emphasis on studying mitochondrial function in AMPK KO beta cells. Islet
ATP levels, mitochondrial membrane potential and oxygen consumption could
be measured in RIPCreα2KO and α1KORIPCreα2KO beta cells. This could
potentially explain the enhanced insulin secretion at basal glucose concentration,
and whether or not the mitochondrial oxidative phosphorylation is reduced in
response to stimulatory glucose concentration.
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6.11 The role of PI3K in pancreatic beta cells
6.12 Importance of study
Phosphatidylinositol 3-kinase (PI3K) mediates signals downstream from insulin
and IGF-1 receptors, which is important for the regulation and maintenance of
cellular processes including cell proliferation and growth, survival and cellular
metabolism (Taniguchi et al., 2006). The PI3K pathway has been implicated in
many human cancers, and it has a significant impact on the regulation of cancer
growth, motility, survival and metabolism (Cantley, 2002; Courtney et al., 2010).
In many cases the development of cancer results from the constant activation of
the PI3K pathway, caused by somatic mutations in several genes that encode for
PI3K regulatory and catalytic subunits (Courtney et al., 2010). Over the years,
several PI3K inhibitors have been developed to be used in the treatment against
various cancers, many of which are under early clinical trials (Courtney et al.,
2010). Deficiency in PI3K, or upstream or downstream signalling molecules of
PI3K, has been shown to be detrimental for energy- and glucose homeostasis
at cellular and whole-body physiological level (Hirsch et al., 2007). Therefore,
it is important to understand what are the potential long-term eﬀects of the
use of PI3K inhibitors in the treatment of cancer. For example, PI3K catalytic
subunit p110α-global-null and p110β-global-null mice die in utero, implicating
the importance of the isoforms for the whole-body physiology and development
(Vanhaesebroeck et al., 2005). Heterozygous p110α knock-in mice that have a
50 % reduction in p110α kinase activity, but preserved stoichiometry between
the catalytic and regulatory subunits were insulin resistant, glucose intolerant,
hyperinsulinaemic and hyperphagic, however no islet phenotype was reported
(Foukas et al., 2006). They also had reduced somatic growth and increased adi-
posity (Foukas et al., 2006). Kinase dead p110β mice had a mild hyperglycaemia
and insulin resistance, accompanied by islet hyperplasia and increased insulin
secretion (Ciraolo et al., 2008).
Even though the role of class IA PI3Ks in peripheral tissues is well studied,
the role of PI3K in pancreatic beta cells has remained inconclusive. The insulin
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receptor/IGF-1 signalling is usually dominated by one of the p110α or p110β
catalytic isoforms, depending on tissue type (p110α in peripheral tissues and
p110β in hypothalamic neurons) (Al-Qassab et al., 2009; Foukas et al., 2006;
Sopasakis et al., 2010). In general it is thought that p110α is the main mediator
of the insulin signalling pathway, but p110β is required for long-term support and
PIP3 production (Ciraolo et al., 2008). However, whether this is also true in beta
cells, remains unknown. No transgenic mouse models of p110α or p110β catalytic
subunits exist that would have studied their role in pancreatic beta cells.
The work in this thesis focuses on the combined role of p110α and p110β
catalytic subunits in pancreatic beta cells and hypothalamic RIPCre neurons,
and their impact on whole-body energy- and glucose homeostasis.
RIPCrep110αβKO mice were created by employing the cre-loxP system to target
the kinase domains of the isoforms, which results in kinase dead subunits, without
changing the stoichiometry between the catalytic and regulatory subunits. Cre-
recombinase is expressed from rat insulin promoter (RIP) which works in the
pancreatic beta cells and in RIPCre expressing hypothalamic neurons (Choudhury
et al., 2005; Ray et al., 1999). Hence, when the impact of kinase inactivation was
studied at the physiological level, both glucose homeostasis and hypothalamic
function were investigated.
6.12.1 Eﬃciency of kinase inactivation
Gene expression levels of p110α, p110β and p85, measured by qRT-PCR, were not
changed in RIPCrep110αβKO islets confirming that stoichiometry of the catalytic
and regulatory subunits remains intact upon RIP-Cre mediated recombination
of floxed p110α and p110β kinase domains. However, the lipid kinase activity
was significantly reduced in the RIPCrep110αβKO islets, demonstrating that
the RIPCrep110αβKO islets have a reduced ability to phosphorylate cellular
PI(3,4)P2 to produce PI(3,4,5)P31. However, the kinase activity was only reduced
≈35 %, which might be due to the kinase activity being measured from whole
islet preparations, which also contain other islet cell types such as alpha and delta
cells, therefore the kinase activity, which will be unaﬀected in non-beta cell cells,
1Experiment conducted by C. Chaussade at Queen Mary, University of London
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will aﬀect the final kinase activity measured.
6.12.2 Glucose homeostasis in RIPCrep110αβKO mice
Impaired whole-body glucose homeostasis in RIPCrep110αβKO mice is consis-
tent with other beta cell transgenic mouse models of the insulin receptor/IGF-1
receptor signalling pathway (Taniguchi et al., 2006; Vanhaesebroeck et al., 2005).
Both upstream and downstream signalling molecules of PI3K have been shown to
have a pivotal role in the regulation of normal glucose homeostasis (Hirsch et al.,
2007).
The diminished glucose homeostasis in RIPCrep110αβKO mice was mani-
fested by fasted and fed hyperglycaemia and marked glucose intolerance, present
already at an early age (5 weeks). Surprisingly, fasted and fed plasma insulin
levels remained unaltered. Similarly to my results, mice with a deletion of insulin
receptor (IR)(RIPCreIRKO) or IGF-1 receptor (RIPCreIgf-1KO) in beta cells
also developed progressive glucose intolerance but fasted plasma insulin levels
were only mildly increased (Kulkarni et al., 1999; Xuan et al., 2002). A sig-
nificant glucose intolerance was also reported in beta cell specific (RIPCre and
PdxCre) IRS-2 KO mice (Cantley et al., 2007; Choudhury et al., 2005; Kubota
et al., 2004; Lin et al., 2004a). Whilst Lin et al. (2004a) and Choudhury et al.
(2005) reported increased fasted plasma insulin levels in RIPCreIRS-2KO mice,
no changes in the insulin levels were reported by Kubota et al. (2004) in their
RIPCreIRS-2KO mice, and Cantley et al. (2007) in PdxCreIRS-2KO. Further-
more, deletion of Pdk1 ( in beta cells (RIPCre) or expression of kinase-dead Akt1
(RIPCre) led to impaired glucose homeostasis, although fasted insulin levels re-
mained unchanged (Bernal-Mizrachi et al., 2004; Hashimoto et al., 2006). On
the other hand, deletion of PTEN, a negative regulator of PI3K, in beta cells
(RIPCrePTENKO) led to improved glucose tolerance and reduced blood glucose
and plasma insulin levels as expected (Nguyen et al., 2006). Peripheral insulin
sensitivity, assessed by insulin tolerance test was normal, which demonstrated
that the RIPCrep110αβKO mice were able to correctly respond to peripheral
insulin stimulus observed as reduced blood glucose levels. This also means that
the glucose intolerance is not caused by peripheral insulin resistance, suggesting a
168
defective insulin secretion from pancreatic beta cells. In vivo glucose-stimulated
insulin secretion (GSIS) demonstrated a loss of first phase and reduced second
phase of insulin secretion. Hence, these results suggest that the impaired glucose
homeostasis in RIPCrep110αβKO mice is caused by impaired insulin secretion
in response to a glucose, which results in hyperglycaemia and inability to han-
dle glucose properly in response to glucose load. Similarly, impaired GSIS was
reported in the beta cell insulin - and IGF-1 receptor KO and IRS-2 KO mice
(Cantley et al., 2007; Kubota et al., 2004; Kulkarni et al., 1999; Xuan et al., 2002).
In the RIPCrePTENKO mice, GSIS remained normal, although a trend towards
increased GSIS was noted (Nguyen et al., 2006). Expression of kd-Akt in beta
cells also led to a significant reduction in GSIS (Bernal-Mizrachi et al., 2004). No
GSIS data was reported in the RIPCrePdk1KO mice (Hashimoto et al., 2006).
Therefore it can be concluded that insulin- and IGF-1 receptor signalling via PI3K
in pancreatic beta cells is required for proper in vivo GSIS and maintenance of
whole-body glucose homeostasis.
6.12.3 Islet physiology in RIPCrep110αβKO mice
Even though the in vivo GSIS was reduced, it is not entirely clear whether it
results from an intrinsic beta cell defect or reduced beta cell mass or altered islet
morphology. Additionally, altered CNS function could also aﬀect the pancreatic
beta cell function. Hence, in vitro GSIS in RIPCrep110αβKO mice islets was
investigated. This showed that insulin secretion in response to low (2 mmol/L)
and high (20 mmol/L) glucose concentration was significantly reduced, suggesting
that the glucose intolerance and impaired GSIS in vivo, were caused by intrinsic
beta cell defect. Similarly to my findings, insulin secretion in response to low and
high glucose concentrations in islets isolated from RIPCreIGF-1KO, PdxCreIRS-
2KO and RIPCrekd-Akt mice was significantly reduced (Bernal-Mizrachi et al.,
2004; Cantley et al., 2007; Kulkarni et al., 2002). In contrast, static incubation
of islets isolated from control and RIPCreIRS-2KO mice demonstrated increased
insulin secretion in response to 11.1 mmol/L glucose (Kubota et al., 2004). Quite
expectedly, perfusion of RIPCrePTENKO pancreases demonstrated preserved
glucose-stimulated insulin secretion (Nguyen et al., 2006).
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Most of the previous PI3K studies in beta cells have used the non-selective
PI3K inhibitors wortmannin and LY-294002, which are likely to inhibit other
kinases such as mTOR (Aspinwall et al., 2000; Puri, 2006). Therefore, any con-
clusions from these studies should be considered with caution. However, the
general consensus is that PI3K catalytic isoforms might be involved in regulat-
ing insulin secretion but whether they are needed to inhibit or stimulate insulin
secretion has remained inconclusive.
It is well established, that insulin stimulates the upregulation of insulin gene
transcription via activation of class IA PI3K (Barker et al., 2002). This was
demonstrated by Leibiger et al. (2001) who showed that treatment of beta cells
with the PI3K inhibitors wortmannin and LY-294002 inhibited insulin stimulated
insulin gene transcription (Leibiger et al., 2001, 1998). The positive insulin au-
tocrine eﬀect on beta cells to stimulate insulin release has been demonstrated to
be dependent on IRS-1 and PI3K (Aspinwall et al., 2000). Stimulation of beta
cells with insulin leads to increase in intracellular calcium, released from the en-
doplasmic reticulum (ER) stores, and stimulation of insulin secretion. However,
both the insulin stimulated intracellular calcium release and insulin secretion were
abolished in IRS-1 KO beta cells or treatment with wt beta cells with the PI3K in-
hibitor wortmannin (Aspinwall et al., 2000). Similarly, thiazolidinediones such as
rosiglitazone (RSG) and BLX-1002 that belong to a group of anti-hyperglycaemic
drugs that have been shown to enhance high-glucose stimulated insulin secretion.
However, the enhanced insulin secretion by RSG and BLX-1002 was abolished
with a treatment with the PI3K inhibitor LY-294002 or wortmannin (Yang et al.,
2001a; Zhang et al., 2009). On the contrary, (Khan et al., 2001) showed that in-
sulin stimulated beta cell KATP -channel activity which led to hyperpolarisation of
the plasma membrane and reduction in intracellular calcium levels. However, this
eﬀect was blocked by treatment of beta cells with wortmannin, demonstrating
that insulin hyperpolarises the plasma membrane via activation of PI3K (Khan
et al., 2001). Furthermore, a study by Kubota et al. (2004) showed that insulin
secretion in response to 11.1 mmol/L glucose was significantly higher when wt
islets were treated with the PI3K inhibitor LY-294002 in comparison to untreated
islets. Similarly, treatment of islets isolated from RIPCreIRS-2KO islets showed
higher insulin secretion in response to high glucose when treated with LY-294002
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than untreated (Kubota et al., 2004).
Arginine also stimulates insulin release by promoting plasma membrane depo-
larisation and increase in intracellular calcium. Interestinly, arginine-stimulated
insulin secretion was also impaired in the IGF-1 receptor KO but not in the IR
KO mice (Kulkarni et al., 1999; Xuan et al., 2002). A study by Aspinwall et al.
(2000) has suggested that insulin can stimulate insulin secretion through PI3K
by promoting calcium release from the intracellular stores. Hence, it might be
possible that IGF-1 receptor acts via PI3K to stimulate insulin secretion.
Insulin receptor/PI3K mediated signalling in pancreatic beta cells have been
considered to be important for the maintenance of beta cell mass. Reduced beta
cell mass can also result in reduced insulin secretion. Beta cell specific deletion
of IRS-2 and Pdk1 for instance have resulted in decreased beta cell mass and
insulin secretion, whereas deletion of PTEN has shown to increase beta cell mass
(Cantley et al., 2007; Choudhury et al., 2005; Kubota et al., 2004; Lin et al.,
2004a; Nguyen et al., 2006). Even thought Akt is one of the main modulators
in regulating cell growth and proliferation, transgenic mouse models of Akt have
shown inconclusive results. Expression of constitutively active Akt1 in beta cells
increased both beta cell size and number (Bernal-Mizrachi et al., 2004; Tuttle
et al., 2001). On the contrary, expression of dominant-negative form of Akt1 in
beta cells, in which Akt activity was reduced by 80 % did not show decreased beta
cell mass (Elghazi et al., 2007). The results reported in this thesis demonstrate
that inactivation of both the p110α and p110β kinase function in beta cells does
not aﬀect the beta cell mass or islet density. In contrast, the heterozygous kinase
dead p110α and kinase dead p110β mice displayed islet hyperplasia and hyperin-
sulinaemia (Foukas et al., 2006). However, it is likely that increased islet mass is
compensatory mechanism for peripheral insulin resistance present in these mice.
In addition, if inactivation of either p110α or p110β isoforms can still lead to
increased islet mass, it is possible that PI3K is not required for the maintenance
of beta cell mass.
Gene expression analysis of some of the key beta cell genes such as Glut2,
insulin, Irs-1 and Akt, did not show any significant changes in mRNA expres-
sion levels, apart from a small increase in expression of pyruvate dehydrogenase
kinase 1 (Pdk1). Pdk1 is a negative regulator of pyruvate dehydrogenase (PDH),
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which is phosphorylated and inactivated by PDK1. PDH decarboxylates pyruvate
to acetyl-CoA before it can enter the mitochondrial TCA cycle. Both PDH as
well as pyruvate carboxylase (PC), which carboxylates pyruvate to oxaloacetate,
are important mediators of metabolic flux to the TCA cycle (whan Kim et al.,
2006). Recent studies have identified PDK1 as a potential regulator of GSIS in
pancreatic beta cells. Knock-down of PDK1 in clonal beta cells lead to increased
PDH activity, increased mitochondrial metabolic flux and oxidative phosphory-
lation coupled to ATP production, which enhanced GSIS in vitro (Krus et al.,
2010).
6.12.4 Energy homeostasis in RIPCrep110αβKO mice
Investigation of whole-body energy homeostasis in RIPCrep110αβKO mice sug-
gests that inactivation of p110α and p110β isoforms in hypothalamic insulin ex-
pressing neurons (RIP) does not aﬀect feeding behaviour or basal metabolic rate,
although mild leptin resistance seems to occur, possibly due to increased plasma
leptin levels. In contrast, increased food intake was observed in RIPCreIRS-2KO
mice reported by three independent studies (Choudhury et al., 2005; Kubota
et al., 2004; Lin et al., 2004b). Similar to my results, all three studies also re-
ported increased plasma leptin levels (Choudhury et al., 2005; Kubota et al., 2004;
Lin et al., 2004b) and mild leptin resistance was also observed by Choudhury et al.
(2005); Kubota et al. (2004).
Body composition is markedly altered in RIPCrep110αβKO mice, demon-
strated by increased body weight, lean body mass, bone mineral content and
significant adiposity. The naso-anal body length was also significantly increased.
Similarly to the RIPCrep110αβKO mice, increased body weight and adipos-
ity were reported in RIPCreIRS-2KO mice (Choudhury et al., 2005; Kubota
et al., 2004; Lin et al., 2004b) and increased somatic growth was reported by
(Choudhury et al., 2005; Lin et al., 2004b). Heterozygous p110α knock-in mice
also displayed increased adiposity and hyperleptinaemia but the body size was
reduced due to reduced lean body mass (Foukas et al., 2006). In contrast,
RIPCrePTENKO mice, in which PI3K signalling is enhanced, exhibited reduced
body growth (Choi et al., 2008).
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Both insulin and melanocortin receptor agonist MT-II, but not leptin, depo-
larise RIPCre neurons (Choudhury et al., 2005). Interestingly both Pomc and
AgRP mRNA expression levels were significantly decreased in the hypothalami of
RIPCrep110αβKO mice. As Pomc mRNA expression levels were also decreased
in RIPCreIRS-2KO mice it is possible that impaired melanocortin signalling
might be responsible for the altered energy homeostasis in the emphRIPCrep110αβKO
mice (Choudhury et al., 2005; Lin et al., 2004b). Even though Pomc mRNA lev-
els were not reported in RIPCrePTENKO mice, it is possible that disruption
of insulin receptor signalling pathway leads to impaired melanocortin signalling,
which is involved in the regulation of body growth and size (Ellacott and Cone,
2006). Therefore, results reported in this thesis as well as earlier studies suggest
that insulin/IGF-1 signalling mediated via IRS-2 and PI3K in RIPCre expressing
neurons has a key role in the regulation of body growth and size.
6.12.5 Summary
Overall, results reported in this thesis imply that p110α and p110β isoforms
are required for normal glucose-stimulated insulin secretion from pancreatic beta
cells. However, they are not involved in the regulation of normal beta cell mass,
islet density and morphology. As these studies are less complete, further exper-
iments are required to understand the underlying cause for defective GSIS, and
involvement of PI3K in the regulation of insulin secretion.
Because the kinase activity of both the p110α and p110β are abolished in
this study, it is not possible to distinguish whether the isoforms are involved in
regulating diﬀerent pathways in the beta cells, as it has been shown in other tissue
types. In hypothalamic POMC and AgRP neurons, p110β was shown to be the
dominating isoform, whereas in peripheral tissues p110α has the dominant role,
although the p110β activity is still required, especially in the long term insulin
receptor signalling (Al-Qassab et al., 2009). Previous studies have also shown that
in tissues, where p110α has a dominant role in insulin receptor signalling, p110β,
in addition to p110γ, mediates signals downstream of G-protein coupled receptors
(GPCR) (Guillermet-Guibert et al., 2008; MacDonald et al., 2004). However, in
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this study, it was more important to establish the general role for PI3K in beta
cells, rather than trying to distinguish isoform specific diﬀerences.
6.12.6 Future studies
Previous studies that have also shown that IRS-1/2 and PI3K regulate insulin se-
cretion, have suggested that one potential mechanism would involve regulation of
calcium release from intracellular calcium stores (Cantley et al., 2007). Therefore,
it would be interesting to study calcium signalling in RIPCrep110αβKO islets,
or wt islets, treated with isoform specific inhibitors. Arginine-stimulated insulin
secretion is thought to act via direct stimulation of plasma membrane depolar-
isation and increase in intracellular calcium. Beta cell specific IGF-1 receptor,
but not insulin receptor KO mice exhibited impaired arginine-stimulated insulin
secretion. Therefore, an arginine-stimulated insulin secretion in vitro should be
performed (Xuan et al., 2002).
As mentioned above, p110β has been shown to mediate signals additionally
downstream of GPCR (Graupera et al., 2008). Whether this is true in beta
cells could suggest an alternative role for p110β in beta cells in mediating insulin
secretion. Deletion of p110γ isoform, which couples signals downstream only from
GPCR, in beta cells lead to impaired GSIS (MacDonald et al., 2004). For example
GLP-1 receptor is a GPCR that stimulates insulin secretion, although it is still
dependent of glucose (Ahre´n, 2009). Hence, using p110α and p110β inhibitors
and measuring insulin secretion in response to a GLP-1 receptor agonist exendin-
4, could potentially indicate whether p110β is coupled to GPCR signalling in beta
cells and whether GPCR signalling is one potential mechanism in the regulation
of insulin secretion.
In conclusion, RIPCrep110αβKO mice develop impaired glucose homeosta-
sis associated with marked hyperglycaemia and glucose intolerance due to in-
trinsic beta cell defect in glucose-stimulated insulin secretion. Due to impaired
p110α and p110β activity additionally in hypothalamic RIPCre expressing neu-
rons, RIPCrep110αβKO mice display increased somatic growth and adiposity.
These findings suggest a key role for PI3K in regulation of insulin secretion in
pancreatic beta cells and regulation of body growth in RIPCre expressing hy-
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pothalamic neurons.
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Appendix A - Solutions
Tissue extraction buﬀer
• 50 mmol/L Tris pH 8.0
• 100 mmol/L EDTA
• 100 mmol/L NaCl
• 1 % SDS
TAE buﬀer
• 40 mmol/L Tris acetate pH 8.3
• 1 mmol/L EDTA
Leptin reconstitution (1.85 mg/ml stock)
• 1.5 ml of 15 mmol/L HCL (add first)
• 1.2 ml of 7.5 mmol/L NaOH (add slowly avoiding precipitation)
2X KRB stock solution
• 136 mmol/L NaCl
• 4.7 mmol/L KCl
• 1.2 mmol/L KH2PO4
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• 5 mmol/L NaHCO3
• 1.2 mmol/L MgSO4 (7H2O)
Quenching buﬀer (1X KRB) pH 7.4
• 2X KRB stock
• 10 mmol/L Hepes
• 1 mmol/L CaCl2
• 2 mmol/L D-glucose
• ddH2O
After pH, supplement with 100 units/ml penicillin + 100 µg/ml streptomycin.
Take an aliquot for Liberase solution and filter. Supplement the rest of the
solution with either newborn calf serum (NCS, Gibco 16010-159), if islets are used
for in vitro culture or with bovine serum albumin (BSA, Sigma A7906), if islets
are used for DNA/RNA/protein extraction. Filter solution after supplementing
with NCS or before supplementing with BSA.
Pancreatic digestion solution
Use the 1X KRB solution (pH 7.4) with penicillin/streptomycin and filter the
solution. Prepare 0.225 mg/ml Liberase solution from 2.5 mg/ml Liberase stock
solution (Liberase TL Research Grade, Roche 05 401 020 001). Keep cold.
Overnight culture medium
• RPM1 1640 GlutaMAX + 25 mM Hepes (Gibco 72400-021)
• 10 % Fetal bovine serum (FBS) (Gibco 10270-106)
• 100 units/ml penicillin + 100 µg/ml streptomycin (Gibco 15070-063)
Secretion buﬀer
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1X KRB solution (as described earlier) supplemented with 0.5 % BSA and
either with 2 mmol/L or 20 mmol/L glucose concentration.
Bouins fixative
• 71.43 % picric acid (saturated aqueous)
• 23.8 % formalin (40 % aqueous formaldehyde)
• 4.76 % glacial acetic acid
Ripa lysis buﬀer
• 1X Ripa buﬀer (Sigma R0278)
• Cocktail protease inhibitor tablet (1/4 tablet in 5 ml of Ripa buﬀer)
• 1 mmol/L PMSF (phenyl-methyl-sulfonyl fluoride)
2x Laemmli buﬀer
• 50 mmol/L Tris-HCL (pH 6.8)
• 2 % SDS
• 0.1 % Bromophenol blue
• 10 % glycerol
• 5 % β-mercapthoethanol
SDS-polyacrylamide gel
12 % Separating gel
• 0.375 mol/L Tris-HCL, pH 8.8
• 12 % acrylamide
• 0.1 % SDS
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• 0.1 % ammonium persulfate
• 0.04 % TEMED (Tetramethylethylenediamine)
5 % Stacking gel
• 0.125 mol/L Tris, pH 6.8
• 5 % acrylamide
• 0.1% SDS
• 0.1 % ammonium persulfate
• 0.1 % TEMED (Tetramethylethylenediamine)
Tris-glycine-SDS running buﬀer
• 25 mmol/L Trizma base (Sigma)
• 192 mmol/L glycine
• 0.1 % SDS
Tris-glycine transfer buﬀer
• 25 mmol/L Trizma base (Sigma)
• 192 mmol/L glycine
• 20 % methanol
• 0.1 % SDS
1X TBST washing buﬀer
• 20 mmol/L Tris-HCL (pH 7.6)
• 137 mmol/L NaCl
• 0.1 % Tween20
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Blocking solution
• 1X TBST washing buﬀer
• 5 % non-fat dried milk
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Appendix B - Abbreviations
4EBP1 Eukaryotic translation initiation factor 4E binding protein-1
ABCC8 ATP-binding cassette, sub-family C, member 8
ACC Acetyl-CoA carboxylase
ADP Adenosine diphosphate
AGC cAMP-dependent, cGMP-dependent and protein kinase C
AgRP Agouti-related peptide
AICAR 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside
AMP Adenosine monophosphate
AMPK AMP-activated protein kinase
ANOVA Analysis of variance
ANT Adenine nucleotide transferase
ARC Arcuate nucleus
AS160 Rab-GTPase-activating protein
ATP Adenosine trisphosphate
Bp Base pair
BSA Bovine serum albumin
CA Constitutively active
Ca2+ Calcium ion
CaMKK Ca2+/calmodulin-dependent protein kinase kinase
cAMP cyclic adenosine monophoshate
CART cocaine-amphetamine-regulated-transcript
CBS Cystathione beta-synthase
CCD Charged coupled device
CDKAL1 CDK5 regulatory subunit associated protein 1-like 1
CDKN2B Cyclin-dependent kinase inhibitor 2B
cDNA complementary deoxyribonucleic acid
Cl− Chloride ion
CM-H2DCFDA 5-(and 6)-chloromethyl-2,7-dicholorodihydrofluorescein diacetate acetylester
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CNS Central nervous system
CoA Coenzyme A
CPT1 Carnitine-palmitoyl-CoA-acyltransferase 1
Cre Cre-recombinase
CREB Cyclic AMP response element binding protein
DAPI 4￿,￿6-diamidino-2-phenylindole
DEXA Dual-energy X-ray absorptiometry
DMSO Dimethyl sulfoxide
DN Dominant negative
DNA Deoxyribonucleic acid
dNTP Deoxynucletide trisphoshate
EDTA Ethylenediaminetetraacetic acid
EGF Epidermal growth factor
EIF4E Eukaryotic translation initiation factor 4E
ELISA Enzyme-linked immunosorbent assay
ER Endoplasmic reticulum
Erk Extracellular signal-regulated kinase
FADH2 Flavin adenine dinucleotide (reduced form)
FBS Fetal bovine serum
FITC Fluorescein isothiocyanate
FoxO Forkhead box, sub-group O
G6Pase Glucose-6-phosphatase
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
GIP Gastric inhibitory polypeptide
GK Glucokinase
GLP-1 Glucagon-like peptide-1
GLUT Glucose transporter
GPCR G-protein coupled receptor
GPX4 Glutathione peroxidase 4
Grb2 Growth factor receptor-bound protein 2
GS Glycogen synthase
GSIS Glucose-stimulated insulin secretion
GSK3 Glycogen synthase kinase-3
GTT Glucose tolerance test
GWAS Genome-wide association study
H2O2 Hydrogen peroxide
HCL Hydrochloric acid
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
HHEX Hematopoietically expressed homeobox
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HI Hyperinsulinism
HK Hexokinase
HMOX1 Heme oxygenase (decycling) 1
HNF-4 Hepatic nuclear factor-4
HPRT Hypoxanthine-guanine phosphoribosyltransferase
HRP Horseradish peroxidase
i.p. Intraperitoneal
IGF-1 Insulin-like growth factor 1
IGF2BP2 Insulin-like growth factor 2 mRNA binding protein 2
IL Interleukin
INS-1 Insulinoma cell line
Ins2 Insulin 2
IP3 Inositol trisphosphate
IR Insulin receptor
IRS-1 Insulin receptor substrate 1
IRS-2 Insulin receptor substrate 2
ITT Insulin tolerance test
JNK c-Jun N-terminal kinase
K+ Potassium ion
KATP ATP sensitive potassium channel
KCNJ11 Potassium inwardly-rectifying channel, subfamily J, member 11
Kd Kinase dead
KIF5B Kinesin family member 5 B
KO Knock-out
KRB Krebs-ringer buﬀer
L-PK Liver type pyruvate kinase
LKB1 Liver kinase B1
MAPK Mitogen-activated protein kinase
MEF Mouse embryonic fibroblast
MODY Maturity onset diabetes of young
mRNA Messenger ribonucleic acid
MT-II Melanotan-II
MTNR1B Melatonin receptor 1B
mTOR Mammalian target of rapamycin
NAD Nicotinamide adenine dinucleotide
NAHD Nicotinamide adenine dinucleotide (reduced form)
NCS Newborn calf serum
ND Neonatal diabetes
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NF-κB Nuclear factor kappa beta
NHS National Health Service
NPY Neuropeptide Y
Nrf1 Nuclear respiratory factor 1
PC Pyruvate carboxylase
PCR Polymerase chain reaction
PDH Pyruvate dehydrogenase
Pdk1 Phosphatidylinositol dependent kinase 1
PDK1 Pyruvate dehydrogenase kinase, isoenzyme 1
Pdx1 Pancreatic and duodenal homeobox 1 promoter
PEPCK Phosphoenolpyruvate carboxykinase
PGC-1α Peroxisome proliferator-activated receptor-gamma coactivator 1alpha
PH Plextrin homology
PHHI Persistent hyperinsulinaemic hypoglycaemia of infancy
PI3K Phosphoinositide 3-kinase
PIP2 Phosphatidyl inositol 3,4-bisphosphate
PIP3 Phosphatidyl inositol 3,4,5-trisphosphate
PKA Protein kinase A
PKB/Akt Protein kinase B
PKC Protein kinase C
PLC-γ Phospholipase C-gamma
POMC Pro-opiomelanocortin
PP Pancreatic polypeptide
PPARG Peroxisome proliferator-activated receptor gamma
PPI Pre-proinsulin
PTB Phosphotyrosine-binding
PtdIns Phosphatidyl inositol
PTEN Phosphatase and tensin homolog
qPCR Quantitative polymerase chain reaction
RIP Rat insulin promoter
RNA Ribonucleic acid
ROS Reactive oxygen species
RPM Revolutions per minute
RSG Rosiglitazone
RT-PCR Reverse transcription-polymerase chain reaction
S6K S6 kinase
SDS Sodium dodecyl sulfate
SEM Standard error of the mean
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SgK Serine/threonine-protein kinase
SH2 Src-homology-2-domain
SIRT1 Sirtuin 1
Slc2a2 Solute carrier family 2 (facilitated glucose transporter) member 2
SLC30A8 Solute carrier family 30 (zinc transporter), member 8
SNAP-25 Synaptosomal-associated protein, 25kDa
SNARE Soluble NSF (N-ethylmaleimide-sensitive factor) attachment protein receptor
SOD Superoxide dismutase
SOS Son-of-sevenless
SUR1 Sulfonylurea receptor subunit 1
T2DM Type 2 diabetes mellitus
TAE Tris-acetate-EDTA
TBST Tris-buﬀered saline Tween20
TCA Tricarboxylic acid
TCF7L2 Transcription factor 7-like 2
TEMED Tetramethylethylenediamine
Tfam Transcription factor A, mitochondrial
Thr Threonine
TNF-α Tumour necrosis factor-alpha
TORC2 Transducer of regulated cyclic AMP response element binding protein activity 2
Tris Tris(hydroxymethyl)aminoethane
TRITC Tetramethyl rhodamine iso-thiocyanate
TSC2 Tuberous sclerosis protein 2
UCP2 Uncoupling protein 2
UV Ultraviolet
VAMP Vesicle-associated membrane protein
VEGF Vascular epidermal growth factor
ZMP 5-aminoimidazole-4-carboxamide ribonucleoside
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Appendix C - Publications
The following publication has arisen as a result of the work described in Chapter
3 and 4 and is included at the back of this thesis:
Craig Beall, Kaisa Piipari et al. (2010). ”Loss of AMP-activated protein ki-
nase α2 subunit in mouse β-cells impairs glucose-stimulated insulin secretion and
inhibits their sensitivity to hypoglycaemia.” Biochemical Journal. 429, 323-333.
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Loss of AMP-activated protein kinase α2 subunit in mouse β-cells impairs
glucose-stimulated insulin secretion and inhibits their sensitivity to
hypoglycaemia
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AMPK (AMP-activated protein kinase) signalling plays a key role
in whole-body energy homoeostasis, although its precise role in
pancreatic β-cell function remains unclear. In the present stusy,
we therefore investigated whether AMPK plays a critical function
in β-cell glucose sensing and is required for the maintenance
of normal glucose homoeostasis. Mice lacking AMPKα2 in β-
cells and a population of hypothalamic neurons (RIPCreα2KO
mice) and RIPCreα2KO mice lacking AMPKα1 (α1KORIP-
Creα2KO) globally were assessed for whole-body glucose
homoeostasis and insulin secretion. Isolated pancreatic islets from
these mice were assessed for glucose-stimulated insulin secretion
and gene expression changes. Cultured β-cells were examined
electrophysiologically for their electrical responsiveness to
hypoglycaemia. RIPCreα2KO mice exhibited glucose intolerance
and impaired GSIS (glucose-stimulated insulin secretion) and this
was exacerbated in α1KORIPCreα2KO mice. Reduced glucose
concentrations failed to completely suppress insulin secretion
in islets from RIPCreα2KO and α1KORIPCreα2KO mice, and
conversely GSIS was impaired. β-Cells lacking AMPKα2 or
expressing a kinase-dead AMPKα2 failed to hyperpolarize in
response to low glucose, although KATP (ATP-sensitive potassium)
channel function was intact. We could detect no alteration of
GLUT2 (glucose transporter 2), glucose uptake or glucokinase
that could explain this glucose insensitivity. UCP2 (uncoupling
protein 2) expression was reduced in RIPCreα2KO islets and the
UCP2 inhibitor genipin suppressed low-glucose-mediated wild-
type mouse β-cell hyperpolarization, mimicking the effect of
AMPKα2 loss. These results show that AMPKα2 activity is
necessary to maintain normal pancreatic β-cell glucose sensing,
possibly by maintaining high β-cell levels of UCP2.
Key words: AMP-activated protein kinase (AMPK), ATP-sens-
itive potassium channel (KATP), β-cell, glucokinase, pancreas,
uncoupling protein 2 (UCP2).
INTRODUCTION
Raised plasma glucose increases the amount of glucose taken
up by pancreatic β-cells predominantly through the glucose
transporter, GLUT2 [1]. This increase in glucose metabolism
occurs over the physiological range of glucose concentrations
by the action of the rate-limiting enzyme GK (glucokinase).
The raised β-cell metabolic flux increases the ratio of cellular
[ATP]/[ADP], which closes KATP (ATP-sensitive potassium)
channels, leading to membrane depolarization, opening of
voltage-gated calcium channels, raised intracellular calcium and
insulin secretion [2]. Thus temporal fluctuations of blood glucose
levels are directly linked to variations in insulin secretion by
the concerted activity of these key pancreatic β-cell proteins.
Therefore these proteins are essential for pancreatic β-cells
to mount an initial rapid insulin secretory response, which is
followed by a slower KATP-independent release of insulin. There
is strong evidence that dysfunctional pancreatic β-cells are central
to the development of Type 2 diabetes [3,4]. A progressive
increase in basal insulin secretion (during fasting) along with
a much reduced or absent first-phase of GSIS (glucose-stimulated
insulin secretion) are considered early and common defects in
Type 2 diabetes. Indeed, the loss or reduction of β-cell secretory
responsiveness to glucose, when imposed on a background of
peripheral insulin resistance, is likely to precipitate early-impaired
glucose tolerance leading rapidly to Type 2 diabetes.
Oral anti-diabetic drug treatment has evolved in recent years to
encompass the widespread use of metformin as a first-line drug
for treatment of Type 2 diabetes [5]. Current evidence suggests
that metformin reduces blood glucose levels by decreasing liver
gluconeogenesis and increasing peripheral glucose uptake. The
mechanisms by which metformin performs these actions have
been linked to increased insulin action and the activation of
AMPK (AMP-activated protein kinase). Consequently, AMPK
has attracted considerable attention as a potential target for the
treatment of Type 2 diabetes [6].
AMPK acts as a cellular integration node for various nutrient
and hormone signals, and subsequent changes in AMPK activity
regulates multiple metabolic pathways of glucose metabolism
[7]. Thus there may be an expectation for AMPK to be
Abbreviations used: AICAR, 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside; AMPK, AMP-activated protein kinase; CM-H2DCFDA, 5-(and-
6)-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate, acetyl ester; CRI-G1, Cambridge rat insulinoma-G1; Gck, glucokinase gene; GFP, green
fluorescent protein; GK, glucokinase; GLUT2, glucose transporter 2; GSIS, glucose-stimulated insulin secretion; KATP channel, ATP-sensitive potassium
channel; NPY, neuropeptide Y; Nrf1, nuclear respiratory factor 1; Pgc1α, peroxisome proliferator-activated receptor γ coactivator 1-α; POMC, pro-
opiomelanocortin; ROS, reactive oxygen species; Slc2a2, solute carrier family 2 (facilitated glucose transporter) member 2; SUR1, sulfonylurea receptor
1; Tfam, transcription factor A, mitochondrial; UCP2, uncoupling protein 2; WT, wild-type.
1 These authors contributed equally to the present study
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critically involved in the regulation of insulin secretion by
glucose. Indeed, diminished AMPK activity has been reported
in islets from Type 2 diabetic patients [8]. However, the
precise role of AMPK in the regulation of insulin secretion
from β-cells is presently unclear and controversial. Activation
of AMPK by AICAR (5-aminoimidazole-4-carboxamide-1-β-D-
ribofuranoside), metformin or overexpression of a constitutively
active form of AMPK reduces GSIS in rodent and human islets
[9–12]. In contrast, overexpression of a dominant-negative form
of AMPK is reported to increase insulin release at low glucose
concentrations [10]. However, others have failed to replicate these
findings [13,14], generating uncertainty over the role of AMPK
in insulin secretion. Therefore to define the role of AMPK in β-
cell function, we generated mice deficient in AMPKα2 (with or
without global deletion of AMPKα1) in β-cells and examined the
relationship between AMPK activity and the mechanisms thought
to mediate normal glucose sensing.
MATERIALS AND METHODS
Animals
Floxed AMPKα2 allele RIPCre mice (The Jackson Laboratory)
were crossed to generate compound heterozygote mice. Double-
heterozygote mice were crossed with AMPKα2+/fl mice to
obtain WT (wild-type), flox+/+, Cre and Creflox+/+. Mice
lacking AMPKα2 in RIPCre-expressing cells were designated
RIPCreα2KO mice. RIPCreα2KO and AMPKα1KO mice were
crossed to generate mice lacking AMPKα1 globally (α1KO)
and AMPKα2 in RIPCre-expressing cells (α1KORIPCreα2KO
mice). All mice were maintained on a 12-h light/12-h dark cycle
with free access to water and standard mouse chow (4% fat,
RM1; Special Diet Services) and housed in pathogen-free barrier
facilities. All procedures were in accordance with the UK Home
Office Animal Procedures Act of 1986 and approved by the
University of Dundee and University College London Animal
Ethics Committees. All mice were studied with appropriate
littermate controls. Genotyping of mice was performed by PCR
amplification of tail DNA as described previously [15,16].
Physiological measurements
Body weight and feeding measurements, and tolerance tests were
performed as described previously [15,17]. Blood glucose and
plasma insulin levels were determined using mouse ELISAs
(Linco Research).
Gene expression studies
Quantitative PCR was performed as described previously
[15,16]. Expression levels of AMPKα2, Gck (glucokinase
gene), HMOX1 (haem oxygenase 1), GPX4 (glutathione
peroxidase 4), NPY (neuropeptide Y), Nrf1 (nuclear respiratory
factor 1), Pgc1α (peroxisome proliferator-activated receptor γ
coactivator 1-α), POMC (pro-opiomelanocortin), Slc2a2 [solute
carrier family 2 (facilitated glucose transporter) member 2;
previously known as Glut2], SOD2 (superoxide dismutase 2),
SUR1 (sulfonylurea receptor 1), Tfam (transcription factor A,
mitochondrial) and UCP2 (uncoupling protein 2) were normalized
to GAPDH (glyceraldehyde-3-phosphate dehydrogenase) or
HPRT (hypoxanthine phosphoribosyltransferase 1) and data were
analysed using the 2−$Ct method [15].
Figure 1 Reduction in islet and hypothalamic AMPKα2 in RIPCreα2KO
mice
(A) Detection of the deletion of the AMPKα2 allele in RIPCreα2KO mice. DNAwas extracted from
different tissues (T, tail; L, liver; M, skeletal muscle; F, fat; C, cerebral cortex; Hy, hypothalamus;
I, islets of Langerhans) and recombination of the floxed AMPKα2 allele was detected by PCR.
The presence of the 750 bp band indicates deletion of AMPKα2. Recombination was only
detected in islets of Langerhans and the hypothalamus from RIPCreα2KO mice. A PCR with IL2
(interleukin-2) as an internal control shows the presence of DNA template in all of the samples.
La, DNA ladder. (B) Representative immunoblot for AMPKα2 from control and RIPCre2αKO
islets.
Western blot analysis
Islet and hypothalamic lysates were prepared as described
previously [15–17] and immunoblots probed with polyclonal
antibodies against ATP synthase (Abcam), AMPKa2 (supplied by
David Carling) andβ-actin (Cell Signalling), with ECL (enhanced
chemiluminescence; Amersham Biosciences) detection.
Pancreas morphometry
Antibodies used were mouse anti-insulin (I-2018; Sigma–
Aldrich), rabbit anti-glucagon (ab9379; Abcam), chicken anti-
mouse Alexa Fluor® 594 and chicken anti-rabbit Alexa Fluor®
488 (both Molecular Probes/Invitrogen). Confocal images were
captured using a Carl Zeiss LSM 700 laser scanning microscope
with 20× air objective.
Islets and CRI-G1 (Cambridge rat insulinoma-G1) experiments
Mouse pancreatic islet isolation, islet insulin secretion studies and
β-cell culture were performed as described previously [16,18].
Treatments of CRI-G1 cells with Compound C (Calbiochem),
AICAR (Toronto Research Chemicals) and A-769662 were
carried out in normal saline+− 10 mM glucose. Hexokinase
activity in CRI-G1 cells was measured as described previously
[19]. Cell lysates were prepared for immunoblotting and analysis
as described previously [20]. For glucose uptake, the fluorescent
glucose analogue 2-NBDG (Molecular Probes) was applied at
100 µM in the presence of glucose+−AICAR and+−Compound C,
and imaged as described previuosly [21]. In control experiments,
CRI-G1 cells took-up 2-NBDG in a linear manner for >1 h. For
immunostaining, CRI-G1 cells were washed and immediately
fixed after treatments and then permeabilized with 0.5% Triton
X-100 in PBS. Non-specific-binding was blocked with 10%
(w/v) BSA and primary antibodies against GLUT2 and GK
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Figure 2 Glucose homoeostasis in RIPCreα2KO mice
(A) Weight curves of male control and RIPCreα2KO mice on a chow diet (n= 5–8). (B) Daily food intake of RIPCreα2KO and control mice (n= 7–9). (C) Intraperitoneal glucose tolerance test
performed on 16-week-old male RIPCreα2KO (!) and control (") mice (n= 8). (D) Insulin tolerance test performed on 20-week-old male RIPCReα2KO (!) and control (") mice (n= 7). (E)
Plasma insulin levels before and after intraperitoneal injection of glucose (2 g/kg of body weight) in 10-week-old male RIPCreα2KO (!) and control (") mice (n= 6–7). Values are means+− S.E.M.
*P < 0.05, **P < 0.01.
(Santa Cruz Biotechnology) were applied at a 1:1000 dilution
for 1 h. For visualization, either Alexa Fluor® 488 (Molecular
Probes) or Cy3 (indocarbocyanine; Jackson ImmunoResearch)-
conjugated secondary antibodies were used according to
the manufacturers’ instructions. CRI-G1 cell nucleotide
determination was performed as described previously [9]. H2O2
levels in individual islets were measured by epifluorescent
microscopy using the fluorescent probe CM-H2DCFDA [5-
(and-6)-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate,
acetyl ester] at a concentration of 1 µM, with a 60 min preloading
time.
Electrophysiological studies
Mouse cultured β-cells were super-fused at room temperature
(22–25 ◦C) with normal saline [135 mM NaCl, 5 mM KCl,
1 mM MgCl2, 1 mM CaCl2, 10 mM Hepes and 10 mM glucose
(pH 7.4)]. Whole-cell recordings were made using borosilicate
glass pipettes (5–10 M#) containing 140 mM KCl, 10 mM
EGTA, 5 mM MgCl2, 3.8 mM CaCl2 and 10 mM Hepes
(pH 7.2)+−ATP at 3.0 mM, 1.0 mM, 0.1 mM and 0 mM. For
voltage-clamp recordings the membrane potential was held at
−70 mV and 20 mV steps of 200 ms duration, with 20 ms
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between pulses, applied (voltage range from −160 to −40 mV).
Voltage-clamp data were analysed using pCLAMP 8.2 software.
Perforated patch recordings were achieved by addition of 25–
50 µg/ml amphotericin B (Sigma–Aldrich) to the pipette solution.
Series resistance was <30 M! for all recordings. Following a
minimum of 10 min of stable recording, the extracellular glucose
concentration was altered or drugs applied by bath superfusion.
Statistics
Data are presented as means+− S.E.M. All statistics were per-
formed using GraphPad (Prism 5) software. Paired or Wilcoxon
signed-rank sum test and unpaired t tests were performed.
P values!0.05 were considered statistically significant.
RESULTS
Deletion of AMPKα2 in the pancreas and a subset of hypothalamic
neurons does not affect body weight or food intake, but impairs
glucose homoeostasis and GSIS in mice
Mice expressing Cre under the control of the rat insulin II
promoter and mice with a floxed allele of AMPKα2 were
crossed to generate mice lacking AMPKα2 in pancreatic
β-cells and a small population [15] of hypothalamic neurons
(RIPCreα2KO mice). We detected recombination of the
floxed AMPKα2 allele in islets and hypothalamus from
RIPCreα2KO mice and protein expression of AMPKα2
was significantly reduced in islets (Figures 1A and 1B).
No significant change in NPY or POMC mRNA was
detected in fasted RIPCreα2KO mice (Supplementary Figure
S1A at http://www.BiochemJ.org/bj/429/bj4290323add.htm).
Furthermore, RIPCreα2KO mice exhibited normal body weight
and unchanged daily food intake compared with littermate
controls (Figures 2A and 2B), suggesting no significant
hypothalamic phenotype. RIPCreα2KO mice displayed normal
fasted and fed blood glucose levels, and fasted plasma insulin
as compared with control mice (Supplementary Figures S1B–
S1D). RIPCreα2KO mice displayed mild glucose intolerance
compared with littermate controls (Figure 2C), but no reduction
in peripheral insulin sensitivity (Figure 2D). However, in
vivo GSIS was depressed in RIPCreα2KO mice (Figure 2E),
potentially explaining their mild glucose intolerance. To address
the possibility of compensatory up-regulation of AMPKα1
expression in cells deleted for AMPKα2, we used mice with
global deletion of AMPKα1 (α1KO), which exhibit a normal
metabolic phenotype [22] and α1KORIPCreα2KO mice (lacking
AMPKα2 in pancreatic β-cells and some hypothalamic neurons
and AMPKα1 in all tissues). The α1KORIPCreα2KO mice
exhibited normal body weight (results not shown) and food
intake compared with controls (Figure 3A), again indicating
no hypothalamic disturbance. However, the α1KORIPCreα2KO
mice displayed profound impairment of glucose tolerance and in
vivo GSIS was markedly depressed in α1KORIPCreα2KO mice
compared with controls (Figures 3B and 3C).
AMPK-deleted islets in vitro exhibit increased insulin release at
basal glucose and decreased GSIS
Because AMPKα2 was also deleted in some hypothalamic
neurons, we were concerned that altered autonomic activity to
peripheral organs, as described for the global AMPKα2KO mouse
[22], was influencing β-cell function. We therefore undertook
further in vitro analysis of β-cell function using RIPCreα2KO
and α1KORIPCreα2KO isolated islets. Static incubation of
RIPCreα2KO islets showed enhanced insulin secretion under
Figure 3 Mice lacking AMPKα1 globally and AMPKα2 in β-cells and
a population of hypothalamic neurons exhibit glucose intolerance and
defective GSIS
(A) Cumulative 24-h food intake in 20-week-oldmale control (open bars) andα1KORIPCreα2KO
(solid bars) mice in response to an overnight fast (n= 5). (B) Intraperitoneal glucose tolerance
test performed on 5-week-old male α1KORIPCreα2KO (!) and control (") mice (n= 8–11).
(C) Plasma insulin levels before and after intraperitoneal injection of glucose (2 g/kg of body
weight) in 10-week-old male α1KORIPCreα2KO (!) and control (") mice (n= 6–7). Values
are means+− S.E.M. **P < 0.01, ***P < 0.001.
basal (2 mM) glucose conditions compared with control islets,
whereas GSIS (glucose raised to 20 mM) displayed a non-
significant trend towards decreased secretion (Figure 4A).
Furthermore, insulin secretion from α1KORIPCreα2KO islets at
2 mM glucose was enhanced and GSIS significantly impaired
compared with control animals (Figure 4B). The increased basal
insulin secretion is consistent with that reported previously with
adenoviral overexpression of a dominant-negative form of AMPK
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Figure 4 Defective GSIS in isolated islets from mice lacking AMPK catalytic α subunits
(A) Insulin secretion from isolated control (open bars) and RIPCreα2KO (solid bars) islets in static cultures in response to 2 and 20 mM glucose. (B) Insulin secretion from isolated control (open
bars) and α1KORIPCreα2KO (solid bars) islets in static cultures in response to 2 and 20 mM glucose. (C) Pancreatic sections from control and α1KORIPCreα2KO islets, from 10-week-old male
mice, co-stained for insulin (red), glucagon (green) and DAPI (4′ ,6-diamidino-2-phenylindole; blue). (D) Mean β-cell mass in islets of control and α1KORIPCreα2KO mice (n= 4). Values are
means+− S.E.M. *P < 0.05, ***P < 0.001.
in β-cells [10]. Taken together, these findings indicate that
appropriate expression of AMPKα subunits is required for normal
glucose sensing and GSIS in pancreatic β-cells.
Deletion of AMPKα2 does not alter β-cell mass
Recent studies show that loss of LKB1, an AMPK kinase,
increases β-cell size and enhances insulin secretion [23,24].
Therefore we undertook islet morphometric analysis in
RIPCreα2KO and control mice to exclude increased β-cell
mass as a contributing factor. Absolute β-cell mass was
unaltered in RIPCreα2KO mice compared with control animals
(Figures 4C and 4D), which indicated that altered β-cell function
underlies the changes observed in basal insulin secretion and
GSIS.
AMPKα2 is required for low-glucose-induced hyperpolarization of
pancreatic β-cells
We next examined whether the high basal insulin secretion was
associated with alteredβ-cell electrical responsiveness to glucose.
Perforated patch recordings from single cultured isolated β-cells
showed that control (WT and RIPCre) β-cells responded
to low glucose (10 mM to 2 mM) by membrane potential
hyperpolarization causing cessation of action potential firing,
actions reversed on returning to 10 mM glucose (Figures 5A
and 5B). In contrast, the majority (19 out of 24) of β-cells
from RIPCreα2KO islets displayed no hyperpolarizing response
to low glucose, maintaining an unchanged membrane potential
in 2 mM and 10 mM glucose (Figure 5C). The remaining five
cells responded normally to hypoglycaemia (results not shown),
consistent with lack of deletion of the floxed allele in all β-cells
[15].
One potential issue with this type of genetic manipulation is that
developmental compensation for loss of the target gene may occur
and modify the observed phenotype. In an attempt to preclude this
possibility, we treated WT mouse culturedβ-cells with adenovirus
containing GFP (green fluorescent protein) as a control or a
kinase-dead mutant form of AMPKα2, which acts as a dominant-
negative towards native AMPK (DNAMPKα2). Control viral
infected β-cells were electrically active and responded, reversibly,
to low glucose by hyperpolarization and inhibition of action
potential firing (Figure 6A), identical with control β-cells. Cells
treated with DNAMPKα2 adenovirus were also electrically active
in 10 mM glucose and, on reduction to 2 mM glucose, a significant
proportion of the infected cells (n= 11/33) displayed no response
to hypoglycaemic challenge (Figure 6B), with the remainder
behaving as controls. The low proportion of β-cells unresponsive
to hypoglycaemia is probably related to infection efficiency, as
obvious GFP expression was observed in <50% of β-cells.
Attempts to increase the MOI (multiplicity of infection) to achieve
higher expression of DNAMPKα2 resulted in cell toxicity.
The non-responsive RIPCreα2KO and DNAMPKα2 β-cells
were demonstrated to be capable of hyperpolarization by their
responsiveness to the KATP activator, diazoxide, as compared with
control β-cells (Figure 6C).
Isolated islets from α1KORIPCreα2KO mice also displayed
significantly higher insulin secretion at 2 mM glucose in
comparison with control mice. Thus to confirm the role of
AMPKα2 in regulating β-cell sensitivity to hypoglycaemia, we
made recordings from β-cells of α1KO and α1KORIPCreα2KO
mice. All α1KO β-cells displayed normal responses to
hypoglycaemic challenge, with rapid hyperpolarization and
cessation of firing, actions reversed on re-addition of 10 mM
glucose (Figure 6D). In contrast, the majority (7 out of 11) of
α1KORIPCreα2KO β-cells displayed little or no sensitivity to
hypoglycaemic challenge (Figure 6E), with the remaining cells
responding like controls (results not shown), as described for
RIPCreα2KO β-cells. Taken together, these findings suggest that
AMPKα2 contributes to the normal glucose sensing behaviour of
pancreatic β-cells.
c© The Authors Journal compilation c© 2010 Biochemical Society© 2010 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.
328 C. Beall and others
Figure 5 Loss of hypoglycaemic sensing in isolated β-cells from
RIPCreα2KO mice
WT (A) and RIPCre (B) mouse cultured β-cells respond, reversibly, to the reduction of glucose
from 10 to 2 mM by hyperpolarization and cessation of firing. (C) RIPCreα2KO β-cells are
unresponsive to a reduction of glucose concentration from 10 to 2 mM. The histograms in (A–C)
are the mean values for membrane potential in β-cells exposed to 10, 2 and 10 mM glucose for
each condition. Values were derived from seven to 19 individual β-cell recordings per group
and are shown as means+− S.E.M. **P < 0.01, ***P < 0.001.
Altered AMPK levels or activity do not modify ATP levels, glucose
uptake or GK activity
Changing AMPK activity may regulate the expression,
localization or activity of GK and GLUT2 [25–28]. Therefore we
explored whether altered AMPK activity modified glucose uptake
or metabolism in β-cells, using RIPCreα2KO islets and a rat β-
cell line. Although AMPKα2 mRNA was significantly reduced in
RIPCreα2KO compared with control islets, levels of GLUT2 or
GK mRNA were unchanged (Figure 7A and Supplementary Fig-
ure S2D at http://www.BiochemJ.org/bj/429/bj4290323add.htm).
Additionally, there was no change in the levels of mRNA for
the low-Km hexokinase isoforms (HK I–III) in RIPCreα2KO
islets compared with control islets (Supplementary Figures
S2A–S2C). The CRI-G1 cell line was used to examine the
actions of AMPK activity modification because it demonstrated
significant GK expression and an innate hypersensitivity to
glucose, whereby reducing glucose from 10 mM to 2 mM did
not affect cell membrane potential or firing frequency, although
lower glucose (<1 mM) levels caused hyperpolarization and
inhibition of firing (Supplementary Figures S3A and S3B
at http://www.BiochemJ.org/bj/429/bj4290323add.htm). CRI-G1
cells exhibited unchanged GLUT2 or GK protein expression,
GK localization (results not shown) and glucose uptake
(Supplementary Figure S3C) following stimulation or inhibition
of AMPK activity with AICAR (1 mM) or compound C
(40 µM) respectively. We next considered the possibility that
AMPKα2 acts as a negative regulator of GK activity. GK is
the primary glucose sensor of β-cells [29] and pharmacological
activation of β-cell GK with GKA50 increases insulin secretion
at 2 mM glucose [30], mimicking the RIPCreα2KO β-cell
phenotype. Indeed, exposure of WT β-cells to 100 nM GKA50
prevented hyperpolarization and inhibition of electrical activity
by hypoglycaemic challenge (Figure 7B). Furthermore, CRI-G1
cells displayed a glucose concentration-dependent increase in GK
activity (Figure 7C), significantly higher than for INS-1 cells
(CRI-G1 cells, ∼90–100 milli-units/mg of protein; INS-1
cells, 8–10 milli-units/mg of protein at 100 mM glucose [31]).
This is consistent with CRI-G1 insensitivity to low glucose as high
GK activity should raise cellular ATP and maintain KATP in the
closed state, analogous to activating GK mutations, which are also
characterized by hypersecretion of insulin at basal glucose levels
[32]. Our initial studies appeared to corroborate this hypothesis,
as AICAR (1 mM) caused significant inhibition (∼30%) of
GK activity in CRI-G1 cells, at glucose concentrations above
0.5 mM, and compound C prevented this effect (Figures 7C
and 7D). Although an attractive explanation for modification of
glucose sensing by AMPK, the inhibition of GK activity was
not replicated when AMPK activity was stimulated with the
direct AMPK activator [33], A-769662 (Figure 7E). Additionally,
the [ATP]/[ADP] ratio of CRI-G1 cells following stimulation or
inhibition of AMPK was unaffected (Figure 7F).
RIPCreα2KO islets also displayed unaltered mitochondrial
mass reflected by unchanged levels of ATP synthase (Figure 7G)
and mRNA levels of transcription factors involved in
mitochondrial energy metabolism, PGC1α, Tfam and Nrf were
unaltered (Figure 7A). In contrast, the mRNA level for the KATP
channel subunit, SUR1 (Figure 7A) was reduced, raising the
possibility that altered KATP current levels or ATP sensitivity
may underlie the lack of responsiveness to hypoglycaemia by
AMPKα2 deletion. However, the maximal KATP current and
ATP-sensitivity (Figures 8A and 8B) were unaltered between
RIPCreα2KO and RIPCre control β-cells. Overall, we could not
identify any alteration to glucose uptake, coupling of glucose
metabolism to mitochondrial ATP production or deficiency in
KATP channel function, which would explain the hypersecretion
of insulin at low glucose or the reduction in GSIS in AMPKα2-
deficient β-cells.
Islets lacking AMPKα2 have reduced UCP2, and UCP2 inhibition
causes glucose insensitivity of β-cells
Increased UCP2 activity has been reported to impair GSIS in islets
[34,35]. Conversely, UCP2 reduction increases GSIS [36,37],
and pharmacological inhibition of UCP2 with genipin stimulates
insulin secretion [38]. UCP2 mRNA was markedly suppressed
in RIPCreα2KO islets (Figure 7A). Furthermore, exposure of
WT β-cells to genipin prevented the hyperpolarization associated
with hypoglycaemic challenge (Figure 8C), but did not influence
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Figure 6 Loss of hypoglycaemic sensing in isolated β-cells lacking AMPK activity
(A) WT mouse cultured β-cells treated with GFP adenovirus display a normal reversible response to reduction of glucose from 10 to 2 mM. (B) WT mouse cultured β-cells treated with DNAMPKα2
adenovirus exhibit loss of electrical responsiveness to hypoglycaemia. The histograms are the mean values for the change in membrane potential associated with reduction in glucose from 10 to
2 mM in responding (R, n= 22) and non-responding (NR, n= 11) β-cells, in comparison with control (WT) β-cells (Cont, n= 7). (C) Mean change in membrane potential of control (n= 12),
RIPCreα2KO (KO, n= 11) and glucose-unresponsive DNAMPKα2-treated (DN, n= 11) β-cells in response to application of diazoxide (250µM). (D) α1KO mouse β-cells respond normally to
reduction of glucose from 10 to 2 mM, showing typical hyperpolarization and inhibition of action potential activity. (E) α1KORIPCreα2KO β-cells are unresponsive, electrically, to hypoglycaemic
challenge. Values are means+− S.E.M. ***P < 0.001. DZX, diazoxide.
the response of the cells to diazoxide (#V control = −19.6+−
1.3 mV; n= 5; #V genipin −19.0+− 3.7 mV; n= 6). Although
genipin has been reported to have a variety of activities, at the
concentration used in the present study it is considered to act
relatively specifically [38]. In addition, genipin excites mouse
arcuate POMC neurons by closure of KATP channels only when
UCP2 is present in the neurons [39]. Consistent with our β-cell
data, hyperpolarization of POMC neurons in response to
reduced glucose is also ablated in AMPKα2KO POMC
neurons [17] and is reversibly occluded by genipin in
WT mouse POMC neurons (Supplementary Figure S4 at
http://www.BiochemJ.org/bj/429/bj4290323add.htm). However,
UCP2 reduction itself, would be predicted to increase GSIS,
whereas the loss of AMPKα2 in β-cells resulted in diminished
GSIS. Thus we sought an alternative explanation. UCP2 activity
plays a key role in the control of mitochondrial-driven ROS
(reactive oxygen species) production [40] and a lack or reduction
of UCP2 in β-cells increases ROS and impairs GSIS from islets
[41]. However, we detected no increase in H2O2 production in
WT, RIPCreα2KO or α1KORIPCreα2KO islets at 2 or 20 mM
glucose, by CM-H2DCFDA-derived fluorescence (Figure 8D).
Furthermore, we did not detect any increase in mRNA level for
antioxidant enzymes in RIPCreα2KO islets (Figure 8E), indicative
of an increased innate adaptive response to oxidative stress, which
has also been reported to impair GSIS [41].
DISCUSSION
A previous study has shown that global AMPKα2KO mice
demonstrate impaired glucose homoeostasis, which was ascribed
to increased catecholamine secretion [22]. In contrast, we show
that RIPCreα2KO and α1KORIPCreα2KO mice exhibit impaired
glucose tolerance associated with dysfunctional GSIS in vivo and
in isolated islets. Electrophysiological examination of AMPKα2-
depleted isolated β-cells showed that the normal inhibitory
electrical response to low glucose was ablated in the majority
of these cells compared with control β-cells, in accordance with
the observed enhanced basal insulin secretion. This outcome
indicates that the KATP channels of AMPKα2-depleted β-cells, in
contrast with control β-cells, remain closed under hypoglycaemic
conditions. Elevated electrical activity and increased insulin
release at low-glucose concentrations have been reported for
β-cells with reduced levels of functional KATP channels in the
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Figure 7 AMPK activity does not correlate with altered GK activity, nucleotide ratios or mitochondrial mass
(A) Relative islet mRNA expression, from 20-week-old male control and RIPCreα2KO mice, of AMPKα2, Gck , Slc2a2, Nrf1, PGC1a, SUR1, Tfam and UCP2 (n= 6). (B) WT mouse cultured β-cells
treated with 100 nM GKA50 fail to respond electrically to hypoglycaemic challenge, but respond normally to diazoxide (250µM; DZX). Histograms are the mean values for membrane potential in
β-cells exposed to 10 mM glucose alone, and 10, 2 and 10 mM glucose in the presence of GKA. (C) Activity of GK in CRI-G1 β-cells as a function of glucose concentration in the absence (!) and
presence (H17009) of AICAR (1 mM). The curved lines (Control, solid; AICAR, broken) represent lines of best fit to the data points (n= 5–8 determinations per point). (D) GK activity, expressed relative to
control conditions (6 mM glucose), in CRI-G1 β-cells exposed to 1 mM AICAR +− 40µM Compound C in 6 mM glucose (n= 5–8 determinations for each condition). (E) Activity of GK in CRI-G1
β-cells as a function of glucose concentration in the absence (!) and presence (H17009) of A-769662 (10µM). The curved lines (Control, solid; A-769662, broken) represent lines of best fit to the
data points (n= 6 determinations per point). (F) Mean values for the [ATP]/[ADP] ratio of CRI-G1 β-cells in control conditions and treated with 10µM A-769662+− 40µM Compound C (n= 3–6
determinations for each condition). (G) Representative immunoblot for ATP synthase from control and RIPCre2αKO islets. A-76, A-769662; cont, control; Cpdc, compound C.
plasma membrane [42,43], or which have loss of function
mutations in one of the KATP channel subunits, KIR6.2 or
SUR1 [44]. It has also been suggested that AMPK can modify
β-cell KATP activity by phosphorylation of KIR6.2 [45] or altered
plasma membrane channel numbers [46]. However, this is
unlikely to explain AMPKα2KO β-cell electrical insensitivity to
hypoglycaemia because the cells display normal hyperpolarizing
responses to diazoxide and exhibit an unaltered maximal KATP
current compared with control cells. An alternative explanation is
that lack of AMPKα2 activity decreases KATP current by increased
channel ATP sensitivity causing maintained KATP closure in
the face of reduced cell ATP levels during the hypoglycaemic
challenge. However, we could detect no difference in the ATP-
sensitivity of KATP comparing AMPKα2-null and control β-cells.
Reduced expression of GLUT2 in rodents and humans
correlates with β-cell glucose insensitivity [8,47]. However, as we
could detect no evidence to link altered AMPK levels or activity
to a change in GLUT2 mRNA or protein levels or to glucose
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Figure 8 Loss of AMPKα2 does not alter β-cell KATP current or ATP-sensitivity or islet ROS response
(A) Representative current–voltage relationships for voltage-clamped currents of RIPCre control (black symbols) and a RIPCreα2KO (grey symbols) cultured β-cells. Mean currents were measured at
various membrane potentials shortly after attaining whole-cell recording (i.e. prior to significant washout of cell ATP; filled squares) and 20 min later (following maximal washout of cellular ATP; filled
circles). (B) Mean slope conductance values for current–voltage relationships as shown in (A), as a function of [ATP] (0, 0.5, 1.0 or 3.0 mM in the pipette solution). Lines of best fit (dose–response)
are shown for RIPCre control (black filled squares) and RIPCreα2KO (grey filled circles) β-cells (n= 3–6). (C) WT β-cells exposed to genipin (100 nM) are electrically unresponsive to the
reduction of glucose from 10 mM to 2 mM. Note that 250µM diazoxide (DZX) hyperpolarizes the cell in the presence of genipin. Histograms are the mean values for membrane potential for
β-cells, in the presence of genipin exposed to 10, 2 and 10 mM glucose respectively (n= 6). (D) H2O2-derived fluorescence in isolated islets of control, RIPCreα2KO and α1KORIPCreα2KO mice
(n= 16–23 islets each) at 2 and 20 mM glucose. A. U., arbitray units. (E) Expression of antioxidant enzymes in isolated islets of RIPCreα2KO mice, normalized to the levels expressed in control
WT mice (n= 8–10). *P < 0.05.
uptake, this component of β-cell glucose sensing is unlikely to be
responsible for the defective control of insulin secretion described
in the present study. Deletion of the upstream AMPK regulator
LKB1 results in improved glucose tolerance, β-cell hypertrophy,
higher insulin content and increased secretion in vivo and in
vitro [23,24]. These results have been interpreted as LKB1, by
increasing AMPK activity, acting to restrain insulin secretion.
However, we observe no change in β-cell mass, and GSIS
in AMPKα2-deleted islets is impaired not enhanced, indicating
that AMPKα2 β-cell deletion is unlikely to be associated with
reduced LKB1 activity. Our results also indicate that the outcome
of LKB1 deletion in β-cells described in these reports may not be
due simply to altered AMPK activity.
GK plays a central role in the control of GSIS because it allows
glucose phosphorylation at physiological glucose concentrations.
Inactivating mutations of GK result in reduced insulin secretion
and Type 2 diabetes, whereas GK-activating mutations cause
insulin hypersecretion and hypoglycaemia [48]. Thus high GK
activity should result in high levels of ATP at low-glucose
concentrations and keep KATP channels closed. Indeed, stimulation
of GK with GKA50 in control β-cells resulted in the loss of
electrical sensitivity to low glucose. In support of this notion, CRI-
G1 cells have reduced sensitivity to hypoglycaemic challenge
and express high GK activity. Furthermore, stimulation of AMPK
activity with AICAR significantly reduced GK activity, which was
prevented by co-application of the AMPK inhibitor compound C.
Although these results encouraged the view that loss of AMPKα2
up-regulated GK activity in β-cells, this effect was not replicated
using the direct AMPK activator A-769662. In addition, we
could detect no change in the levels of low-Km hexokinases in
AMPKα2-deleted islets, abrogating an induction of one or more
of these hexokinases as a potential loss-of-function mediator.
Taken together with the lack of change in bulk [ATP]/[ADP]
ratio in CRI-G1 cells, we think it unlikely that modification of
GK activity explains the insensitivity of β-cell electrical activity
to low glucose in AMPKα2-deficient cells.
β-cells have a relatively modest endogenous antioxidant
defence system and are very susceptible to toxicity induced
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by ROS [49]. Increased respiratory energy production raises
mitochondrial electron transport, which drives the generation of
ROS. To counter this, pancreatic β-cells exhibit high UCP2 levels
and activity, which uncouples respiratory energy production,
reduces the mitochondrial membrane potential and attenuates
ROS production [37]. UCP2 may be a crucial component
of β-cell function as inappropriately high UCP2 levels (e.g.
associated with chronic hyperglycaemia or obesity) or UCP2
overexpression causes β-cell dysfunction by lowering ATP levels
and reducing GSIS [36]. Conversely, knockdown of UCP2 in
islets or global UCP2-deficient mice exhibit raised islet ATP levels
and increased insulin secretion [34]. Our finding that AMPKα2
deletion reduces UCP2 mRNA levels in islets might therefore have
led to the prediction that insulin secretion would be increased.
Clearly, this was not the case when GSIS was examined in
vivo or in vitro in RIPCreα2KO and α1KORIPCreα2KO mice.
Indeed, in isolated islets although basal insulin secretion in
the presence of low glucose was enhanced, GSIS was either
relatively unaffected (RIPCreα2KO mice) or significantly reduced
(α1KORIPCreα2KO mice) compared with controls.
The finding that AMPKα2 deletion also ablates the KATP-
mediated hyperpolarization associated with hypoglycaemia in
hypothalamic POMC neurons [17] supports the notion that
AMPKα2 deletion alters β-cell glucose sensing capability.
Furthermore, KATP activation by low glucose is occluded in both
cell types by genipin, supporting the idea that UCP2 activity is
a key component of hypoglycaemic sensing in these specialized
cells. So how might we explain the reduced GSIS associated
with loss of AMPKα2 and reduced UCP2 in β-cells? There is a
growing body of evidence to indicate that β-cell ROS production
contributes to glucose-sensing behaviour and the regulation of
insulin secretion, either as a signal for insulin secretion or as
a mediator of the adaptive antioxidant response [41]. However,
the reduction of UCP2 in AMPKα2-deleted islets was not
accompanied by any significant alteration in ROS levels at low- or
high-glucose concentrations, and we could detect no evidence for
an adaptive response causing raised levels of antioxidant enzymes.
The permanently depolarized nature of AMPKα2-null β-cells
may be, at least partly, responsible for the overall reduction of
GSIS and impaired glucose tolerance we observe in RIPCreα2KO
mice. This notion arises from reports that suppression of insulin
secretion by pharmacological opening of KATP channels causing
cell hyperpolarization and a period of rest for the insulin secretion
process improves glucose tolerance and β-cell function in animal
models of diabetes and preserves and improves human islet
function [50]. Thus maintenance of AMPK activity may be
an important component of β-cell protection against chronic
overstimulation and loss of islet function.
In conclusion, loss of AMPKα2 appears to cause permanently
dampened UCP2 levels in islets, which is associated with
dysfunctional β-cell glucose sensing and diminished GSIS. Lack
of AMPKα2 may therefore result in disconnection of the normal
response to nutrient deprivation whereby raised AMPK activity
and UCP2 levels would act to lower insulin secretion at low-
glucose levels and maintain secretion at high-glucose levels. Thus
we hypothesize that AMPK plays a key role in connecting nutrient
fluctuations and UCP2 regulation with maintenance of GSIS in
β-cells.
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Figure S1 Hypothalamic mRNA expression profile and glucose homoeostasis parameters in RIPCreα2KO mice
(A) Expression of mRNA in the hypothalamus of RIPCreα2KO mice, relative to control WT mice (n= 5). Fasting (B) and fed (C) blood glucose levels in control (n= 8) and RIPCreα2KO 16- and
20-week-old male mice respectively (n= 8). (D) Fasted plasma insulin levels in control (n= 9) and RIPCreα2KO 10-week-old male mice (n= 7).
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Figure S2 Expression of mRNA in islets of RIPCreα2KO mice, relative to control (RIPCre) islets for (A) HK I, (B) HK II, (C) HK III, and (D) GK
Values are means+−S.E.M. for n= 7–9 determinations for each. The probes used were: Hexokinase I, Mm01145241_m1; Hexokinase II, Mm00443395_m1; and Hexokinase III, Mm01341937_m1.
Figure S3 CRI-G1 β-cells exhibit glucose-sensing behaviour, and AMPK
manipulation does not influence glucose uptake
Representative perforated patch recordings from CRI-G1 β-cells, showing (A) the lack of
electrical response to reduction of glucose from 10 mmol/l to 2 mmol/l and (B) the
hyperpolarization and inhibition of firing on reduction of glucose from 10 mmol/l to 0.1
mmol/l. Note that the application of 250µmol/l diazoxide (DZX) hyperpolarizes the β-cell in the
presence of 10 mmol/l glucose. (C) Glucose uptake, as measured by 2-NBDG uptake, in CRI-G1
β-cells is unaltered by treatment of cells (1 h) with 1 mmol/l AICAR+−40 µmol/l compound C
(CpdC) (n= 44, from six separate experiments).
Figure S4 Representative perforated patch recording from a POMC arcuate
nucleus neuron
Reducing glucose from 2 mM to 0.1 mM reversibly hyperpolarizes and reduces firing frequency,
but this effect is reversibly occluded by the presence of 20 µM genipin. The broken line in the
trace represents 0 mV.
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